Glutamate Receptor Ion Channels: Structure, Regulation, and Function


Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (S.F.T., K.M.V., K.K.O., K.B.H., H.Y., S.J.M., R.D.); Department of Neurobiology and Behavior & Center for Nervous System Disorders, Stony Brook University, Stony Brook, New York (L.P.W.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland (C.J.M.); and cyclicM LLC, Mystic, Connecticut (F.S.M.)

Abstract ............................................................................ 406

I. Introduction and nomenclature ............................................. 407

II. Structure .......................................................................... 407
   A. Subunit organization and quaternary structure ................. 407
   B. Subunit stoichiometry .................................................... 409
   C. Receptor assembly and trafficking .................................... 411
   D. The extracellular ligand binding domain ......................... 412
   E. The extracellular amino-terminal domain ....................... 414
   F. The transmembrane domain ......................................... 415
   G. The intracellular carboxyl-terminal domain and protein binding partners .................. 415
   H. Transmembrane α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor regulatory proteins and other auxiliary subunits .......................... 418

III. Regulation of transcription and translation .......................... 419
   A. α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors .......................... 419
      1. Gria1 ..................................................................... 419
      2. Gria2 ..................................................................... 420
      3. Gria3 and Gria4 ...................................................... 421
   B. Kainate receptors Grik1 to Grik5 ....................................... 421
   C. N-Methyl-D-aspartate receptors ....................................... 421
      1. Grin1 ..................................................................... 421
      2. Grin2a .................................................................... 422
      3. Grin2b .................................................................... 422
      4. Grin2c, Grin2d, Grin3a, and Grin3b ................................ 423
   D. Translational control of glutamate receptors ..................... 424

IV. Post-translational regulation ................................................ 425
   A. α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and kainate receptor phosphorylation .................................. 425
   B. N-Methyl-D-aspartate and δ receptor phosphorylation ........ 427
   C. Other post-translational modifications of glutamate receptors. 429
   D. Proteolysis of glutamate receptors ................................... 430

V. Agonist and antagonist pharmacology ................................. 431
   A. α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, kainate, and δ receptor agonists .............................................. 431
   B. N-Methyl-D-aspartate receptor agonists ............................. 434
   C. α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and kainate receptor competitive antagonists .......................... 437
   D. N-Methyl-D-aspartate receptor competitive antagonists ........ 439

Address correspondence to: Dr. Stephen Traynelis, Dept Pharmacology, Emory University School of Medicine, Rollins Research Center, 1510 Clifton Road, Atlanta GA 30322-3090. E-mail: strayne@emory.edu

1Current affiliation: Mnemosyne Pharmaceuticals, Inc., Providence, Rhode Island.

This article is available online at http://pharmrev.aspetjournals.org.

E. Noncompetitive antagonists .......................................................... 440
F. Uncompetitive antagonists .......................................................... 443
VI. Allosteric regulation .................................................................... 445
A. Positive and negative allosteric modulators ................................. 445
B. Divalent ions ................................................................................ 447
C. Monovalent ions .......................................................................... 448
D. Protons .......................................................................................... 449
E. Polyamines .................................................................................... 449
F. Neurosteroids .............................................................................. 450
G. Fatty acids .................................................................................... 450
H. Other allosteric modulators .......................................................... 450
VII. Molecular determinants of gating ............................................... 450
A. Time course of glutamate receptor activation and deactivation ....... 450
B. Mechanisms linking agonist binding to channel gating ................. 451
C. Molecular determinants and mechanisms of partial agonism ........... 453
D. Molecular determinants and mechanisms of gating ....................... 455
E. Molecular determinants of desensitization .................................... 457
VIII. Molecular determinants of ion permeation and block ................. 458
A. Nature of the ion permeation pathway .......................................... 458
B. Mechanisms of ion permeation ..................................................... 460
C. Voltage-dependent channel block by endogenous ions ................... 462
IX. Role in synaptic function and plasticity ......................................... 463
A. Synaptic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors .......................................................................................................................... 463
B. Synaptic kainate receptors ............................................................ 464
C. Synaptic and extrasynaptic N-Methyl-D-aspartate receptors .......... 465
D. Synaptic plasticity .......................................................................... 466
1. N-Methyl-D-aspartate receptors .................................................. 466
2. α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors .... 467
X. Therapeutic potential ..................................................................... 467
A. Glutamate receptor antagonists and the prevention of acute neuronal death ............................................................................................................. 467
B. The next generation α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and kainate receptor antagonists ................................................................. 469
C. The next generation N-methyl-D-aspartate receptor antagonists .... 469
D. N-Methyl-D-aspartate antagonists ............................................... 470
1. Neuropathic pain .......................................................................... 470
2. Major depression .......................................................................... 471
3. Parkinson’s disease ....................................................................... 471
E. α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and kainate receptor potentiation .............................................................. 471
F. N-Methyl-D-aspartate receptor potentiation .................................... 472
XI. Conclusions .................................................................................. 473
Acknowledgments ........................................................................... 474
References ....................................................................................... 474

Abstract—The mammalian ionotropic glutamate receptor family encodes 18 gene products that coassemble to form ligand-gated ion channels containing an agonist recognition site, a transmembrane ion permeation pathway, and gating elements that couple agonist-induced conformational changes to the opening or closing of the permeation pore. Glutamate receptors mediate fast excitatory synaptic transmission in the central nervous system and are localized on neuronal and non-neuronal cells. These receptors regulate a broad spectrum of processes in the brain, spinal cord, retina, and peripheral nervous system. Glutamate receptors are postulated to play important roles in numerous neurological diseases and have attracted intense scrutiny. The description of glutamate receptor structure, including its transmembrane elements, reveals a complex assembly of multiple semiautonomous extracellular domains linked to a pore-forming element with striking resemblance to an inverted potassium channel. In this review we discuss International Union of Basic and Clinical Pharmacology glutamate receptor nomenclature, structure, assembly, accessory subunits, interacting proteins, gene expression and translation, post-translational modifications, agonist and antagonist pharmacology, allosteric modulation, mechanisms of gating and permeation, roles in normal physiological function, as well as the potential therapeutic use of pharmacological agents acting at glutamate receptors.
I. Introduction and Nomenclature

The past decade has revealed both breathtaking advances in our understanding of structure and function and a growing sophistication at virtually all levels of experimental design. The structure of a membrane-spanning tetrameric glutamate receptor has been described, revealing unprecedented features of channel structure together with long-awaited details on the pore-forming elements and the channel gate, subunit arrangement, and the nature of linkers connecting multiple semiautonomous domains that comprise the extracellular portion of the receptor. These compelling data have set the stage for a predictably explosive increase in work on all aspects of function and hold the promise of catalyzing timely breakthroughs in therapeutic strategies.

Assembling this review was an exciting yet daunting task. A staggering volume of literature has been published over the last 11 years, the period this review most seeks to summarize. We have focused primarily on the pharmacology of glutamate receptors, the structural basis of receptor function as it relates to neuronal function and neurological disease, and the regulation of receptor function by phosphorylation. We only touch upon the full spectrum of talented individuals and productive laboratories engaged in this field. We regret that space does not allow a complete listing of relevant work related to each point made; many fine articles simply could not be cited.

After the first report appeared in December 1989 of the cloning of a glutamate receptor subunit (Hollmann et al., 1989), the early 1990s witnessed a flurry of activity, resulting in reports of more than a dozen glutamate receptor clones in various species within the subsequent 6 months. As might be expected, the nomenclature was uncoordinated, with species-or laboratory-specific names for the same transcript being promoted in the literature. This situation has resolved slowly. An excellent history of glutamate receptor cloning and nomenclature has appeared (Lodge, 2009).

II. Structure

A. Subunit Organization and Quaternary Structure

Ionotropic glutamate receptors are integral membrane proteins composed of four large subunits (>900 residues) that form a central ion channel pore. Sequence similarity among all known glutamate receptor subunits, including the AMPA, kainate, NMDA, and δ receptors, rizes the nomenclature used throughout this review for both genes and gene products.
receivers, suggests they share a similar architecture (Table 2). Glutamate receptor subunits are modular structures that contain four discrete semiautonomous domains: the extracellular amino-terminal domain (ATD), the extracellular ligand-binding domain (LBD), the transmembrane domain (TMD), and an intracellular carboxyl-terminal domain (CTD) (Fig. 1A). Apart from the CTD and the M4 segment, each of the individual domains exhibits low sequence homology to bacterial proteins with known structures and, in some instances, a related function (O’Hara et al., 1993; Wo and Oswald, 1995). This subunit arrangement relates one ATD to the membrane plane; the extracellular ATDs and LBDs are organized as dimers of dimers, and the ion receptor has an overall 2-fold symmetry perpendicular to the membrane (MacKinnon, 2003; Miyazawa et al., 2003; Sobolevsky et al., 2009) as well as the isolated ATDs and LBDs in complex with various agonists, antagonists, and modulators (discussed in section VI). These data, along with functional and biochemical experiments, have begun to define the relationship between receptor structure and function.

The first views of the quaternary glutamate receptor structure were provided by single particle images of recombinant and native AMPA receptors obtained by electron microscopy (Safferling et al., 2001; Tichelaar et al., 2004; Nakagawa et al., 2005, 2006; Midgett and Madden, 2008). Although these images show the receptors at lower resolution (~40–20 Å), some structural features could be extracted. For example, an internal 2-fold rotational symmetry was observed for some of these receptor structures (Tichelaar et al., 2004; Midgett and Madden, 2008), consistent with indications that glutamate receptors assemble as a dimer of dimers. This proposed 2-fold rotational symmetry for glutamate receptors is in contrast to the symmetry observed in structures of other ion channels, such as tetrameric K⁺-channels and the pentameric nicotinic acetylcholine receptor, in which the quaternary subunit arrangement leads to rotational symmetries that correlate with subunit-number (MacKinnon, 2003; Miyazawa et al., 2003; Sobolevsky et al., 2004; Wollmuth and Sobolevsky, 2004).

Crystallographic studies have provided the first detailed structure of a membrane-spanning glutamate receptor (Sobolevsky et al., 2009) as well as the isolated ATDs and LBDs in complex with various agonists, antagonists, and modulators (discussed in section VI). These data, along with functional and biochemical experiments, have begun to define the relationship between receptor structure and function.

The first views of the quaternary glutamate receptor structure were provided by single particle images of recombinant and native AMPA receptors obtained by electron microscopy (Safferling et al., 2001; Tichelaar et al., 2004; Nakagawa et al., 2005, 2006; Midgett and Madden, 2008). Although these images show the receptors at lower resolution (~40–20 Å), some structural features could be extracted. For example, an internal 2-fold rotational symmetry was observed for some of these receptor structures (Tichelaar et al., 2004; Midgett and Madden, 2008), consistent with indications that glutamate receptors assemble as a dimer of dimers. This proposed 2-fold rotational symmetry for glutamate receptors is in contrast to the symmetry observed in structures of other ion channels, such as tetrameric K⁺-channels and the pentameric nicotinic acetylcholine receptor, in which the quaternary subunit arrangement leads to rotational symmetries that correlate with subunit-number (MacKinnon, 2003; Miyazawa et al., 2003; Sobolevsky et al., 2004; Wollmuth and Sobolevsky, 2004).

Crystallographic studies have provided the first detailed structure of a membrane-spanning glutamate receptor (3.6 Å) (Fig. 1B). This structure of an antagonist-bound tetrameric rat GluA2 demonstrates that the receptor has an overall 2-fold symmetry perpendicular to the membrane plane; the extracellular ATDs and LBDs are organized as dimers of dimers, and the ion channel domain exhibits a 4-fold symmetry (Sobolevsky et al., 2009). This subunit arrangement relates one ATD dimer to another and one LBD dimer to the second, and half of the pore-forming TMDs to the other half. The symmetry mismatch between the ATDs and LBDs arises be-

### Table 1: Glutamate receptor subunits

<table>
<thead>
<tr>
<th>IUPHAR Name</th>
<th>HUGO Symbol</th>
<th>Common Names</th>
<th>Human Chromosome</th>
<th>Amino Acids in Longest Splice Variant</th>
</tr>
</thead>
<tbody>
<tr>
<td>GluA1</td>
<td>GRIA1</td>
<td>GluR1, GluRA</td>
<td>5q31.1</td>
<td>906</td>
</tr>
<tr>
<td>GluA2</td>
<td>GRIA2</td>
<td>GluR2, GluRB</td>
<td>4q32-3q33</td>
<td>901</td>
</tr>
<tr>
<td>GluA3</td>
<td>GRIA3</td>
<td>GluR3, GluRC</td>
<td>Xq25-q26</td>
<td>894</td>
</tr>
<tr>
<td>GluA4</td>
<td>GRIA4</td>
<td>GluR4, GluRD</td>
<td>11q22</td>
<td>902</td>
</tr>
<tr>
<td>GluK1</td>
<td>GRK1</td>
<td>GluK1</td>
<td>21q22.11</td>
<td>918</td>
</tr>
<tr>
<td>GluK2</td>
<td>GRK2</td>
<td>GluK2</td>
<td>6q16.3-q21</td>
<td>908</td>
</tr>
<tr>
<td>GluK3</td>
<td>GRK3</td>
<td>GluK3</td>
<td>1p34-p33</td>
<td>919</td>
</tr>
<tr>
<td>GluK4</td>
<td>GRK4</td>
<td>KA1</td>
<td>11q22.3</td>
<td>956</td>
</tr>
<tr>
<td>GluK5</td>
<td>GRK5</td>
<td>KA2</td>
<td>19q13.2</td>
<td>981</td>
</tr>
<tr>
<td>GluN1</td>
<td>GRN1</td>
<td>NMDAR1, NR1, GluR1</td>
<td>9q34.3</td>
<td>938</td>
</tr>
<tr>
<td>GluN2A</td>
<td>GRN2A</td>
<td>NMDAR2A, NR2A, GluR1</td>
<td>16p13.2</td>
<td>1464</td>
</tr>
<tr>
<td>GluN2B</td>
<td>GRN2B</td>
<td>NMDAR2B, NR2B, GluR2</td>
<td>12p12</td>
<td>1484</td>
</tr>
<tr>
<td>GluN2C</td>
<td>GRN2C</td>
<td>NMDAR2C, NR2C, GluR3</td>
<td>17q25</td>
<td>1238</td>
</tr>
<tr>
<td>GluN2D</td>
<td>GRN2D</td>
<td>NMDAR2D, NR2D, GluR4</td>
<td>19q13.1-pter</td>
<td>1336</td>
</tr>
<tr>
<td>GluN3A</td>
<td>GRN3A</td>
<td>NR3A</td>
<td>9q11.1</td>
<td>1115</td>
</tr>
<tr>
<td>GluN3B</td>
<td>GRN3B</td>
<td>NR3B</td>
<td>19p13.3</td>
<td>1043</td>
</tr>
<tr>
<td>GluD1</td>
<td>GRID1</td>
<td>δ1, GluR delta-1</td>
<td>10q22</td>
<td>1009</td>
</tr>
<tr>
<td>GluD2</td>
<td>GRID2</td>
<td>δ2, GluR delta-2</td>
<td>4q22</td>
<td>1007</td>
</tr>
</tbody>
</table>
cause the receptor contains two conformationally distinct subunits, which can be denoted A/C and B/D subunits (Fig. 1, C and D). Consequently, the A/C subunits will couple differently to the ion channel gate than will the B/D subunits, which may have important implications for the function of the glutamate receptors.

In the tetrameric structure (Sobolevsky et al., 2009), the ATD forms two distinct types of subunit-subunit contacts. The most extensive contact is formed between A/B and C/D subunits, and this contact is identical to that observed between subunits in the structure of the isolated GluA2 and GluK2 ATD dimer (Clayton et al., 2009; Jin et al., 2009; Kumar et al., 2009). The other contact is located on the 2-fold symmetry axis and is formed between B and D subunits of the A/B and C/D dimers (Fig. 1C). In addition, at the level of the LBD, two distinct types of subunit-subunit contacts are formed. The LBDs are arranged as A/D and B/C dimers with contacts between the A and C subunits (Fig. 1C). The domain swapping or subunit crossover causes a different subunit arrangement at the levels of the ATD and the LBD. As predicted by topology studies (Hollmann et al., 1994; Bennett and Dingledine, 1995) and the homology to the tetrameric K⁺-channels (Wo and Oswald, 1995; Wood et al., 1995; Kuner et al., 2003), the glutamate receptor TMD consists of three transmembrane helices (M1, M3, and M4) and a membrane re-entrant loop (M2) (Sobolevsky et al., 2009). In addition, the subunits have a short helix (pre-M1) that is oriented parallel to the membrane. M1, M2, and M3 form a structure that closely resembles that of an inverted K⁺-channel pore, and M4 primarily makes contacts with the TMD of an adjacent subunit.

The observation that subunits with the same polypeptide sequence adopt two distinct conformations in the tetrameric receptor complex is without precedent in an ion channel (Sobolevsky et al., 2009). The subunit crossover between the ATD and LBD levels of the tetramer (Fig. 1D) is primarily mediated by the ATD-S1 amino acid linkers that connect the ATD with the LBD. The ATD-S1 linkers of the A/C subunits adopt a compact conformation, whereas the ATD-S1 linkers of the B/D subunits have an extended conformation. This structural role of the ATD-S1 linker is intriguing, because previous studies have implicated this segment in the control of the open probability of NMDA receptors (Gielen et al., 2009; Yuan et al., 2009a). The symmetry mismatch between the LBD and the TMD levels also is mediated primarily by the linkers connecting the two domains (S1-M1, M3-S2, and S2-M4 linkers). Also here, the linkers adopt two different conformations corresponding to the A/C subunits and the B/D subunits. The involvement of the TMD-LBD linkers in the function of glutamate receptors has been extensively studied (Krupp et al., 1998; Villarroel et al., 1998; Sobolevsky et al., 2002a,b; Watanabe et al., 2002; Yelshansky et al., 2004; Balannik et al., 2005; Schmid et al., 2007), and the tetrameric structure provides an excellent opportunity to interpret these and other results in a structural context. Whereas tetrameric kainate receptors appear to have the same extracellular architecture as AMPA receptors (Das et al., 2010), it remains to be shown how well the tetrameric AMPA receptor structure corresponds to structures for NMDA receptors.

### B. Subunit Stoichiometry

The glutamate receptors assemble as tetrameric complexes of subunits (Laube et al., 1998; Mano and Teichberg, 1998; Rosenmund et al., 1998; Greene, 2001; Matsumura et al., 2005; Nakagawa et al., 2005; Sobolevsky et al., 2009), and functional receptors are formed exclusively by assembly of subunits within the same functional receptor class (Partin et al., 1993; Kuusinen et al., 1999; Leuschner and Hoch, 1999; Ayalon and Stern-Bach, 2001; Ayalón et al., 2005). Glutamate receptors are grouped into four distinct classes based on pharmacology and structural homology, including the AMPA receptors (GluA1–GluA4), the kainate receptors (GluK1–GluK5), the NMDA receptors (GluN1, GluN2A–GluN2D, GluN3A, and GluN3B), and the δ receptors (GluD1 and GluD2). The AMPA receptor subunits GluA1 to GluA4 can form both homo- and heteromers. The kainate receptor subunits GluK1 to GluK3 also form both homo- and heteromers, but GluK4 and GluK5 form functional receptors only when coexpressed with GluK1 to GluK3. The δ receptors GluD1 and GluD2 are capable of forming homomeric receptors yet seem incapable of forming heteromers with AMPA, kai-
Glutamate receptor subunits have a modular structure composed of two large extracellular domains (the ATD (green) and the LBD (blue)); a TMD (orange) that forms part of the ion channel pore; and an intracellular CTD. The LBD is defined by two segments of amino acids termed S1 and S2. The TMD contains three membrane-spanning helices (M1, M3, and M4) and a membrane re-entrant loop (M2). The isolated S1 and S2 segments have been constructed by deleting the ATD along with the TMD and joining S1 and S2 with a hydrophilic linker (dotted line). SP, signal peptide. B, crystal structure at 3.6 Å of the membrane-spanning tetrameric GluA2 AMPA receptor (PDB code 3KG2). C, subunit interfaces between the ATD, LBD, and TMD of the four subunits in the membrane-spanning tetrameric GluA2 AMPA receptor. The subunits are viewed from top down the 2-fold axis of symmetry. The ATDs and LBDs have a 2-fold axis of symmetry, whereas the TMDs have 4-fold axis of symmetry. D, the symmetry mismatch between the TMDs and the extracellular domains (ATDs and LBDs) as well as the subunit crossover (or domain swapping) from the LBD to the ATD give rise to two distinct types of subunits in the homotetrameric GluA2 receptor with two distinct conformations. The subunits are referred to as the A/C and B/D subunits. [Adapted from Sobolevsky AI, Rosconi MP, and Gouaux E (2009) X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature 462:745–756. Copyright © 2009 Nature Publishing Group. Used with permission.]

Functional NMDA receptors require assembly of two GluN1 subunits together with either two GluN2 subunits or a combination of GluN2 and GluN3 subunits (Monyer et al., 1992; Schorge and Colquhoun, 2003; Ulbrich and Isacoff, 2007, 2008). NMDA receptors further require simultaneous binding of both glutamate and glycine for activation (Johnson and Ascher, 1987; Kleckner and Dingledine, 1988; Lerma et al., 1990). The GluN1 and GluN3 subunits provide the glycine binding sites (Furukawa and Gouaux, 2003; Furukawa et al., 2005; Yao et al., 2008), and the GluN2 subunits form the glutamate binding sites (Furukawa et al., 2005). The GluN1 subunit expressed alone in Xenopus laevis oocytes responded weakly to coapplication of glutamate and glycine (Moriyoshi et al., 1991; Nakanishi et al., 1992; Yamazaki et al., 1992). These responses have been proposed to arise because X. laevis oocytes express low levels of endogenous NMDA receptor subunits (XenGluN1 and XenGluN2) that under some circumstances functionally assemble with GluN1 (Green et al., 2002; Schmidt et al., 2006, 2009; Schmidt and Hollmann, 2008, 2009), which can com-
GluN2D receptors in different brain regions and in specific units to form triheteromeric receptors. Numerous studies support the formation of GluN1/GluN2A/GluN2B, GluN1/GluN2A/GluN2C, GluN1/GluN2B/GluN2D, GluN1/GluN2A/GluN2D receptors in different brain regions and in specific neuronal subpopulations (Chazot et al., 1994; Sheng et al., 1994; Chazot and Stephenson, 1997; Luo et al., 1997; Sundström et al., 1997; Dunah et al., 1998a; Cathala et al., 2000; Green and Gibb, 2001; Piña-Crespo and Gibb, 2002; Brickley et al., 2003; Dunah and Standaert, 2003; Fu et al., 2005; Jones and Gibb, 2005; Lu et al., 2006; Brothwell et al., 2008). Few studies have addressed the functional implications of the presence of two different GluN2 subunits in the NMDA receptor complex (Brimecombe et al., 1997; Cheffings and Colquhoun, 2000; Hatton and Paoletti, 2005).

The GluN3 subunits bind glycine and do not form functional receptors alone (Chatterton et al., 2002; Yao and Mayer, 2006). When coexpressed with GluN1 in X. laevis oocytes, GluN1/GluN3 receptors can form receptors that are activated by glycine alone (Chatterton et al., 2002), but these excitatory glycine receptors have not yet been observed in GluN3-expressing neurons (Matsuda et al., 2003). At present, surface expression of glycine-activated GluN1/GluN3A or GluN1/GluN3B receptors in HEK293 cells is unresolved, but GluN1/GluN3A/GluN3B shows some functional expression (Smothers and Woodward, 2007). When GluN3 is coexpressed with GluN1 and GluN2 in X. laevis oocytes, NMDA- and glutamate-activated current amplitudes are reduced compared with current from GluN1/GluN2, suggesting that either triheteromeric GluN1/GluN2/GluN3 receptors form that have a lower conductance, or GluN3 expression reduces trafficking or assembly of GluN1/GluN2 (Das et al., 1998; Perez-Otano et al., 2001; Ulbrich and Isacoff, 2007, 2008). Triheteromeric GluN1/GluN2/GluN3 receptors presumably form in cortical neurons based on the observation of single-channel currents with properties that could not be attributed to either GluN1/GluN2 or GluN1/GluN3 receptors (Sasaki et al., 2002). The subunit stoichiometry and surface expression of GluN3-containing NMDA receptors and the physiological relevance of triheteromeric GluN1/GluN2/GluN3 receptors are not fully resolved.

C. Receptor Assembly and Trafficking

AMPA receptors assemble as dimers of dimers with ATD interactions presumably mediating the initial dimer formation. Subsequent tetramerization (i.e., assembly of two subunit dimers) occurs through interactions of the LBDs and the TMDs (Ayalon and Stern-Bach, 2001; Mansour et al., 2001; Ayalon et al., 2005). Receptor assembly occurs in the endoplasmic reticulum (ER), where quality control mechanisms ensure correct subunit folding and assembly. Data suggests that conformational changes associated with the normal function of glutamate receptors, such as ligand binding, activation, and desensitization, take place in the ER lumen, and these conformational changes may influence trafficking (Gugger et al., 2002; Fleck et al., 2003; Grundwald and Kaplan, 2003; Mah et al., 2005; Valluru et al., 2005; Greger et al., 2006; Priel et al., 2006; Penn et al., 2008). Consequently, glutamate receptors may require ligands or “chemical chaperones” for efficient folding and export from the ER. This is evident when the conformational changes associated with the normal function are modified by mutagenesis. Nondesensitizing GluA2(L438Y) mutants exit from the ER inefficiently, whereas GluA2 (N754D), which has increased desensitization, exits efficiently from the ER (Greger et al., 2006). Block of desensitization has been shown to similarly influence kainate receptor trafficking (Priel et al., 2006; Nayem et al., 2009). The mechanisms are unclear, but block of desensitization could interfere with association and/or dissociation of chaperones and/or transport proteins, with potential candidates being TARPs or CNIHs that are thought to be auxiliary subunits (see section II.H).

Data suggest that the ATD plays a crucial role in receptor oligomerization and perhaps trafficking (Kuusinen et al., 1999; Leuschner and Hoch, 1999; Ayalon and Stern-Bach, 2001; Ayalon et al., 2005; Qiu et al., 2009). The interaction between the ATDs is sufficient to allow isolated ATDs to form stable dimers in solution (Clayton et al., 2009; Jin et al., 2009; Kumar et al., 2009). A key role of the AMPA receptor ATD may be to direct assembly of the tetrameric receptor and to prevent kainate or NMDA receptor subunits from entering the tetramer (Kuusinen et al., 1999; Leuschner and Hoch, 1999; Ayalon et al., 2005), and some segments of the AMPA receptor ATD have been implicated in subtype-specific assembly (Leuschner and Hoch, 1999; Ayalon et al., 2005). In addition, AMPA receptor subunit stoichiometry is controlled by RNA editing, which precedes mRNA splicing and protein synthesis at two sites that modulate function: the RG site within the GluA2 to GluA4 LBD, and the QRN site at tip of the reentrant pore loop. Editing switches the codon at the QRN site from Gln to Arg in a majority of GluA2 RNA. These sites are located within subunit interfaces and are thought to affect receptor assembly by favoring heterodimerization over homodimerization, which partly explains why GluA2-containing AMPA receptors are mostly heteromers (Mansour et al., 2001; Greger et al., 2002, 2003, 2006). In addition, GluA2 subunits edited at the QRN site have increased dwell time in the ER compared with other AMPA receptor subunits, thereby increasing their availability for assembly with other subunits (Greger et al., 2002).

Three models have been suggested for assembly of NMDA receptors. The first model suggests that GluN1-GluN1 and GluN2-GluN2 homodimers initially form...
and subsequently coassemble to form the tetrameric receptor (Meddows et al., 2001; Schorge and Colquhoun, 2003; Papadakis et al., 2004; Qiu et al., 2005). The second model proposes that a GluN1-GluN1 homodimer forms a correctly folded stable complex to which two GluN2 monomers are added sequentially to form the NMDA receptor tetramer (Atlason et al., 2007). The third model suggests initial GluN1-GluN2 heterodimer formation and subsequent tetramerization (Scherer et al., 2008). At present, there are insufficient data to distinguish between the different models. However, the two conformationally distinct subunits with two types of subunit-subunit contacts observed in the GluA2 AMPA receptor structure (Sobolevsky et al., 2009) might provide the structural framework needed to design experiments to resolve this issue. Similar to AMPA receptors, the ATD is thought to mediate initial dimer formation of NMDA receptor subunits (Meddows et al., 2001; Papadakis et al., 2004).

D. The Extracellular Ligand Binding Domain

The LBD is highly conserved within the different glutamate classes (Table 2) and is formed by two extracellular stretches of amino acids historically referred to as S1 and S2 (Stern-Bach et al., 1994) (Fig. 1A). The structures of excised S1 and S2 amino acid sequences joined by an artificial polypeptide linker to form the LBDs have been described both with agonist and antagonist bound. All LBD structures adopt a clamshell-like conformation, where the polypeptide segment S1, located on the amino-terminal side of membrane helix M1, forms most of one half of the clamshell (D1), and the segment S2 between the M3 and M4 membrane helices forms most of the opposite half of the clamshell (D2) (Fig. 1A). The agonist binding pocket is located within the cleft between these two lobes. Several lines of experimental work have validated that the agonist-binding site in the soluble LBDs used for crystallization faithfully resembles the binding sites in intact receptors (Armstrong and Gouaux, 2000; Furukawa and Gouaux, 2003; Du et al., 2005; Gonzalez et al., 2008; Sobolevsky et al., 2009). In addition, comparison of UV absorption spectra that probe the molecular configuration of the AMPA receptor antagonist CNQX bound to either the isolated GluA2 LBD or the full-length GluA2 suggests that the structure of the soluble LBD resembles that within the full-length receptor (Deming et al., 2003).

The initial step in glutamate receptor activation is binding of the agonist to the LBD. Glycine, D-serine, aspartate, and glutamate analogs are agonists and uniformly contain moieties that correspond to the α-amino and α-carboxyl groups. The regions of the binding pocket that form atomic interactions with the α-carboxyl and α-amino groups are similar in all LBD structures and are composed primarily of residues from D1 (Fig. 2; see also section V.A). Crystallography studies together with homology modeling of the AMPA receptor subunits GluA1 to GluA4 show that residues that directly interact with α-carboxyl and α-amino groups of glutamate, AMPA, and kainate are conserved (Armstrong et al., 1998; Armstrong and Gouaux, 2000; Bjerrum et al., 2003, Pentikäinen et al., 2003; Gill et al., 2008) (Fig. 2). Greater variation is observed for the binding mode of the γ-positioned groups among AMPA receptor agonists, with a variety of atomic contacts being made for different agonists. Residues lining the agonist binding cavities of kainate receptor subunits are not fully conserved, providing opportunities for the development of subunit-specific antagonists.

![Fig. 2. Alignments of agonist-binding residues of glutamate receptor subunits. Residue numbering is according to the total protein including the signal peptide (initiating methionine is 1). For reference, the predicted size of the signal peptide (SP) is included in parenthesis at the end of the alignment. Amino acid numbering in AMPA and kainate receptor subunits has historically been for the mature protein without the signal peptide, whereas amino acid numbering of NMDA and GluD receptor subunits has started with the initiating methionine as 1. Fully conserved residues are yellow, conserved residues are blue, and similar residues are green. # denotes residues capable of forming hydrogen bonds or electrostatic interactions with the agonist; + denotes residues capable of forming van der Waals contacts with the agonist.](image-url)
selective agonists (Mayer, 2005) (Fig. 2; discussed in section V). Residues that interact with agonists in the NMDA receptor GluN2 subunits are fully conserved (Anson et al., 1998; Laube et al., 2004; Chen et al., 2005; Hansen et al., 2005a; Kinarsky et al., 2005; Erreger et al., 2007). As expected from sequence alignments, the agonist binding pockets of GluN1 and GluN3 are similar to those of GluA2 and GluN2A, but several key differences suggest how these subunits discriminate between glutamate and glycine (discussed in section V). Glutamate receptor activation involves a conformational change of the LBD upon binding of the agonist. Direct structural evidence for this idea arose from comparison of GluA2 LBD structures with and without agonist bound, as well as structures with bound competitive antagonists (Armstrong and Gouaux, 2000). In the antagonist-bound and the unbound apo structures, D1 and D2 are separated and adopt a more open conformation than in the agonist-bound structure, where D1 and D2 adopt a closed conformation (see also section VII.B for more detail). This mechanism is likely to be conserved in all glutamate receptor subunits, because all agonist-bound LBDs examined so far adopt conformations that are closed to different degrees relative to the apo structure.

Agonist-induced cleft closure within the LBD dimer, arranged with 2-fold symmetry in a back-to-back fashion, is an early conformational event that triggers the subsequent transition of the ion channel domain into an open state (see section VII). The intersubunit D1-D1 contacts formed across the dimer interface create both monovalent and divalent ion binding sites as well as sites for drug-like allosteric modulators (see section VI). In brief, upon agonist binding, the D2 lobes move and probably trigger rearrangement of the short segments that link the ion channel-containing TMD to the LBD, which drive rearrangement of M3 and subsequent channel opening (Erreger et al., 2004; Mayer, 2006; Hansen et al., 2007) (Fig. 3 discussed in section VII). The movement of D1 and D2 relative to each other results in instability at the TMD and at the LBD dimer interface. Stability can be restored by LBD reopening, which is the first step in the process of agonist dissociation, and we assume that it must be preceded by channel closure (or a change in subconductance state). Alternatively, the reduced stability of the interactions at the LBD dimer interface upon agonist binding can lead to a rearrangement of the dimer interface, allowing the receptor to enter a desensitized state (Sun et al., 2002; Jin et al., 2003, 2005; Horning and Mayer, 2004; Armstrong et al., 2006; Weston et al., 2006b) (Fig. 3; see section VII).

Alternative splicing of the AMPA receptor subunits generates two isoforms of the LBD termed flip and flop (Sommer et al., 1990), which control desensitization and deactivation as well as sensitivity to allosteric modulators (Mosbacher et al., 1994; Partin et al., 1994, 1995). The growing list of structures for LBDs from all subfamilies in complex with different agonists provides a firm basis for understanding agonist selectivity. For several of these ligands, structural studies in combination with site-directed mutagenesis and homology modeling have provided the structural determinants within the binding pocket that guide subunit selectivity (see section V).

Fig. 3. Conformational changes in the functioning AMPA receptor. Ribbon diagrams of the crystal structures of the GluA2 LBD dimer in conformations that correspond to the resting state (apo form; PDB code 1FT0), active state (glutamate-bound; PDB code 1FTJ) and desensitized state (glutamate-bound; PDB code 2V3V). In these structures, the LBD exists in a bilobed clamshell-like arrangement with the agonist-binding pocket located deep within the cleft between the two lobes referred to as D1 and D2. Binding of glutamate induces a transition of D2 that leads to separation of the linker segments that replace the TMDs in the full-length subunits (represented here by cylinders). The NTD and CTD are omitted for clarity. Distances between the linkers that face the TMD and distances between a glycine residue (Gly739) at the top of the dimer are taken from Armstrong et al. (2006). Upon glutamate binding and domain closure, separation of the linkers can result in reorientation of the transmembrane helices and opening of the ion channel. The active, nondesensitized receptor conformation is unstable, and stability can be restored either by reopening of the ABD or by rearrangement at the dimer interface. Rearrangement at the dimer interface results in desensitization by repositioning the transmembrane helices such that the ion channel is closed.
E. The Extracellular Amino-Terminal Domain

Beginning at the extracellular ATD, all glutamate receptors contain a short signal peptide (14–33 residues) that targets the protein to the membrane and is removed by proteolysis after membrane insertion. Subsequent to the signal sequence, the first ~400 to 450 residues in all glutamate receptor subunits (except bacterial GluR0, which lacks the ATD) fold into a semi-autonomous domain. Glutamate receptor ATDs have sequence homology and are structurally similar to the LBD of the metabotropic glutamate receptor mGluR1α and a group of soluble bacterial periplasmatic amino acid binding proteins, such as the leucine/isoleucine/valine binding protein (O’Hara et al., 1993; Paas et al., 1996; Paas, 1998; Masuko et al., 1999a; Paoletti et al., 2000; Clayton et al., 2009; Jin et al., 2009; Karakas et al., 2009; Kumar et al., 2009). However, the similarity is confounded by numerous structural differences, such as the different locations of disulfide bonds, as well as inserts and deletions. Nonetheless, the similarity between the glutamate receptor ATD and these proteins suggests that the function of the ATD could be to bind endogenous ligands, perhaps within a putative pocket located between the lobes. Numerous mutant subunits have been created that lack the entire ATD (Fayyazuddin et al., 2000; Pasternack et al., 2002; Horning and Mayer, 2004; Matsuda et al., 2005; Rachline et al., 2005; Gielen et al., 2009; Yuan et al., 2009a), and these truncated subunits seem to assemble into receptors that are functionally similar to wild-type receptors. The nonessential nature of the ATD for the core function of the glutamate receptor subunits is consistent with a regulatory role for this domain. Truncations of the ATD have been found to influence open probability, deactivation, desensitization, and regulation of subunit-specific assembly (Kuusinen et al., 1999; Leuschner and Hoch, 1999; Ayalon and Stern-Bach, 2001; Meddows et al., 2001; Ayalon et al., 2005; Gielen et al., 2009; Yuan et al., 2009a). The ATD also harbors binding sites for divalent cations, such as Zn$^{2+}$, and subunit-selective negative allosteric modulators, such as the phenylethanolamine ifenprodil (see sections V and VI). In addition, the ATD may contain binding sites for extracellular proteins, such as N-cadherin (Saglietti et al., 2007) and neuronal pentraxins (NARP and NP1) for AMPA receptors (O’Brien et al., 1999; Sia et al., 2007) the ephrin receptor for NMDA receptors (Dalva et al., 2000; Takasu et al., 2002); cerebellin1 precursor protein for GluD2 receptors (Matsuda et al., 2010; Uemura et al., 2010; see also Uemura and Mishina, 2008; Kakegawa et al., 2009).

The glutamate receptors are glycosylated during their passage through the endoplasmic reticulum and Golgi. The consensus sites for N-linked glycosylation primarily are located in the ATD, but a few are located in the LBD (Hollmann et al., 1994; Standley and Baudry, 2000). It is not clear how many of these consensus sites are glycosylated, but cell-specific differences in glycosylation of the glutamate receptor subunits might contribute to the differences in ligand affinities, trafficking, and molecular weights observed between different native receptors and those expressed in heterologous systems (Chazot et al., 1995; Sydow et al., 1996; Everts et al., 1997; Standley et al., 1998; Standley and Baudry, 2000; Clayton et al., 2009; Kumar et al., 2009). Although the effects of glycosylation on glutamate receptor function have not been studied in detail, glycosylation can affect desensitization and maximal currents of AMPA and kainate receptors (Hollmann et al., 1994; Everts et al., 1997). In addition, the lectin concanavalin A (con A) inhibits desensitization of kainate receptors in a manner that involves association of con A with the N-linked oligosaccharides (Partin et al., 1993; Everts et al., 1997, 1999) (see section VI).

Like the glutamate receptor LBDs, the GluN2B ATD is a clambshell-like structure, roughly composed of two halves (R1 and R2) tethered together by loops (Karakas et al., 2009). The N terminus is located at the top of R1, and the linker to the LBD is located at the bottom of R2. Overall, the GluN2B ATD structure resembles the ligand binding domain of the metabotropic glutamate receptor mGluR1 (Kunishima et al., 2000), although the position of R1 is 50° twisted relative to R2 in GluN2B ATD compared with mGluR1. The cleft between R1 and R2 can be divided into three sites: 1) the hydrophilic pocket at the outer end of the cleft, which contains polar residues involved in Zn$^{2+}$ binding; 2) the hydrophobic pocket deep inside the cleft, which contains residues that seem to affect ifenprodil binding; and 3) the ion-binding site that accommodates Na$^+$ and Cl$^-$ ions with unknown physiological relevance. Binding of ifenprodil to GluN2B and Zn$^{2+}$ to GluN2A or GluN2B has been proposed to stabilize a closed-cleft conformation of the ATD (see section VI; Karakas et al., 2009), although structural data in support of the hypothesized intracleft binding site is lacking. Nevertheless, the proposed cleft-closure has been speculated to lead to separation of the two R2 lobes in the ATD dimer (Gielen et al., 2008, 2009).

In contrast to NMDA receptors, no ions or small molecules are known to bind to the AMPA or kainate receptor ATD. Crystal structures of the GluA2 and the GluK2 ATDs show that these AMPA and kainate receptor ATDs adopt an overall structure similar to that of the ATD from the NMDA receptor subunit GluN2B, but the twist between R1 and R2 in GluN2B ATD was less pronounced in GluA2 and GluK2 ATDs (Clayton et al., 2009; Jin et al., 2009; Kumar et al., 2009). Unlike GluN2B, the isolated GluA2 and the GluK2 ATDs form dimers in solution and in the crystal lattice. Likewise, the ATDs of GluA1 and GluA4 also form dimers in solution (Kuusinen et al., 1999; Wells et al., 2001b; Jin et al., 2009).
Comparison of the R1 and R2 lobes of GluA2 and GluK2 ATDs with the corresponding domains of mGluR1 shows that the GluA2 and GluK2 ATDs adopt a conformation that is intermediate between the canonical open-cleft and closed-cleft states of mGluR1. In addition, there are extensive interactions between the two ATD subunits of the dimer for both GluA2 and GluK2 that involve multiple R1-R1 and R2-R2 domain contacts (Clayton et al., 2009; Jin et al., 2009; Kumar et al., 2009). The extensive interactions between the R2 lobes are mostly hydrophobic contacts situated in a large patch that is buried after dimerization of the ATD. The residues in this hydrophobic patch are conserved or conservatively substituted between AMPA and kainate receptors. In NMDA receptors, the sequence conservation is lower at the R2-R2 interface, consistent with the idea that binding of modulators to the NMDA receptor ATD could stabilize ATD cleft closure and separation at the R2-R2 interface (Gielen et al., 2008, 2009). A separation at the R2-R2 interface in the non-NMDA receptor ATD dimer would expose the large hydrophobic patch on the R2 lobe to the solvent, which would be energetically unfavorable. The “weak” R2-R2 interface in the NMDA receptor could better allow closure of the R1-R2 clampshell and separation at the R2-R2 interface, thereby triggering allosteric modulation of the ion channel. Solution of dimeric forms of the ATD will help clarify these ideas.

F. The Transmembrane Domain

In all glutamate receptors, the LBD is connected to the conserved TMD through three short linkers (Fig. 1A). The transmembrane helices M1, M3, and M4 from each of the four subunits contribute to formation of the core of the ion channel and have a small but significant sequence homology with the inverted ion channel domain of K⁺ channels (Wo and Oswald, 1995; Kuner et al., 2003). This similarity is further highlighted by the bacterial glutamate receptor, GluR0, which shares strong functional and structural homology with the mammalian glutamate receptors and is a potassium-selective channel with inverted topology compared with the mammalian glutamate receptors (Chen et al., 1999a). The permeation properties of GluA2-containing AMPA receptors and GluK1 and GluK2 kainate receptors are modified post-transcriptionally by RNA editing at the Gln codon that resides at the apex of the re-entrant M2 loop (QRN site). The glutamine within the QRN site is converted to arginine by adenosine deaminase (Sommer et al., 1991; Bass, 2002). For GluA2, the overwhelming majority of RNA is edited. AMPA or kainate receptors that contain the unedited form of GluA2 (Q) have high permeability to Ca²⁺ and are insensitive to extracellular and intracellular polyamine channel blockers, whereas AMPA receptors containing the edited form of GluA2 (R) have low Ca²⁺ permeability and are insensitive to polyamine channel blockers (see section VIII.C). It is noteworthy that the extended region of the M2 loop in the new GluA2 structure that encompasses the QRN site is disordered. It is unclear whether this reflects crystallization conditions or a native conformation, which might have significant functional consequences for ion permeation and block.

The structure of the antagonist-bound tetrameric rat GluA2 shows that the four subunits arrange their TMDs in a 4-fold axis of symmetry with the core of the ion channel (M1–M3), strikingly similar to K⁺ channels (Sobolevsky et al., 2009) (Fig. 1C). The M2 loop lines the inner cavity of the pore, whereas the M3 helices line the outer cavity, with positions at the apex tightly opposed, presumably forming the gate that occludes the flux of ions in the closed state (see sections VII and VIII). The M1 helix is positioned on the exterior of M2 and M3. It is noteworthy that the M4 segment from one subunit is associated with the ion channel core (M1-M3) of an adjacent subunit. In addition, the linker region preceding M1 (pre-M1) makes a short helix that is oriented parallel to the plane of the membrane, making contacts with carboxyl- and amino-terminal ends of transmembrane helices M3 and M4, respectively. The pre-M1s from the four subunits resemble a cuff around the external surface of the ion channel pore that could be an important determinant for channel gating (see section VII).

G. The Intracellular Carboxyl-Terminal Domain and Protein Binding Partners

The CTD is the most diverse domain in terms of amino acid sequence (Table 2), varying in sequence and in length among the glutamate receptor subunits (Figs. 5–7). It shows no sequence homology to any known proteins but encodes short docking motifs for intracellular binding proteins. No structural details exist for this domain except for part of the GluN1 CTD with bound Ca²⁺/calmodulin (Ataman et al., 2007). The CTD is thought to influence membrane targeting, stabilization, post-translational modifications (see section IV), and targeting for degradation. For some glutamate receptor subunits (e.g., GluN1, GluN2A), deletion of this domain does not abolish function but does alter regulation (Köhr and Seeburg, 1996; Ehlers et al., 1998; Krupp et al., 1998; Vissel et al., 2001), because the CTDs contain different phosphorylation sites (see section IV) and binding sites for intracellular proteins important for regulation of membrane trafficking and receptor function. Several ER retention signals reside in alternatively spliced exons of GluN1, as well as in GluN2B (Horak and Wenthold, 2009). It is noteworthy that there is also a short span of sequence immediately C-terminal to M4 in GluN2 that also participates in trafficking (Hawkins et al., 2004).

Virtually all members of the glutamate receptor family bind to a variety of intracellular proteins, which fall into several classes. Tables 3 and 4 contain comprehensive lists that summarize some of the better known
## Table 3

### Carboxyl-terminal protein binding partners for AMPA and kainate receptor subunits

Entries indicate data supporting direct interactions between the indicated protein and glutamate receptor subunit.

<table>
<thead>
<tr>
<th>Protein</th>
<th>Class</th>
<th>GluA1</th>
<th>GluA2</th>
<th>GluA3</th>
<th>GluA4</th>
<th>GluK1</th>
<th>GluK2</th>
<th>GluK3</th>
</tr>
</thead>
<tbody>
<tr>
<td>CASK</td>
<td>PDZ</td>
<td></td>
<td>Y2H, colIP, IHC&lt;sup&gt;2,3,4,5&lt;/sup&gt;</td>
<td>Y2H, colIP, IHC&lt;sup&gt;2,3,4,6&lt;/sup&gt;</td>
<td>Y2H, colIP, IHC&lt;sup&gt;7&lt;/sup&gt;</td>
<td>Y2H, colIP, EP&lt;sup&gt;6&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GRIP2</td>
<td>PDZ</td>
<td></td>
<td></td>
<td>Y2H, colIP, IHC&lt;sup&gt;4,5,7&lt;/sup&gt;</td>
<td>Y2H, colIP, IHC&lt;sup&gt;4,7&lt;/sup&gt;</td>
<td>Y2H, colIP, IHC&lt;sup&gt;7&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mLIN-10</td>
<td>PDZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PICK1</td>
<td>PDZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, colIP, IHC&lt;sup&gt;2,6&lt;/sup&gt;</td>
<td>Y2H, colIP, IHC&lt;sup&gt;2,6&lt;/sup&gt;</td>
<td>Y2H, colIP, EP&lt;sup&gt;6&lt;/sup&gt;</td>
</tr>
<tr>
<td>FSD95</td>
<td>PDZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SAP97</td>
<td>PDZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SAP102</td>
<td>PDZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shank3</td>
<td>PDZ</td>
<td></td>
<td>Y2H, colIP, IHC&lt;sup&gt;13&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Syntentin</td>
<td>PDZ</td>
<td></td>
<td>Y2H&lt;sup&gt;14&lt;/sup&gt;</td>
<td></td>
<td>Y2H&lt;sup&gt;14&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RIL</td>
<td>PDZ/LIM</td>
<td>Y2H, colIP, IHC, EP&lt;sup&gt;15&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>α-Actinin-1</td>
<td>Cytoskeletal</td>
<td>Y2H, colIP, IHC&lt;sup&gt;16&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actinin</td>
<td>Cytoskeletal</td>
<td></td>
<td></td>
<td>Y2H, colIP, IHC&lt;sup&gt;18&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contactin</td>
<td>Cytoskeletal</td>
<td></td>
<td></td>
<td>Y2H, colIP, IHC&lt;sup&gt;18&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dynamin-1</td>
<td>Cytoskeletal</td>
<td></td>
<td></td>
<td>Y2H, colIP, IHC&lt;sup&gt;20&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Profilin</td>
<td>Scaffold</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spectrin</td>
<td>Scaffold</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AP2</td>
<td>Adaptor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, colIP, IHC&lt;sup&gt;19&lt;/sup&gt;</td>
</tr>
<tr>
<td>NSF</td>
<td>ATPase</td>
<td></td>
<td>Y2H, colIP, IHC, EP&lt;sup&gt;23,24,25,26&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IQGAP1</td>
<td>GTPase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calmodulin</td>
<td>Ca&lt;sup&gt;2+&lt;/sup&gt; sensor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VILIP1</td>
<td>Ca&lt;sup&gt;2+&lt;/sup&gt; sensor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VILIP3</td>
<td>Ca&lt;sup&gt;2+&lt;/sup&gt; sensor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H4-3-3</td>
<td>Other&lt;sup&gt;22&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPI</td>
<td>Other&lt;sup&gt;22&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G-(a/11)</td>
<td>Other&lt;sup&gt;22&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SUMO</td>
<td>Other&lt;sup&gt;22&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, colIP, IHC, EP&lt;sup&gt;30&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Y2H, yeast two-hybrid; colIP, coimmunoprecipitation or pull-down assay; EP, electrophysiology; IHC, immunohistochemistry.

TABLE 4
Carboxyl-terminal protein binding partners for NMDA and delta receptor subunits

Entries indicate data supporting direct interactions between the indicated protein and glutamate receptor subunit.

<table>
<thead>
<tr>
<th>Protein</th>
<th>GluN1</th>
<th>GluN1</th>
<th>GluN2A</th>
<th>GluN2B</th>
<th>GluN2C,D</th>
<th>GluN3A</th>
<th>GluD1</th>
<th>GluD2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delphilin</td>
<td>PDZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIN7</td>
<td>PDZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, IHC1</td>
<td></td>
</tr>
<tr>
<td>nPIST</td>
<td>PDZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PICOIK1</td>
<td>PDZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSD83</td>
<td>PDZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSD95</td>
<td>PDZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, IHC2</td>
</tr>
<tr>
<td>SAP97</td>
<td>PDZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, IHC5</td>
</tr>
<tr>
<td>SAP102</td>
<td>PDZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, IHC8</td>
</tr>
<tr>
<td>Shank1</td>
<td>PDZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, IHC10</td>
</tr>
<tr>
<td>Shank2</td>
<td>PDZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, IHC10</td>
</tr>
<tr>
<td>S-SCAM</td>
<td>PDZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, IHC12</td>
</tr>
<tr>
<td>α-actinin-2</td>
<td>Cytoskeletal</td>
<td>Y2H, coIP, IHC</td>
<td>Y2H, coIP, IHC</td>
<td>Y2H, coIP, IHC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EMAP</td>
<td>Cytoskeletal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, IHC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAP15</td>
<td>Cytoskeletal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, IHC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plectin</td>
<td>Scaffold</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, IHC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RACK1</td>
<td>Scaffold</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, IHC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPECTrin</td>
<td>Scaffold</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, IHC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AP2</td>
<td>Adaptor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, IHC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AP4</td>
<td>Adaptor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, IHC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PACSIN1</td>
<td>Adaptor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, IHC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calmodulin</td>
<td>Ca²⁺ sensor</td>
<td>coIP, EP</td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, EP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CARP1</td>
<td>Other²⁵</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, EP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COFI</td>
<td>Other²⁵</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, EP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GIP2</td>
<td>Other²⁵</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, EP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SALM1</td>
<td>Other²⁵</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y2H, coIP, EP</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

coIP, coimmunoprecipitation or pull-down assay; EP, electrophysiology; IHC, immunohistochemistry; Y2H, yeast two-hybrid.

interactions between glutamate receptor C-terminal and PDZ, cytoskeletal, scaffolding, adaptor, anchoring, structural, signaling, and other proteins. In addition to these interactions, several glutamate receptor subunits bind directly to signaling proteins, including GluA1 and cGMP-dependent protein kinase II (Serulle et al., 2007), GluA4 and PKC (Correia et al., 2003), multiple NMDA receptor subunits and Ca2+/calmodulin-dependent protein kinase (CamK) II (Gardoni et al., 1998; Strack and Colbran, 1998; Leonard et al., 1999, 2002), as well as tyrosine phosphatase and GluD2 (Hironaka et al., 2000). These interactions allow local signaling to proceed, providing the possibility of spatial and temporal specificity to receptor regulation. Additional localization of signaling molecules can be mediated by adjacent proteins, and the glutamate receptors are embedded into a rich complex of signaling molecules that are localized by a myriad of adaptor and scaffolding proteins within the post synaptic density (Husi et al., 2000). Further enhancing the complexity among different subunits, alternative RNA splicing of several AMPA and kainate receptor subunits as well as the NMDA receptor subunit GluN1 causes variation in the CTD that also will affect binding sites for intracellular proteins.

H. Transmembrane α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptor Regulatory Proteins and other Auxiliary Subunits

A confound in the study of AMPA receptor biophysical properties has been the occasional lack of congruence between the properties of recombinant receptors expressed in heterologous systems and those of native receptors studied in isolated tissue. This mismatch suggests that heterologously expressed receptors lack a modulatory component that can influence essential properties. The discovery of the interaction between AMPA receptor subunits and the transmembrane AMPA receptor regulatory proteins (TARPs) has solved many of these discrepancies. TARPs are integral membrane proteins with four transmembrane domains (Letts et al., 1998; Hashimoto et al., 1999; Chen et al., 2000; Tomita et al., 2003; Coombs and Cull-Candy, 2009) that selectively interact with AMPA receptors early in synthesis and trafficking and direct proper expression and localization of the receptor at the cell surface (Hashimoto et al., 1999; Chen et al., 2000; Schnell et al., 2002; Tomita et al., 2004, 2005a; Vandenberghe et al., 2005). TARPs are present in the majority of AMPA receptor complexes in the brain, suggesting that TARPs are auxiliary subunits for native AMPA receptors (Fukata et al., 2005; Nakagawa et al., 2005, 2006; Vandenberghe et al., 2005). It has been suggested that two or four TARPs can associate with the AMPA receptor tetramer, depending on availability (Vandenberghe et al., 2005; Milstein et al., 2007; Shi et al., 2009). The interaction sites between TARPs and AMPA receptors involve intracellular, transmembrane, and extracellular regions of both proteins (Tomita et al., 2005a, 2007; Bedoukian et al., 2006; Milstein and Nicoll, 2009; Sager et al., 2009).

The classic members of TARPs, γ-2, γ-3, γ-4, and γ-8, interact with all four AMPA receptor subunits. The prototypical TARP (γ-2 or stargazin) originally was identified in the cerebellum as a protein essential for delivery of AMPA receptors to the plasma membrane (Letts et al., 1998; Chen et al., 2000). The functional properties of AMPA receptors associated with the TARP subtypes γ-2, γ-3, γ-4, and γ-8 are different from those of AMPA receptors devoid of auxiliary subunits. In addition to their trafficking capabilities, TARPs increase single channel conductance, increase open probability, increase the activation rate, slow the deactivation time course, and reduce desensitization (Yamazaki et al., 2004; Priel et al., 2005; Tomita et al., 2005a; Turetsky et al., 2005; Zhang et al., 2006b; Kato et al., 2007; Soto et al., 2007, 2009). Prolonged activation of AMPA receptors triggers a form of desensitization that results from dissociation of the TARP, potentially providing a novel mechanism for receptor tuning (Morimoto-Tomita et al., 2009). Finally, γ-2 reduces GluA2-lacking AMPA receptor affinity for polyamine block, resulting in receptors with weak inward-rectification (Soto et al., 2007).

The TARP γ-5 increases glutamate potency and glutamate-evoked peak currents, reduces steady-state currents, and accelerates the time course of deactivation and desensitization only in GluA2-containing receptors, but this modulation does not involve regulation of GluA2 surface expression (Kato et al., 2008). The TARP γ-7 shares many of these properties but is not selective for receptors comprising GluA2-containing subunits, enhancing peak currents in channels containing GluA1 or GluA2 (Kato et al., 2007). In contrast, other studies show that γ-5 interacts with all AMPA receptor subunits and modifies their behavior (Soto et al., 2009).

Proteins with homology to TARP (STG-1 and STG-2) and with similar functional roles have been discovered in Caenorhabditis elegans, Apis mellifera, and Drosophila melanogaster (Walker et al., 2006a; Wang et al., 2008). However, an important difference between TARPs and STG-1 and STG-2 is the obligatory requirement of an additional transmembrane auxiliary subunit (SOL-1) that is structurally unrelated to TARPs and interacts directly with invertebrate AMPA receptor subunits (GLR-1 and GLR-2) to slow and reduce the extent of receptor desensitization (Zheng et al., 2006; Walker et al., 2006a,b).

Another distinct class of transmembrane proteins has been shown to associate with and regulate AMPA receptors (Schwenk et al., 2009). These proteins, CNIH-2 and CNIH-3, are members of the mammalian CNIH family and are homologous to the cornichon proteins from flies and yeast (Roth et al., 1995; Bökel et al., 2006; Castro et al., 2007). CNIH proteins are necessary for the export of a number of proteins from the endoplasmic reticulum, including the epidermal growth factor receptor ligands.
The role of the CNIIH proteins in AMPA receptor regulation is not yet fully understood.

Accessory proteins for NMDA and kainate receptors have also recently been described. Neto1 possesses a single transmembrane domain containing two complement C1r/C1s, Uegf, Bmp1 domains and is a component of the NMDA receptor complex (Ng et al., 2009). Neto1 interacts with an extracellular domain of GluN2 as well as through an intracellular interaction with PSD95. Loss of Neto1 in transgenic mice preferentially results in a loss of synaptic GluN2A expression, with only a modest impact on GluN2B expression, which leads to impaired hippocampal LTP and hippocampal-dependent learning and memory (Ng et al., 2009). A second C1r/C1s, Uegf, Bmp1 domain-containing protein, Neto2, interacts with GluK2 to increase peak amplitude and open probability and to slow the decay time course of both GluK2 recombinant receptors and kainate receptor-mediated mEPSCs in cerebellar granule cells (Zhang et al., 2009c). In recombinant expression systems, Neto2 had no impact on GluK2 surface expression.

III. Regulation of Transcription and Translation

The level of expressed glutamate receptors reflects a balance of transcription, translation, mRNA level, protein stability, receptor assembly, and presentation at the cell surface, all of which are integrated through numerous environmental stimuli. Therefore, the particular subunits that each neuron chooses to express are strong determinants of synaptic phenotype, and this is the rationale for understanding how the genetic cis elements and trans factors regulate gene transcription in neural cells. Over the past decade steady work toward understanding the control of ionotropic glutamate expression in neuronal and non-neuronal cells has occurred, roughly doubling the number of subunits studied and the identification of promoter elements controlling expression in neuronal cells. Furthermore, how chromatin remodeling affects glutamate receptor expression in both neurons and non-neuronal cells has been identified after, for example, status epilepticus or transient ischemia. Most studies have employed a combination of protein-DNA binding assays with functional analysis of native and mutant promoter constructs driving a reporter gene, overexpression of candidate transcription factors in cultured cells or in vivo, occupancy of cis elements by transcription factors in vivo using chromatin immunoprecipitation (ChIP) assays, and the use of real-time quantitative polymerase chain reaction experiments. The use of ChIP assays and real-time quantitative polymerase chain reaction on endogenous gene transcripts (and also on exogenously expressed constructs) have been particularly fruitful in helping to advance our understanding of how an acute stimulus causes a change in transcript level dependent on candidate promoter elements and trans-acting factors. Studies such as these have begun to tie neuronal activity, energy metabolism, and glutamate receptor expression together more coherently. Furthermore, an appreciation for the role of epigenetic modifications and chromatin remodeling at glutamate receptor promoters is also emerging and holds promise for new understanding of the neurobiology of glutamate receptors. Despite this progress, vexing questions still remain regarding the mechanisms that control cell-specific and developmental expression for glutamate receptor subunits.

Glutamate receptor genes have a number of features in common, such as multiple transcriptional start sites in a TATAA-less promoter with high GC content. The 5′UTR ranges between 200 bp (Gria1) to over 1200 bp (Grin2a) and, in the case of Gria4, Grik5, Grin2a, Grin2b, and Grin2c, is formed from multiple exons. Finally, one or more Sp1 elements reside near the major transcriptional start site of all genes studied, several glutamate receptor promoters contain NFκB, CRE, AP1/2, Tbr-1, NRF-1, and RE1/NRSE sites, and gene expression of many is responsive to neuronal activity. The schematic organization of the promoter regions is presented in Fig. 4. It also should be noted that NMDA, AMPA, and kainate receptors are key mediators of signal transduction events that convert environmental stimuli into genetic changes through regulation of gene transcription and epigenetic chromatin remodeling in neural cells, an area of emerging interest (Carrasco and Hidalgo, 2006; Wang et al., 2007; Cohen and Greenberg, 2008; Lubin et al., 2008).

A. α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors

1. Gria1. The rat Gria1 gene has been evaluated for transcriptional initiation and regulation of promoter function by transfection of constructs into primary mixed neuronal cultures. Gria1 promoter activity was stronger in neurons, neuronal specificity being primarily dependent on sequences lying within the regions −1395 to −743 and −253 to −48. Although five CRE sites were able to bind recombinant CRE binding-bZIP proteins, conditions under which these CRE sites come into play in native neurons are unknown. GluA1 receptors (like all AMPA receptor subunits) are expressed by neurons and glial cells in vivo and in vitro (Gallo and Ghiani, 2000), but the density of functional receptors is much lower in astrocytes than neurons. In oligodendrocyte progenitor O-2A cells, the transcriptional rate of GluA1 is increased by platelet-derived growth factor and basic fibroblast growth factor (Chew et al., 1997). Regulation of Gria1 transcription occurs via acid sphingomyelinase and NFκB sites in the Gria1 promoter (Borges and Dingledine, 2001), which was found to both account for the elevation of GluA1 by tumor necrosis factor-α (Yu et al., 2002) and contribute to the sensitization by tumor necrosis factor-α of NT2-N cells to kainate-induced cell death.
2. **Gria2.** The relative use of 5′ transcriptional start sites in Gria2 is different in cortex and cerebellum, longer transcripts being more dominant in cerebellum (Myers et al., 1998). Analysis of Gria2 promoter constructs in cultured forebrain neurons and glia revealed that the Gria2 promoter was 30-fold neuronal selective. In this study, Sp1 and NRF-1 positive regulatory elements, nestled at the 5′ end of a 141-bp transcription initiation region, and an RE1/NRSE proximal promoter silencer element were important for neuron-selective expression. The RE1/NRSE repressed expression 2- to 3-fold in non-neuronal cells compared with neuronal cells (Myers et al., 1998). Suppression of GluA2 expression in glia occurs by occupancy of the Gria2 RE1/NRSE element by the REST/NRSF repressor, which in turn recruits histone deacetylase (HDAC) complexes to the Gria2 promoter, resulting in chromatin remodeling and decreased expression (Huang et al., 1999). In neurons, the Gria2 promoter is associated with acetylated H3 and H4 histones, whereas in C6 glioma cells, there is little to no association with acetylated histones, consistent with active and inactive gene expression, respectively (Huang et al., 1999). After induction of status epilepticus by pilocarpine, the acetylation of histone H4 bound to the Gria2 promoter was reduced before GluA2 expression became down-regulated in rat hippocampal CA3 neurons. Seizure-induced GluA2 mRNA down-regulation was reversed by the HDAC inhibitor trichostatin A (Huang et al., 2002a). Likewise, Calderone et al. (2003) showed that global ischemia triggers expression of the repressor REST and reduces GluA2 expression in CA1 neurons destined to die. Moreover, kainate reduces activity of the neuronal Gria2 promoter in a manner consistent with REST occupancy of the RE1 element, recruitment of HDAC to the promoter, and reduced histone acetylation (Jia et al., 2006). It is noteworthy that a preconditioning sublethal ischemic episode can prevent subsequent ischemia-induced down-regulation of GluA2 in CA1 neurons (Tanaka et al., 2002) by preventing an increase in REST expression in these same neurons (Calderone et al., 2003).

TTX reduces GluA2 expression in visual cortical neurons, suggesting that expression is linked to neuronal activity (Wong-Riley and Jacobs 2002; Bai and Wong-Riley 2003). The transcription factor NRF-1 binds to the Gria2 promoter (Dhar et al., 2009), confirming earlier studies identifying the NRF-1 element as a critical feature for neuronal Gria2 transcription (Myers et al., 1998). NRF-1 is a nuclear transcription factor important for regulating multiple cytochrome oxidase (COX) genes.

**Fig. 4.** Schematic diagram of the proximal promoter regulatory regions of glutamate receptors. The proximal promoter regions of the GluN1, GluN2A, GluN2B, and GluN2C NMDA receptors, the GluA1 and GluA2 AMPA receptors, and the GluK5 kainate receptor are shown. Promoters are shown as thin lines and introns as thin lines with hashmarks. The 5′-untranslated exon sequences are represented by open bars; blackened bars designate the protein coding domains. Glutamate receptor regulatory elements are identified; those requiring further confirmation are in parentheses. The promoter regions are not drawn to scale.
Reduction of NRF-1 with small hairpin RNA prevented the depolarization-stimulated increase of GluA2 expression, whereas overexpression of NRF-1 restored GluA2 expression in the face of TTX treatment. Changes in GluA1, GluA3, and GluA4 expression were not observed, rendering NRF-1 control specific to GluA2 (Dhar et al., 2009). Thus, neuronal activity is tightly coupled at the molecular level to GluA2 expression by a process that involves NRF-1.

3. Gria3 and Gria4. The human GRIA3 gene is on the long arm of the X chromosome and is subject to X inactivation through methylation (Gécz et al., 1999). The Gria3 transcript contains a TC repeat in the 5′-UTR that is polymorphic and is also present in rodent transcripts. The 5′-UTR and ATG codon are contained in a large 1102-bp exon 1 and are conserved in rodent and human sequences. Neither an RE1 repressor element nor an NRF-1 site was identified.

GluA4 is widely expressed in brain; however, its abundance is less than GluA1–3 (Petralia and Wenthold, 1992). In transfected mixed cortical cultures, Gria4 promoter constructs drove luciferase expression predominantly in neurons, indicating a 6- to 12-fold neuronal preference (Borges et al., 2003). Deletion of the Gria4 transcriptional initiation region decreased luciferase activity in neurons, but increased activity in C6 cells, suggesting that neuronal regulatory elements reside in this region. Sp1, Ikaros, and basic helix-loop-helix binding element sites are conserved in rat, mouse, and human genes within ±150 bp of transcription initiation sites; however, specific evaluation of these elements requires further investigation. A distal region of Gria4, −4427 to −4885, is in a long interspersed element sequence that has been suggested to recruit chromatin remodeling enzymes to the Gria4 gene (Borges et al., 2003).

B. Kainate Receptors Grik1 to Grik5

Regulatory cis elements have been computationally predicted in promoter regions of human GRIK1 and GRIK2 genes but not functionally evaluated (Barbon and Barlati, 2000; Barbon et al., 2001). However, GRIK2 was identified as a novel epigenetic target in gastric cancer as a potential tumor suppressor gene (Wu et al., 2010). There are no reports on the functional evaluation of transcriptional regulation of the Grik3 and Grik4 genes.

Initial studies of the rat Grik5 gene identified a negative regulatory sequence in the first intron that binds nuclear orphan receptors such as chicken ovalbumin upstream promoter transcription factor I in both neural and non-neural cells (Huang and Gallo, 1997; Chew et al., 1999). Transgenic mouse lines carrying 4 kb of the 5′-flanking sequence showed lacZ reporter expression predominantly in the nervous system. Reporter assays in central glial (CG-4) and non-neural cells indicated that a 1200-bp 5′-flanking region could sustain neural cell-specific promoter activity (Chew et al., 2001). Sp1 binding suggests a functional role for Sp1 in initiator-mediated activation of Grik5 transcription that involves transcription factor II D-mediated basal activity (Chew et al., 2001). Removal of two putative AP2 sequences reduced promoter activity in both neural and non-neural cells, suggesting that these sites are also important for basal transcription. Furthermore, a 77-bp sequence termed the kainate cell-specific enhancer region, involved in cell-specific expression, includes a functional Sp1 site that when placed downstream of the Grik5 promoter, silenced reporter expression in NIH3T3 fibroblasts and attenuated activity in CG-4 cells. These studies show that elements contributing to tissue-specific expression are contained within the first exon (Chew et al., 2001).

C. N-Methyl-D-aspartate Receptors

1. Grin1. Rat, human, and chicken Grin1 promoter regions have been cloned and characterized (Bai and Kusiak, 1993, 1995; Zimmer et al., 1995; Moreno-González et al., 2008). Transcription of the Grin1 gene is controlled by both positive and negative regulatory elements. A consensus RE1/NRSF silencer in exon1 contributes to neuronal-specific expression (Bai et al., 1998, Okamoto et al., 1999). Ablation of the RE1/NRSF site elevated GluN1 expression in non-neural cell lines and undifferentiated P19 cells (Bai et al., 1998, 2003; Okamoto et al., 1999, 2002). Likewise, during differentiation of P19 cells, REST/NRSF is down-regulated, resulting in de-repression of the Grin1 promoter (Okamoto et al., 1999). De-repression of the Grin1 promoter by absence of REST/NRSF occurs before subsequent expression of positive acting trans factors required for full Grin1 promoter activity (Bai et al., 2003). A 27-bp GC-rich region (GC-box) proximal to the transcription start sites has been identified that controls induction of the Grin1 gene upon differentiation of P19 cells, and this site is recognized by Sp1 and myc-associated zinc finger protein transcription factors (Okamoto et al., 2002). These sites previously were known to respond to Sp1, -3, and -4 transcription factors (Bai and Kusiak, 1995, 1997; Bai et al., 1998; Liu et al., 2001) and interact with an element further 5′ in the promoter (−520/−529) that is recognized by myocyte enhancer factor 2C (Kraine et al., 1998). Studies with Grin1 promoter constructs in PC12 cells suggest that NGF uses both the Ras/extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase pathways to up-regulate Grin1 promoter activity through Sp1 (Liu et al., 2001). Activation of serum glucocorticoid kinase 1, a downstream target of phosphatidylinositol 3-kinase, increases Grin1 promoter activity in PC12 cells and hippocampal neurons in an NFkB-independent manner (Tai et al., 2009). This finding is consistent with a previous report that the Sp-related factors regulate Grin1 promoter activity through occupancy of a putative NFkB consensus element −3 kb.
upstream of the GC box in neurons and in cell lines (Liu et al., 2004a).

AP1 protein complexes containing ΔFosB bind the rat Grin1 promoter at the AP1 consensus element, and AP1 binding is up-regulated after electroconvulsive shocks. Furthermore, an increase in Fos-like immunoreactivity was observed in the same cortical neurons that showed an increase in GluN1 immunoreactivity. Accordingly, up-regulation of GluN1 did not occur after seizures in fosB(−/−) mice (Hiroi et al., 1998).

GluN1 expression might be coupled to energy metabolism based on evidence that both the Grin1 and mitochondrial COX genes are under control of the NRF-1 transcription factor via binding elements in their respective proximal promoter regions (Dhar et al., 2008, Dhar and Wong-Riley, 2009). Grin1 and Grin2b, but not Grin2a or Grin3a, are positively regulated by the NRF-1 transcription factor through NRF-1 promoter elements. Furthermore, control of Grin1 and Grin2b by NRF-1 was activity-dependent. KCl up-regulated and TTX down-regulated expression in cultured rat cortical neurons, and NRF-1 itself is up-regulated at both protein and mRNA levels by depolarization (Yang et al., 2006; Dhar and Wong-Riley, 2009). Thus, NRF-1 is an essential transcription factor in the coregulation of Grin1, Grin2b, Gria2, and COX genes, coupling coordinated expression of glutamate receptors and energy metabolism at the transcriptional level (Wong-Riley et al., 1998a,b; Dhar et al., 2008, 2009; Dhar and Wong-Riley, 2009).

A nonpalindromic T-box element in the Grin1 promoter is likely to be recognized and regulated by Tbr-1/CASK protein complexes in vivo because GluN1 expression was reduced in Tbr-1(−/−) (T-brain-1) mice by ~50% (Wang et al., 2004b). Tbr-1 is a neuron-specific T-box factor (Hsueh et al., 2000) that may play a role in neurogenesis and induction of GluN1. GluN1 expression is subject to control by hypoxia-inducible factors that function under stress conditions, especially during hypoxia (Yeh et al., 2008). Based on GluN1 up-regulation after lipopolysaccharide injection into the prefrontal cortex and in cultured neurons, the predicted cis hypoxia response elements were localized within the Grin1 promoter. However, 1 h of ischemia produced by middle cerebral artery occlusion decreased GluN1 (Gascón et al., 2005), possibly as a result of activation of the RE1 silencer (Fig. 4).

2. Grin2a. Regulation of the rat Grin2a promoter was explored with a series of 3′- and 5′-truncated constructs in primary neurons, primary glia, and non-neuronal cell lines (Desai et al., 2002; Richter et al., 2002; Liu et al., 2003). The core promoter resides in exon 1, prefers neurons but also requires downstream sequences for full activity, and does not use a consensus TATA box. On the basis of overexpression studies and gel shift assays in stable cell lines, three GC-boxes (A, B, and C) seem to regulate Sp1 and Sp4 but not Sp3 trans-activation (Liu et al., 2003).

Two regions of the mouse Grin2a promoter, from −9.2kb/−210 or −1253/−210, were able to confer nervous system expression of a transgene reporter. Based on primary cultures prepared from a −9.2kb/−210 Grin2a luciferase mouse, there was ~700-fold selective expression in neuronal enriched cultures compared with glial cultures. Two RE1/NRSE-like sequences that contain key mismatches in the consensus sequences were identified at −989 and −427 and do not seem to act as silencers of the Grin2a gene. Thus, neuronal specificity for GluN2A expression seems to result from transcriptional activation selectively in neurons rather than by non-neuronal silencing. Furthermore, three regions were identified (~1253/−1079, −486/−447, 8 kb 5′ of −1253) that are important for maximal neuron-selective expression. Sequences between −9.2 kb and −1253 bp contribute to the maturational increase of Grin2a expression in cultured neurons and elements residing between −1253 and −1180 bp are crucial for this up-regulation (Desai et al., 2002).

Two NFκB sites were identified in the Grin2a promoter, which, when removed by mutation, resulted in loss of modification of transactivation by constitutively active SGK (SGK-S422D) that activates NFκB (Tai et al., 2009). Furthermore, the transactivation of a Grin2a construct was sensitive to the NFκB inhibitor peptide SN50 (Lin et al., 1995). A putative CRE element variant found in numerous promoters was identified at −1195 in mouse and −1215 in rat and raises interest in activity-dependent elevation of Grin2a in vivo. The putative CRE site resides in a region important for positive neuronal expression in both rat and mouse promoters (Desai et al., 2002; Richter et al., 2002; Liu et al., 2003).

3. Grin2b. Initial promoter analysis using transgene constructs in mice (Sasner and Buonanno, 1996) revealed that the proximal promoter region and exon 1 (~550+/255 relative to the 5′-most transcription site) were sufficient to restrict tissue specificity to brain. However, inclusion of intron 1 and exon 2 in the transgene (~550+/1627) were required both to restrict expression to brain and to recapitulate the proper developmental profile of GluN2B expression in cerebellar granule cells. The presence of an RE1/NRSE-like element at the end of exon 1 was not responsible for conferring neural-selective expression in the mouse transgenes (Sasner and Buonanno, 1996). Of several putative RE1/NRSE elements in the more distal Grin2b promoter, the −2029/−2049 NRSE element bound REST/NRSF and repressed expression of Grin2b reporter constructs transfected into cultured neurons. Moreover, ethanol treatment of cortical cultures reduced REST/NRSF expression, resulting in GluN2B derepression (Qiang et al., 2005). Analysis of the Grin2b promoter identified Sp1 and CRE elements (Klein et al., 1998), and the CRE site was later confirmed to bind to phosho-CREB in a gel-shift assay. Mutation of the CRE motif in the Grin2b promoter region significantly de-
increased promoter activity in transfected cortical cells and also abolished ethanol-induced increase in promoter activity (Rani et al., 2005). Likewise, an AP-1 site was active in cultured neurons and responsive to ethanol treatment (Qiang and Ticku, 2005). Furthermore, it was found that long-term ethanol exposure promoted demethylation of CpG islands in the Grin2b promoter region that could result in up-regulation of the gene in mouse cortical neurons (Ravindran and Ticku, 2005).

Two nonpalindromic T-box elements in the Grin2b promoter were identified that are conserved across rat, human, and mouse (Wang et al., 2004b), and these elements are recognized by the Tbr-1 protein (Wang et al., 2004b). Functional and mutational studies in rat hippocampal cultures showed that overexpression of Tbr-1 alone and in combination with CASK elevated promoter-driven luciferase activity by up to 120-fold dependent on each T-box element with the upstream T-box element dominant. Recognition of the Grin2b T-box elements by a Tbr-1–CASK complex in vivo was demonstrated by ChIP analysis using rat hippocampal cultured neurons (Wang et al., 2004a). In Tbr-1–null mice, GluN2B expression was decreased up to 60%, and GluN2B expression was down-regulated in brain regions where Tbr-1 immunoreactivity was lost in the mutant mice. These two T-box elements reside within the minimal transgene construct sufficient for neuron-specific expression of the Grin2b gene (Sasner and Buonanno, 1996). A point mutation in CASK that disrupts CASK–Tbr-1–CASK-interacting nucleosome assembly protein complexes down-regulates Grin2b promoter activity (Huang and Hsueh, 2009). CASK interacts with transcription factor Tbr-1 and CASK-interacting nucleosome assembly protein–cell division autoantigen-1–differentially expressed nucleolar transforming growth factor-β1 target in the nuclei of neurons, which may remodel the chromatin structure flanking Tbr-1 binding sites (Hsueh et al., 2000; Wang et al., 2004a).

As shown for the Grin2a promoter, activation of serum glucocorticoid kinase 1 pathway elevates Grin2b gene expression in hippocampal neurons and Neuro2A cells in an NFκB-dependent manner. The site of NFκB binding in the Grin2b promoter was not specifically identified but was proposed to reside between −1480 and −2020 bp from the rat transcription start site (Tai et al., 2009).

Stimulation of cortical cultures with bicusculine elevated GluN2B expression in a transcription- and calcineurin-dependent manner (Qiu and Ghosh, 2008) and revealed association of the Grin2b promoter with CREST, brahma-related gene 1, CRE binding protein, and HDAC-1. Bicusculine stimulation increased CRE binding protein, decreased HDAC1, and increased the association of the Grin2b promoter with acetylated histones. The increase in GluN2B expression also required NMDA receptor activation and was shown to depend on CREST in vivo because a bicusculine-induced increase in GluN2B expression was absent in CREST-null neurons. These findings suggest that the activity-dependent increase in GluN2B expression involves a switch from a repressor to activator complex and requires CREST function that may involve CRE and Sp1 sites in the promoter in a manner similar to regulation of the immediate early gene c-fos.

Evidence for the coupling of GluN2B expression to energy metabolism has also been described through a series of electrophoretic mobility shift assay, supershift, and ChIP assays and promoter mutations (Yang et al., 2006; Dhar et al., 2009). GluN2B was shown to be regulated in cultured neurons by NRF-1 transcription factor via an NRF-1 element in the proximal promoter region. GluN1, GluN2B, and NRF-1 transcripts are up-regulated by KCl and down-regulated by TTX in cultured primary neurons. Thus, NRF-1 coordinates the coregulation of Grin1, Grin2b, and COX genes (Dhar et al., 2008; Dhar and Wong-Riley, 2009).

4. Grin2c, Grin2d, Grin3a, and Grin3b. Elements within Grin2c exon 1 and intron 1 in transgenic mouse lines selectively drive expression of β-galactosidase in cerebellar granule cells (Suchanek et al., 1995, 1997). This region contains a consensus RE1/NRSE silencer, but the role of this element has not been fully evaluated. Furthermore, Sp1 and COUP-TF consensus elements (Nagasawa et al., 1996; Pieri et al., 1999) bound Sp1 and fushi tarazu factor 1/COUP-TF protein in gel shift assays, but mutations did not modify promoter function in a transfected neuronal cell line (Pieri et al., 1999). The COUP-TF site seems to require other elements for function. Coexpression of steroiogenic factor-1 elevated Grin2c promoter activity modestly in a neuronal cell line dependent on a promoter region centered −250 from transcription + 1 site (Pieri et al., 1999); however, direct expression in neurons was not examined.

The developmental up-regulation of GluN2C in the adult cerebellum upon innervation of mossy fibers onto granule cells has been reported to be due to neuregulin-β (Ozaki et al., 1997). Neuregulin-β potently up-regulated GluN2C with no change in GluN2B expression in cultured mouse cerebellar slices; up-regulation was sensitive to block by TTX or the NMDA antagonist 2-amino-5-phosphonopentanoate, suggesting that synthaptically activated NMDA receptors are involved (Ozaki et al., 1997). Activity regulates GluN2B expression in cerebellar granule cells (Vallano et al., 1996), and both GluN2B and GluN2C in organotypic cultures (Audinat et al., 1994), although the stimulatory effect of neuregulin-β on GluN2C was not recapitulated in cultures of dissociated granule cells (Rieff et al., 1999). For granule cells cultured in low (5 mM) KCl, BDNF up-regulated GluN2C mRNA via the tyrosine kinase receptor ERK1/2 cascade, whereas under 25 mM KCl, depolarization stimulated Ca2+ entry through voltage-sensitive Ca2+ channels and activated Ca2+/calmodulin-dependent calcineurin phosphatase, which opposed GluN2C mRNA up-regulation.
(Suzuki et al., 2005). However, the depolarization-induced Ca\(^{2+}\) increases simultaneously up-regulated BDNF mRNA via CaMK. Thus, convergent mechanisms of the BDNF and Ca\(^{2+}\) signaling cascades are important for GluN2C induction in granule cells during development (Suzuki et al., 2005). NMDA receptor activation was shown to coordinate both the up-regulation of GluN2C and the down-regulation of GluN2B mRNA, including a switch of GluN2 subunit associated with cell surface NMDA receptors in cultured mouse granule cells (Iijima et al., 2008). Although much has been learned about the signal transduction pathways leading to receptor subunit changes in granule cells, the promoter control elements responsible for transcription subunit switching remain to be identified.

In the human GRIN2D gene, the 3′-UTR contains four half-palindromic estrogen responsive elements within a 0.2-kb region that are highly preserved in the rat, suggesting that the GluN2D subunit may be up-regulated in vivo via neuroendocrine control. In ovariectionized rats, up-regulation of GluN2D mRNA in the hypothalamus upon 17β-estradiol treatment was observed (Watanabe et al., 1999), and the Grin2d half-palindromic estrogen responsive elements, placed in a 5′ or 3′-UTR position in a chloramphenicol acetyltransferase promoter construct, were responsive to estrogen and thyroid hormone exposure in an orientation- and hormone receptor-dependent manner (Watanabe et al., 1999; Vaseudevan et al., 2002).

The amino acid sequences and expression profile for Grin3a and Grin3b have been reported (Ciabarra et al., 1995; Sucher et al., 1995; Andersson et al., 2001; Nishi et al., 2001; Chatterton et al., 2002; Eriksson et al., 2002; Matsuda et al., 2002; Bendel et al., 2005). Studies describing control of transcription with respect to cis regulatory elements and trans factors have not been reported.

D. Translational Control of Glutamate Receptors

The translation of mRNA to protein is regulated by mechanisms that control 5′ capping, 3′ polyadenylation, splicing, RNA editing, mRNA transport, stability, and initiation and elongation (VanDongen and VanDongen, 2004; Coyle, 2009). The 5′-UTR of most glutamate receptor mRNAs is unusually long. These long 5′-UTRs often exhibit stretches of high GC content and sometimes contain multiple out-of-frame AUG codons that could act as decoys for scanning ribosomes, reducing or preventing translation initiation at the true glutamate receptor AUG (Myers et al., 1999; VanDongen and VanDongen, 2004). Translational suppression has been inferred for GluN1 mRNA natively expressed in PC12 cells because no GluN1 protein can be detected despite a moderately high mRNA level (Sucher et al., 1993). On the basis of that study (Sucher et al., 1993), it was proposed that translation of GluN1 message may be suppressed, perhaps by an unidentified motif in the 5′- or 3′-UTR. Two pools of GluN1 mRNA with different translational activities have been identified in neonate and adult brain, further implicating potential translation control mechanisms at work in neurons (Awobuluyi et al., 2003). Whether GluN1 translation rate was determined by alternative 3′UTRs was not explored. Visual deprivation in juvenile mice reduced the GluN2A/GluN2B ratio in the deprived cortex with the finding that translation of GluN2B is probably a major regulatory mechanism (Chen and Bear, 2007).

The efficiency of translation of another subunit, GluN2A, also depends upon features of the 5′-UTR. Here, in both in vitro translation in rabbit reticulocyte lysate and the X. laevis oocyte expression system, removal of most of the 282 bases of the 5′-UTR from the cDNA increased GluN1/GluN2A protein expression by more than 100-fold. Mutation of three of the five upstream AUG codons modestly increased translation; however, disruption of a proposed GC-rich stem-loop structure 170 bases upstream of the AUG increased GluN2A translation by 40-fold (Wood et al., 1996). Translation suppression of GluN2A transcripts in vivo is one interpretation of the finding that high GluN2A mRNA levels were measured in the inferior and superior colliculus and striatum of adult rats (Goebel and Poosch, 1999), whereas immunocytochemical studies showed staining for the GluN2A protein to be light in these areas (Petraila et al., 1994).

The translation efficiencies of several GluA2 5′-UTR transcripts in rabbit reticulocyte lysates, X. laevis oocytes, and primary cultured neurons has been investigated (Myers et al., 2004). Transcripts containing long 5′ leaders were translated poorly compared with those with shorter leaders, and short transcripts were preferentially associated with polyribosomes in vivo. Suppression of GluA2 translation was dominated by a 34- to 42-nucleotide imperfect GU repeat sequence in the 5′-UTR predicted to form a secondary structure. It is noteworthy that the GU repeat domain is polymorphic in man and is included in a subset of rat and human GluA2 transcripts based on the site of transcription initiation (Myers et al., 1998, 2004). GluA2 translation was not modified significantly by deletion of any or all of the five upstream AUG codons. An interpretation of both the GluN2A and GluA2 studies is that a scanning ribosome encounters the proposed stem-loop and stalls because of an inability to “melt” the stem-loop structure; alternatively, a ribosome may encounter a blocking protein bound at the stem-loop motif. Either case could result in dissociation of the ribosome from the mRNA.

GluA2 transcripts are processed to form either a short or a long 3′-UTR giving rise to two pools of GluA2 mRNAs of 4 and 6 kb in length in brain. In the hippocampus, long 3′-UTR GluA2 transcripts are retained primarily in translationally dormant complexes of ribosome-free messenger ribonucleoprotein, whereas GluA2 transcripts bearing the short 3′-UTR are associated
mostly with actively translating ribosomes (Irier et al., 2009b). After pilocarpine-induced status epilepticus, selective translational derepression of GluA2 mRNA mediated by the long 3′-UTR transcripts was observed, suggesting that the long 3′-UTR of GluA2 mRNA alone is sufficient to suppress translation and that an activity-dependent regulatory signaling mechanism exists that differentially targets GluA2 transcripts with alternative 3′-UTRs (Irier et al., 2009b). Differential effects of antibiotics that target translational initiation and elongation suggest that the long 3′-UTR suppresses GluA2 at the initiation step, implying a loop-back mechanism (Irier et al., 2009a). The mechanism of translation is not known but could involve binding of a cytoplasmic polyadenylation element binding protein (CPEB). Among the CPEB proteins, CPEB3 is expressed specifically in neurons (Theis et al., 2003) and seems to bind to GluA2 long 3′-UTR. RNA interference knockdown of CPEB3 mRNA induces GluA2 protein expression in cultured hippocampal neurons (Huang et al., 2006). CPEB protein regulates translation initiation (Richter and Sonenberg, 2005), facilitates targeting of mRNAs to dendrites (Huang et al., 2003), and has been implicated in control of GluN1 translation (Wells et al., 2001a). A related report identified a deletion allele in the Grik4 gene 3′-UTR that was negatively associated with bipolar disorder, and it was proposed, on the basis of expression data, that RNA secondary structure modified mRNA stability to enhance protein expression (Pickard et al., 2008).

The localization of translation machinery near postsynaptic sites (Steward and Levy, 1982; Steward and Reeves, 1988) and differential distribution of mRNAs to dendrites, including those for GluA1, GluA2, and GluN1, have been investigated (Steward and Schuman, 2001; Schratt et al., 2004; Grooms et al., 2006). It is becoming clear that these dendritic mRNAs may form a pool poised for translation to modify neuronal plasticity. Other studies have demonstrated that protein synthesis in dendrites is critical for long-term potentiation (LTP) and long-term depression (LTD) (Kang and Schuman, 1996; Huber et al., 2000; Tang and Schuman, 2002; Bradshaw et al., 2003; Cracco et al., 2005; Mameli et al., 2007). The induction of protein synthesis is, not unexpectedly, dependent upon NMDA receptor activation (Scheetz et al., 2000; Huang et al., 2002b; Gong et al., 2006; Tran et al., 2007).

IV. Post-Translational Regulation
A. α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid and Kainate Receptor Phosphorylation

Considerable advances have been made to identify dynamically regulated post-translational phosphorylation sites on the C-terminal domains of most of the glutamate receptor subunits and to understand the functions of these modifications. Phosphorylation has been shown to regulate glutamate receptor trafficking from the ER, insertion into the plasma membrane, endocytosis, synaptic localization, and binding to other proteins (Malinow and Malenka, 2002). In a few cases, phosphorylation seems to regulate the relative frequency of opening for different subconductance levels of the channels in a manner independent of trafficking. However, more work is needed to understand the mechanisms by which phosphorylation can control glutamate receptor function. In some cases, the strategic combination of specific phosphoprotein antibodies, site-directed mutagenesis, and chromophore-tagged receptors has made it possible to associate the functional consequences of kinase activation with phosphorylation of specific amino acid residues. However, the specific functional roles of many phosphorylation sites have simply not yet been explored, and in nearly all cases, the molecular mechanisms by which phosphorylation changes receptor function (membrane insertion, open probability, etc.) are unknown. These topics represent excellent opportunities for future progress.

The C-terminal domains are shown for each of the subunits in Figs. 5–7, with residues that have been shown to be post-translationally modified in living cells in red; residues identified only in cell-free kinase assays are omitted. Authors have variably included the signal sequence in the numbering schemes and studied various C-terminal splice variants. Here, sites will be referred to by residue position in the literature. To minimize confusion with numbering schemes, we simply include the surrounding sequences in the text together with the most commonly used residue number. This number diverges from the numbering in Figs. 5 to 7 when authors indexed the predicted signal peptide cleavage site as 1.

The GluA1 C terminus has multiple phosphorylation sites, including four for PKC, one for PKA, and one for CAMKII. Phosphorylation of the two membrane-proximal PKC sites (SR817ES818KR) enhances interaction between the actin-binding 4.1N protein and the GluA1 C-terminal domain, which facilitates insertion of this subunit into the plasma membrane (Boehm et al., 2006; Lin et al., 2009), a mechanism involved in long-term potentiation. Phosphorylation of TST840LPR by PKC has been suggested to influence synaptic transmission in an age-dependent fashion (Lee et al., 2007b). Two other GluA1 phosphorylation sites control functional properties of AMPA receptor channels. Phosphorylation of RNS845GA by PKA (Roche et al., 1996) increases the open probability of homomeric GluA1 channels studied in outside-out patches (Banke et al., 2000), which has been proposed to reflect a change in the equilibrium of GluA1 with an inactive state, perhaps relating to phoshodependent binding of intracellular regulatory proteins. PKA phosphorylation additionally drives GluA1 subunits into synaptic membranes (Esteban et al., 2003; Man et al., 2007). Phosphorylation of QQS851IN by CAMKII or PKC (Barria et al., 1997; Mammen et al.,
1997) increases single channel conductance (Derkach et al., 1999; Oh and Derkach, 2005). In vivo evidence from transgenic animals suggests that GluA1 phosphorylation is critical for synaptic plasticity (Lee et al., 2000, 2003; Whitlock et al., 2006; Tsui and Malenka, 2006). Considerably more work will be required before we achieve adequate understanding of the relative contribution of phosphorylation-linked changes in trafficking and channel function to changes in synaptic strength (Song and Huganir, 2002; Derkach et al., 2007; Kessel and Malinow, 2009) (see sections IX.E and IX.F).

GluA2 splice variants create short and long C termini (Fig. 5), phosphorylation of which influences receptor trafficking, synaptic plasticity, and several receptor-protein interactions. The long tail has a phosphorylation site at VM\_T874PE that is a Jun kinase target (Thomas et al., 2008). Dephosphorylation at this site is activity-dependent and promotes reinsertion of internalized GluA2 back into the plasma membrane. Targeted disruption of the PKC recognition sequence around IE\_S880VK eliminated LTD in mouse cerebellum (Steinberg et al., 2006), confirming a major role for this modification in synaptic plasticity. The activity-dependent phosphorylation of GluA2-short by PKC on IE\_S880VK weakens its binding to GRIP but improves binding to protein interacting with C kinase 1, which slows recycling of GluA2-containing AMPA receptors back to the plasma membrane after internalization (Matsuda et al., 1999; Chung et al., 2000; Seidenman et al., 2003; Lin and Huganir, 2007; Park et al., 2009). The situation is complex, however, because States et al. (2008) identified a large population of synaptic GluA2 receptors bearing phospho-Ser880, which presumably had secured synaptic anchors other than GRIP. Finally, phosphorylation of the nearby NV\_Y876GI by src family kinases also seems to weaken association with GRIP (Hayashi and Huganir, 2004).

Three phosphorylation sites have been identified by mass spectrometry (Munton et al., 2007; Ballif et al., 2008; Trinidad et al., 2008) on the GluA3 C-tail but have not yet been studied functionally. The TE\_S891VK site near the terminus is surrounded by sequences homologous with those of the other AMPA receptor subunits and may be a PKC target.

GluA4 has alternate C-tails, with the short tail terminated by a PKC target at TE\_S899IK (Esteban et al., 2003). The long GluA4 C-tail harbors a combined PKC/PKA target at RLS\_S842IT (Carvalho et al., 1999; Gomes et al., 2002).
al., 2007) and may bind directly to some PKC isoforms (Correia et al., 2003). Phosphorylation is enhanced by synaptic activity and promotes surface expression of GluA4 by disrupting its association with α-actinin-1 (Nuriya et al., 2005). Similar to GluA2, the Jun kinase site on GluA4 (VT855PD) is phosphorylated at rest but rapidly dephosphorylated within minutes of synaptic activity and presumably functions, as in GluA2-long, to enhance surface expression of GluA4 (Thomas et al., 2008). The functional consequence of GluA4 phosphorylation by c-Jun NH2-terminal kinase has not yet been examined.

Most studies have suggested a trafficking function for phosphorylation of specific residues in AMPA receptor C termini, and a similar pattern seems to exist for kainate receptor phosphorylation. Serine residues KK879RT and GK885SF of GluK1 are phosphorylated by PKC, resulting in internalization (Rivera et al., 2007). These sites, previously identified by Hirbec et al. (2003) on the basis of in vitro kinase assays, may be involved in auto-regulation by kainate receptor activation (Rivera et al., 2007). The long C-tail of GluK2 is phosphorylated by PKA on serine residues KFS825FC and RMS837LK, which potentiates receptor activation in whole-cell patch studies (Kornreich et al., 2007), apparently through an increase in receptor open probability (Traynelis and Wahl, 1997). There are no reported modification sites in the C-tail of GluK3 or GluK5, whereas GluK4 has four phosphorylation sites identified by mass spectrometry.

B. N-Methyl-d-aspartate and δ Receptor Phosphorylation

Given the function of NMDA receptors in synaptic plasticity (see section IX), a wealth of studies exist describing the consequences of modification of specific residues on its C termini. GluN1 has four different C-terminal tails created by alternative splicing (Fig. 6), only the longest of which has been shown to influence phosphorylation. Disrupting a ring of tyrosine residues adjacent to the M4 domain by site-directed mutagenesis of IA837KR on GluN1 and LF842WK on GluN2A prevented use-dependent desensitization of GluN1/GluN2A receptors (Vissel et al., 2001). It is noteworthy that tyrosine phosphorylation of GluN2A but not GluN1 was detected with phosphotyrosine antibodies (Lau and Huganir, 1995). This same ring of tyrosines is present in all NMDA receptor subunits as well as all AMPA and kainate receptor subunits except GluK4 and GluK5 (Figs. 5 to 7), but whether each of these tyrosines is subject to phosphorylation by src family kinases with resulting functional consequences has yet to be explored. PKC targets serine residues ASS890FK and RSS896SK on GluN1, and PKA targets the adjacent RSS897KD. Within minutes of PKC activation, phosphorylation of ASS890FK disrupts surface clusters of NMDA receptors (Tingley et al., 1997). The dual PKC-PKA phosphorylation of RSS896S897K on the other hand, promotes exit of the subunit from the endoplasmic reticulum and transit...
to the surface membrane (Scott et al., 2001, 2003). The phosphorylation of GluN1 ASS890FK and RRS896SK is achieved by PKCγ/H9253 and PKCα/H9251, respectively (Sanchez-Perez and Felipo, 2005), potentially contributing to the selective modulation of NMDA receptor function and/or intracellular localization. Prolonged synaptic activation during status epilepticus initially causes dephosphorylation of ASS890FK, then hyperphosphorylation that develops over hours and subsides within a day (Niimura et al., 2005). The PKA site RS897KD behaves similarly, but the adjacent PKC site RR896SK seems untouched by status epilepticus, demonstrating a remarkable specificity.

The GluN2A subunit also occurs with alternative C-termini (Fig. 6) (444 and 626 amino acids), and each has phosphorylation sites that can modify function. The conformation of phosphorylation of LFY842WK, which is present on both C-termini, was described above. Both C-termini also harbor MRS1292PF; phosphorylation of this serine by CDK5 is associated with increased NMDA-evoked currents (Li et al., 2001), and excitotoxic death of hippocampal CA1 pyramidal cells (Wang et al., 2003). Krupp et al. (2002) demonstrated that glycine-independent desensitization of GluN1/GluN2A receptors could be eliminated by mutation of either of two serine residues proximal to the fourth transmembrane domain, LRS909K and RGS932LI, but the kinases acting on these serines have not been identified. Nine additional serines or tyrosines have been reported by mass spectrometry as phosphorylated on both long and short C-termini, but phosphorylation of exclusive residues near the end of the longer C-tail regulates NMDA receptor modulation. For example, src kinase weakens high-affinity zinc inhibition of recombinant GluN1/GluN2A receptors, an effect that is eliminated by mutation of DPY1387KH (Zheng et al., 1998; but see Xiong et al., 1999); this same tyrosine was shown to account for approximately 30% of the src-induced phosphorylation of GluN2A (Yang and Leonard, 2001). Src also phosphorylated HSY1292DN (Yang and Leonard, 2001), but this had no effect on zinc inhibition (Zheng et al., 1998). By contrast, mutation of QVY1267QQ blocked the src effect on zinc inhibition, but this residue does not seem to be directly phosphorylated by src (Yang and Leonard, 2001). These results, considered together, raise the possibility that the electrophysiological consequences of mutating Tyr1267 are due to an allosteric effect on receptor function.

Insulin potentiates the activation of GluN2A-containing NMDA receptors, an effect traced to two serines phosphorylated by PKC, QHS1291YD, and SIS1312-LK.
(Jones and Leonard, 2005). It is noteworthy that Ser1291 is immediately adjacent to the src target Tyr1292, yielding high potential for cross-talk between these kinases; one wonders, for example, whether the lack of effect of Tyr1292 on zinc inhibition (Zheng et al., 1998) was due to obstructive phosphorylation of the adjacent Ser1291 by PKC.

The GluN2B C-tail (Fig. 7) contains a prominent src target very near the C terminus on HVY1427EK, which may regulate endocytosis in some conditions (Cheung and Gurd, 2001; Nakazawa et al., 2001; Snyder et al., 2005). Phosphorylation of this tyrosine is eliminated in a 

fyn

knockout (Abe et al., 2005) and is increased in hippocampal CA1 during LTP (Nakazawa et al., 2001) as well as in a chronic neuropathic pain model (Abe et al., 2005). Although regulation of this tyrosine by 

caspase

kinase is well understood, the immediate functional consequence of phosphorylation has not been studied. This tyrosine is also phosphorylated in an activity-dependent manner by the transmembrane tyrosine kinase EphrinB2 (Nateri et al., 2007), which is activated by upstream ERK pathways. Therefore, multiple kinases target Tyr1472 in an activity-dependent manner.

Another major modification of GluN2B in the postsynaptic density fraction of the forebrain occurs by phosphorylation of QHS1303YD by CaMKII (Omkumar et al., 1996). The CaMKII system provides a mechanism by which GluN2B-containing NMDA receptors can be modified rapidly upon Ca2+ influx associated with NMDA receptor activation and in this sense may represent the prototype of a kinase activated by its target (Bayer et al., 2001), but the functional consequences of this modification have not been directly addressed. Finally, the C-terminal PDZ domain of GluN2B contains a site, IES1480DV, that, when phosphorylated by casein kinase II, disrupts the interaction of GluN2B with PSD-95 and SAP102, thereby decreasing surface expression of this receptor (Chung et al., 2004). This represents another activity-dependent phosphorylation that regulates trafficking of GluN2B in the plasma membrane. The association between active CaMKII and GluN2B seems to be required for LTP, although the phosphorylation target has not been identified (Barria and Malinow, 2005).

PKC and PKA both phosphorylate GluN2C RIS1230SL (Fig. 7) near the extreme carboxyl terminus but exert no apparent effect on surface expression of GluN2C or on its interaction with PDZ family proteins on the adjacent PDZ domain. However, a phosphomimetic GluN2C(S1230E) mutant exhibited faster activation and inactivation kinetics in outside-out patches (Chen et al., 2006). Thus, unlike other glutamate receptor subunits, phosphorylation of this serine near the PDZ domain does not affect trafficking but instead alters channel properties. A site in the C-terminal domain of GluN2C, HAS1096LP, is a unique (among the glutamate receptors) target for PKB/ Akt; interestingly, phosphorylation of Ser1096 creates a binding site for 14-3-3 (Chen and Roche, 2009), which apparently assists in the trafficking of GluN2C to the surface membrane. Phosphorylation of Ser1096 is enhanced by insulin-like growth factor-1 stimulation or NMDA receptor activation, providing a link between hormonal state and NMDA receptor function. Three phosphorylated serines in GluN2D have been identified by mass spectroscopy (Fig. 7) but have not yet been studied functionally. Likewise, a phosphotyrosine antibody labels GluN2D immunoprecipitated from rat thalamus (Dunah et al., 1998b), but the targeted tyrosines have not been identified.

No modifications of GluN3A, GluN3B, or GluD1 have been described yet, but GluD2 has four phosphoserines, one of which (TLS945AK) was shown to be a PKC target (Fig. 7) (Kondo et al., 2005). The GluD2 subunit is expressed mainly by cerebellar Purkinje cells, and both it and PKC seem to be essential for long-term depression at the parallel fiber-Purkinje cell synapse (Kashiwabuchi et al., 1995; Kondo et al., 2005). However, LTD could be rescued in a GluD2-null mouse by a GluD2(S945A) transgene, demonstrating that phosphorylation of Ser945 plays no role in LTD (Nakagami et al., 2008). Indeed, a transgene lacking the transmembrane domains could rescue LTD (Kakegawa et al., 2007b), suggesting that GluD2 might function as a scaffolding protein rather than an ionotropic receptor.

C. Other Post-Translational Modifications of Glutamate Receptors

Additional post-translational modifications can affect glutamate receptor localization or activity. All ionotropic glutamate receptor subunits seem to be glycosylated (see section II), which seems to be involved in proper folding of the subunit during synthesis (Everts et al., 1997; Mah et al., 2005; Nanao et al., 2005; Gill et al., 2009). In addition, multiple glutamate receptor subunits undergo dynamic regulation by palmitoylation (Figs. 5–7). The AMPA receptors have two known palmitoylation sites in the membrane domain 2 and C-tail. All AMPA receptors have a conserved cysteine residue proximal to M4 that undergoes palmitoylation (GluA1-EFC811YK, GluA2-C836, GluA3-C841, GluA4-C817) (Hayashi et al., 2005). In GluA1 and GluA2, palmitoylation of the C-tail residue reduces insertion rate (Hayashi et al., 2005) and regulates phosphorylation of the two serines on the C-terminal tail by PKC (Lin et al., 2009). Thus, the interplay between palmitoylation and phosphorylation of residues on this membrane-proximal region of GluA1 influences membrane insertion and thus synaptic availability of this subunit. All AMPA receptors have another conserved cysteine residue just downstream of the QRN site (GluA1-QGC585DI, GluA2-C610, GluA3-C615, GluA4-C611) that, when palmitoylated, increases AMPA receptor surface expression (Hayashi et al., 2005). The homomeric kainate receptor GluK2 undergoes palmitoylation of the cysteines SFC583SA and LKC571QR, both of which have no apparent effect on basal receptor function. In addition to
palmitoylation, GluK2 has been shown to be SUMOylated at lysine IVK_{396}TE, a process that facilitates endocytosis after kainate receptor activation (Martin et al., 2007). GluK3 has been shown to be SUMOylated, although the site has not been identified (Wilkinson et al., 2008).

Like AMPA and kainate receptors, the GluN2A and GluN2B subunits also undergo palmitoylation at their C termini (Hayashi et al., 2009). Both of these subunits have two separate clusters of cysteine residues that are palmitoylated with distinct consequences on receptor expression and internalization. The first cluster of palmitoylated cysteine residues within GluN2A (RFC_{848}FT, GVC_{853}SD, YSC_{876}IH) and the homologous cysteines in GluN2B (Fig. 7) increase nearby tyrosine phosphorylation of the C-tails by src family kinases, regulating surface expression and receptor internalization. Tyrosine phosphorylation of the C-tails eliminated receptor interaction with activator protein-2, decreasing clathrin-mediated endocytosis. Palmitoylation of the second cluster of cysteine residues within GluN2A (THC_{1214}RSC_{1217}LS, FKC_{1236}DAC_{1239}LR) and the homologous residues in GluN2B plus EAC_{1245}KK leads to accumulation of the NMDA receptors in the Golgi apparatus and decreased surface expression (Hayashi et al., 2009). Thus, palmitoylation of GluN2A and GluN2B provides a dual mechanism by which post-translational modification controls NMDA receptor surface expression. It is unknown if GluN2C or GluN2D subunits undergo palmitoylation, but both have cysteine residues homologous to GluN2A and GluN2B within their C-terminal tails, leading to the possibility that palmitoylation also regulates their surface expression. Studies so far suggest that the GluN1 subunit does not undergo palmitoylation (Hayashi et al., 2005).

Both GluN1 and GluN2 subunits undergo S-nitrosylation on cysteine thiol groups by endogenous nitric oxide (NO) and exogenously applied S-nitrosothiols. The GluN1 subunit has two cysteine residues within the M3–M4 extracellular linker, KQC_{743}DL and QEC_{798}DS, and the GluN2A subunit has three cysteine groups within the ATD, HVC_{57}DL, ASC_{325}YG, and SDC_{399}EP, that can be S-nitrosylated (Choi et al., 2000). The S-nitrosylated cysteine residues within the GluN1 and GluN2 subunits mainly fit the S-nitrosylation consensus motif of a cysteine residue preceded by an acidic or basic residue and followed by an acidic residue (Stamler et al., 1997). S-Nitrosylation of any of these cysteine residues within GluN1/GluN2A leads to moderate NMDA receptor inhibition, decreasing the response to agonist-evoked currents by approximately 20%, but a majority of the inhibition is due to Cys399 on the GluN2A subunit ATD (Choi et al., 2000). Inhibition of GluN2A current amplitude through S-nitrosylation of Cys399 is due to decreased channel opening, which may be caused by the increased affinity of the receptor for Zn^{2+} and glutamate, leading to receptor desensitization (Paoletti et al., 2000; Zheng et al., 2001; Lipton et al., 2002). The GluN2A subunit is sensitized to S-nitrosylation when Cys744 and Cys798 of the GluN1 subunit are S-nitrosylated (Takahashi et al., 2007). It is not known whether the remaining GluN2 subunits are S-nitrosylated or inhibited by this modification. The ability of NO to regulate NMDA receptors may provide a feedback mechanism to prevent excessive receptor activity, because NMDA receptor-catalyzed transmembrane currents increase the local Ca^{2+} concentration, which activates neuronal nitric-oxide synthase through their mutual association with PSD-95 (Sattler et al., 1999; Rameau et al., 2003).

NMDA receptors are regulated by the extracellular redox state; sulfhydryl reducing agents such as dithiothreitol and dihydrolipoic acid potentiate NMDA-evoked currents through the formation of free thiol groups, whereas oxidizing agents such as 5,5′-dithio-bis(2-nitrobenzoic acid) and oxidized glutathione inhibit currents through the formation of disulfide bonds (Aizenman et al., 1989; Sucher and Lipton, 1991; Köhr et al., 1994; Choi and Lipton, 2000). Both GluN1 and GluN2 subunits are responsible for redox modulation. Disulfide bonds formed between two pairs of cysteine residues within GluN1 (SVC_{756}ED and RGC_{308}VG within the ATD and Cys744 and Cys798 in the LBD) cause the intermediate and slow components of redox modulation for all GluN2-containing NMDA receptors (Sullivan et al., 1994; Choi et al., 2001). A disulfide bond has been proposed to form in the GluN2A subunit between Cys87 and Cys320 of the GluN2A ATD and has been shown to form between Cys86 and Cys321 in the crystal structure of GluN2B ATD (Karakas and Furukawa, 2009). This disulfide bond has been suggested to mediate a fast-component of redox modulation, although this may also reflect modification of the Zn^{2+} binding site (Köhr et al., 1994; Choi et al., 2001). Reducing agents can chelate zinc, and transient potentiation that occurs only in the presence of agents such as dithiothreitol reflects in part the relief of zinc inhibition through zinc chelation (Paoletti et al., 1997). In addition, reduction of cysteine residues within GluN1/GluN2A NMDA receptors also reduces high-affinity voltage-independent Zn^{2+} inhibition of NMDA receptors (Choi et al., 2001).

D. Proteolysis of Glutamate Receptors

A number of proteases can cleave glutamate receptors. Principal among these are serine proteases, which can act on GluN1, GluN2A, and GluN2B. Tissue plasminogen activator can cleave GluN1 at ALR_{260}YA, whereas plasmin and thrombin cleave at multiple sites within GluN1, presumably with functional consequences (Gingrich et al., 2000; Fernández-Monreal et al., 2004; Samson et al., 2008). A specific plasmin cleavage site (EAK_{317}AS) has been described in GluN2A, proteolysis of which leads to removal of the ATD and the high-affinity Zn^{2+} binding site contained therein (Yuan et al., 2009b). Thrombin cleaves the analogous residue (Lys318) in GluN2B (Leung et al., 2007). In addition, the
calcium-dependent nonlysosomal protease family calcipains can cleave the C termini of GluA1, GluN2A, GluN2B, and GluN2C, resulting in receptor degradation and reduced synaptic activity (Bi et al., 1998a,b; Guttman et al., 2001, 2002; Rong et al., 2001; Simpkins et al., 2003; Araújo et al., 2005). It is noteworthy that specific proteolytic cleavage has been proposed to occur in pathological situations such as ischemia (Yuen et al., 2007), blood-brain barrier breakdown (Yuan et al., 2009b), and status epilepticus (Araújo et al., 2005). In addition, matrix metalloproteinase-7 has been shown to cleave the LBDs of the GluN1 and GluN2A subunits, decreasing the NMDA receptor-mediated calcium influx and increasing the ratio of AMPA to NMDA receptors in cortical slices (Szklarczyk et al., 2008). Among the AMPA receptors, GluA3 has been reported to serve as a substrate for proteolysis by gamma secretase and granzyme B (Gahring et al., 2001; Meyer et al., 2002); glycosylation of ISN388DS protects GluA3 from cleavage by granzyme B during breakdown of the blood-brain barrier. GluA1 can be cleaved at SHD865FP through activation of calpain and caspase8-like activity (Bi et al., 1996; Meyer et al., 2002). AMPA receptor proteolysis may be common in neuropathological conditions (Bi et al., 1998a; Chan et al., 1999).

V. Agonist and Antagonist Pharmacology

Amino acid numbering in AMPA and kainate receptor subunits has historically been for the mature protein without the signal peptide, whereas amino acid numbering of NMDA and GluD2 receptor subunits has started with the initiating methionine as 1. To simplify comparison with the published literature, we will maintain this informal convention here.

A. α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid, Kainate, and δ Receptor Agonists

Glutamate activates all AMPA and kainate receptors by binding within the cleft between domains D1 and D2 of the LBD to induce domain closure. Neither NMDA nor L-aspartate can activate the non-NMDA receptors, and D-aspartate acts as a low-affinity competitive antagonist for native AMPA receptors (Gong et al., 2005). In the structure of the glutamate-bound GluA2 LBD (Fig. 8A) (Armstrong and Gouaux, 2000), the α-amino group of glutamate forms a tetrahedral network of interactions with the backbone carbonyl oxygen of Pro478, the side chain hydroxyl of Thr480, and the carboxylate group of Glu705. The α-carboxyl group of glutamate forms a bidentate interaction with Arg485 and receives hydrogen bond interactions from the backbone carbonyl groups of Pro478 and Thr480.

![Fig. 8. Agonist binding pockets of glutamate receptors. A, binding of glutamate (yellow) in the agonist binding pocket of GluA2 (PDB code 1FTJ). Only side chains of interacting residues are shown. Not all residues are labeled. B, binding of glutamate in GluK2 (PDB code 1S7Y). Compared with the glutamate-bound ligand binding pocket of GluA2, there is a loss of a direct hydrogen bond to the α-amino group of glutamate at position Ala487 in GluK2, which is the site equivalent to Thr480 in GluA2. An additional water molecule forms a hydrogen bond to the α-amino group of glutamate in GluK2. C, binding of glutamate in GluN2A (PDB code 2A5T). Compared with glutamate bound in GluA2, the salt bridge between Asp731 and the positively charged α-amino group of glutamate is absent. Instead, the α-amino group of glutamate forms water-mediated hydrogen bonds to Glu413 and Tyr761. D, binding of glycine in GluN1 (PDB code 2A5T). Specificity of GluN1 for glycine can be explained by the hydrophobic environment created by Val689 and the steric barrier formed by Trp731. E, binding of glycine in GluN3A (PDB code 2RC7). Trp731 of GluN1 is replaced by M844, allowing room for a water molecule in the pocket. F, binding of D-serine in GluD2 (PDB code 2V3U).](image-url)
bonds from the backbone amide nitrogens of Thr480 and Ser654. The glutamate γ-carboxyl group interacts with the hydroxyl group and backbone amide nitrogen of Thr655 (Fig. 8A), whereas the isoxazole hydroxyl group of AMPA interacts with the amide nitrogen of Thr655 via a water molecule. Furthermore, the side chain of Tyr450 forms an electron-dense ring structure above the glutamate α- and β-carbon atoms resembling a lid above the agonist binding pocket (Fig. 8A). Structures of the kainate receptor subunits GluK1 and GluK2 LBDs show similar atomic contacts for the α-carboxyl group, α-amino group, and γ-carboxyl groups of glutamate, although residues lining the GluK1 agonist binding pocket are smaller than GluK2 (Mayer, 2005; Nanao et al., 2005; Naur et al., 2005; Mayer et al., 2006) (Fig. 8B). There are several noteworthy differences among the kainate receptor LBDs, such as the loss of a hydrogen bond to the agonist α-amino group at GluK2 Ala487, which is equivalent to Thr480 in GluA2 and Thr503 in GluK1. This may contribute to the higher glutamate EC50 for GluK2 compared with GluK1 (Mayer, 2005). A central feature of AMPA and kainate receptor agonist binding is closure of the cleft in which the agonist binds, a conformational change mediated by movement of D2 relative to D1 within the bilobed LBD (Armstrong and Gouaux, 2000; Mayer, 2005) (see sections II.D, VII.B).

In addition to glutamate, a number of naturally occurring molecules, such as ibotenic acid and willardine, plus an array of AMPA, ibotenic acid, and willardine analogs, activate AMPA and kainate receptors (Table 5). It has been difficult to identify naturally occurring or synthetic agonists that discriminate well between all AMPA and kainate receptors. AMPA acts as a partial agonist at some kainate receptor subunit combinations (Herb et al., 1992; Swanson et al., 1996; Schiffer et al., 1997), and kainate can induce very rapid desensitization of neuronal AMPA receptors (Patneau et al., 1993). Nevertheless, there are some examples of kainate receptor-selective agonists, such as (2S,4R)-4-methylglutamic acid (SYM2081) and perhaps ATPA, a tert-butyl analog of AMPA (see Tables 5 and 6). Crystal structures of the GluK1 and GluK2 LBDs have revealed differences between kainate and AMPA receptors that partly explain these kainate receptor-selective actions. The agonist-binding cavities of GluK1 and GluK2 are 40 and 16% larger, respectively, than GluK2, allowing GluK1 and GluK2 to accommodate larger ligands (Mayer, 2005; Naur et al., 2005). Indeed, steric occlusion between the 4-methyl group of SYM2081 and GluA2 Leu650 contributes to its selectivity for GluK1 and GluK2, both of which have a smaller valine in the corresponding positions (GluK1, Val670; GluK2, Val654) (Armstrong et al., 1998, 2003; Mayer, 2005). Likewise, the isoprenyl group of kainate shows reduced steric occlusion in GluK1 and GluK2 compared with GluA2 because of the smaller valine residues. Steric occlusion also may explain selectivity of ATPA for GluK1, because its bulky tert-butyl group interacts with Leu650, Thr686, and Met708 in GluA2, which are replaced by the smaller amino acids Val670, Ser706, and Ser726, respectively, in GluK1 (Lunn et al., 2003). The availability of crystallographic data for multiple kainate receptor subunits emphasizes how useful structural information can be across each subunit family. Thus, there remains the need for new crystallographic data for additional members of each glutamate receptor subtype, as opposed to the reliance on homology modeling and molecular dynamics simulations. Although useful, molecular dynamics simulations of homology models carry significant caveats, including uncertainty associated with representation of amino acid insertions, placement of new ligands, approximations of force fields for membrane-spanning elements, and computational limitations in simulating large multisubunit protein assemblies. At the same time, crystals are rarely formed on demand, low resolution can create ambiguities in protein threading and details of ligand binding pose, and dynamic aspects ranging from ligand interactions to domain coupling are not revealed by a static X-ray structure. Early in a project, in the absence of a three-dimensional structure, a homology model can offer unique insights, whereas in late phases of a project, possession of a crystal structure can benefit significantly from dynamic refinement and
### TABLE 6

<table>
<thead>
<tr>
<th>Agonist</th>
<th>GluK1</th>
<th>GluK2</th>
<th>GluK3</th>
<th>GluK1/GluK2</th>
<th>GluK1/GluK5</th>
<th>GluK2/GluK5</th>
</tr>
</thead>
<tbody>
<tr>
<td>l-Glutamate</td>
<td>47±</td>
<td>9±</td>
<td>5000±</td>
<td>48±</td>
<td>19±</td>
<td>8±</td>
</tr>
<tr>
<td>AMPA</td>
<td>208±</td>
<td>N.E.</td>
<td>N.E.</td>
<td>154±</td>
<td>123±</td>
<td>137±</td>
</tr>
<tr>
<td>Kainate</td>
<td>4.9±</td>
<td>1.1±</td>
<td>7.4±</td>
<td>1.5±</td>
<td>0.6±</td>
<td></td>
</tr>
<tr>
<td>Willardine</td>
<td>28.8±</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F-Willardine</td>
<td>1.8±</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Br-Willardine</td>
<td>0.0091±</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-Willardine</td>
<td>0.21±</td>
<td>N.E.</td>
<td>0.47±</td>
<td>0.06±</td>
<td>30±</td>
<td></td>
</tr>
<tr>
<td>(S)ATPA</td>
<td>0.33±</td>
<td></td>
<td>0.8±</td>
<td>0.38±</td>
<td>106±</td>
<td></td>
</tr>
<tr>
<td>SYM2081</td>
<td>0.18±</td>
<td>0.29±</td>
<td>0.35±</td>
<td>0.34±</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Domoic acid</td>
<td>0.36±</td>
<td>0.07±</td>
<td>0.19±</td>
<td>0.05±</td>
<td>0.12±</td>
<td></td>
</tr>
<tr>
<td>LY339434±</td>
<td>2.5±</td>
<td>&gt;100±</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DYSXihbaine</td>
<td>0.0005</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>neoDH</td>
<td>0.008±</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACPA</td>
<td>22±</td>
<td>10±</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(S)AHCP</td>
<td>0.13±</td>
<td>N.E.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(S)Thio-ATPA</td>
<td>0.1±</td>
<td>N.E.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-Me-Tet-AMPA</td>
<td>8.7±</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8-Deoxy-neoDH</td>
<td>0.0015±</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9-Deoxy-neoDH</td>
<td>0.169±</td>
<td>&gt;100±</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSH-19</td>
<td>3.9±</td>
<td></td>
<td>N.E.</td>
<td>(&gt;100)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Values are means ± SEM from 3--10 experiments. EC50 for MSVIII-19 at GluK1 receptors was greater than 10,000 μM (Small et al., 1998). Data from willardine-evoked currents from HEK293 cells expressing GluK2/GluK5 (Fukushima et al., 2001). Data from calcium influx (fluorometric imaging plate reader) in HEK293 cells stably transfected with human receptors and treated with Con A (Alt et al., 2004). Data for dysiherbaine and neodysiherbaine are not determined; N.E., no effect; neoDH, neodysiherbaine.

### Trajectory Analysis

The approaches are complementary both in terms of a project's evolution and the information content provided by the two structural perspectives.

A few agonists show useful selectivity between the GluA1/GluA2 and GluA3/GluA4 subunits (Table 5). Br-HIBO, an analog of ibotenic acid, preferentially activates GluA1 and GluA2 versus GluA3 and GluA4 receptors (Coquelle et al., 2000) through involvement of water-mediated hydrogen bonding to Tyr702 in GluA1 and GluA2, which is Phe in GluA3 and GluA4. Thus, ordered water molecules within the agonist binding site interact with the ligand to influence specificities among GluA subunits (Banke et al., 2001; Hogner et al., 2002; Pentikäinen et al., 2003; Frandsen et al., 2005). Cl-HIBO was synthesized after molecular modeling predicted that the exchange of bromine for chlorine would improve selectivity (Bjerrum et al., 2003). Cl-HIBO activates GluA1 and GluA2 with 275- to 1600-fold selectivity over GluA3 or GluA4, respectively. The agonist 2-benzyl-tetrazol-AMPA shows 40-fold selectivity for GluA4 over GluA1 (Jensen et al., 2007). Crystal structures of 2-benzyl-tetrazol-AMPA bound to the GluA2 LBD reveal that the benzyl group occupies a novel cavity opened up by movement of Met708 in GluA2, and the selectivity of 2-benzyl-tetrazol-AMPA is due to residues adjacent to this cavity (Val690 and Ala691), which are conserved in GluA2 to GluA4 but correspond to Met686 and Ile687 in GluA1 (Vogensen et al., 2007).

Although some agonists discriminate between GluA1/GluA2 and GluA3/GluA4 subunits, it remains to be shown whether agonists that act selectively at an individual GluA subunit can be developed. The amino acid sequences for the LBDs of the four GluA subunits are 80% identical (Table 2). Ligands with agonist activity at AMPA receptors contain a chemical moiety equivalent to the α-amino and α-carboxyl groups of glutamate, and the binding of this moiety is conserved for the agonists crystallized thus far. Moreover, crystal structures and homology models show the residues in direct contact with agonists such as glutamate, AMPA, and kainate are fully conserved across all GluA subunits. Crystallization of LBDs bound to additional agonists, however, could allow identification of novel binding modes or differences in agonist binding that could be exploited through medicinal chemistry efforts to achieve greater subunit selectivity. Alternatively, molecular modeling, which can account for important motions within the receptor, could allow for analysis of binding to subunits that have not been crystallized and has been used successfully, for example, to predict the activity of Cl-HIBO.
The development of useful subunit-selective compounds is further complicated by the formation of heteromeric receptors in native tissue, which contain two different GluA subunits, and by the association of AMPA receptors with interacting partners. Association of the TARP auxiliary subunits with AMPA receptors (see section II.H) increases efficacy and affinity for a range of AMPA receptor agonists, including kainate (Turetsky et al., 2005; Kott et al., 2007). Because agonist pharmacology has been studied extensively in recombinant systems without coexpression of TARPs, the caveat exists as to whether agonist properties (Table 5) will remain the same in the presence of TARPs.

Kainate has a 2-carboxyppyrolidine-3-acetic acid backbone, and analogs containing this backbone, known as kainoids (Sonnenberg et al., 1996; Hodgson et al., 2005; Sagot et al., 2008; Bunch and Krogsgaard-Larsen, 2009), include domoic acid (Hampson et al., 1992; Alt et al., 2004) and acromelic acid (Kwak et al., 1992; Smith and McIlhinney, 1992). Agonist potency and efficacy are subunit-specific, because kainate and domoic acid are potent agonists of GluK1 and GluK2 but show low potency at GluK3 receptors (Table 6; Jane et al., 2009). Agonists acting preferentially at kainate receptors over AMPA receptors include the glutamate analogs SYM2081 (Zhou et al., 1997), dysiherbaine (Sakai et al., 1997), and neodysiherbaine (Sakai et al., 2001a). SYM2081 has similar potencies for GluK1 and GluK2 and causes pronounced desensitization (Jane et al., 2009). Dysiherbaine has nanomolar affinity for GluK1 and GluK2 and micromolar affinity for GluK5 (Sakai et al., 2001b; Swanson et al., 2002; Sanders et al., 2005). Because of its high affinity for GluK1, dysiherbaine promotes a desensitized state of the receptor that persists for at least 20 to 45 min after removal. This unique activity of dysiherbaine was used to block GluK1 subunits in GluK1/GluK5 diheteromeric receptors, which revealed that glutamate evokes a desensitizing response from the remaining GluK5 subunits (Swanson et al., 2002). This finding suggests that kainate receptors undergo subunit-specific gating similar to AMPA receptors (Jin et al., 2003).

Multiple agonists act selectively at GluK1 over the other kainate receptor subunits (Table 6). The neodysiherbaine analogs 8-deoxy-neodysiherbaine, 9-deoxy-neodysiherbaine, and MSVIII-19 show nanomolar affinity for GluK1 and >1000-fold selectivity over GluK2, GluK3, and GluK5, with 8- and 9-deoxy-neodysiherbaine acting as a partial and full agonists, respectively (Lash et al., 2008). MSVIII-19 was originally reported as a GluK1 antagonist (Sanders et al., 2005), but crystallographic studies revealed that it induces full domain closure of the GluK1 LBD, prompting further functional studies that showed it to be an agonist of extremely low efficacy (Frydenvang et al., 2009). (2S,4R,6E)-2-Amino-4-carboxy-7-(2-naphthyl)hept-6-enoic acid (LY339434), ATPA, (S)-2-amino-3-(3-hydroxy-7,8-dihydro-6H-cyclohepta[d]isoxazol-4-yl)propionic acid, (S)-5-iodowillardiine, and (4R)-isopentyl glutamate are potent agonists at homomeric GluK1 receptors but have little to no activity at GluK2 receptors (Clarke et al., 1997; Jane et al., 1997; Zhou et al., 1997; Small et al., 1998; Brehm et al., 2003; Bunch et al., 2009). GluK1 selectivity arises from the larger GluK1 binding cavity, which relieves steric occlusion of the bulky tert-butyl group of ATPA and halogen atom of (S)-5-iodowillardiine (Mayer, 2005). Likewise, steric occlusion explains why AMPA binds GluK1 but not GluK2, because the isoxazole ring cannot make key contacts with D2 (Mayer, 2005). Mutagenesis studies have confirmed the importance of cavity size, and the exchange of Ser706 in GluK1 to the larger Asn690 in GluK2 predictably alters potency of AMPA, iodowillardiine, and ATPA toward GluK1 (Swanson et al., 1997a, 1998; Nielsen et al., 2003).

The LBD of the GluD2 (δ2) family of glutamate receptor subunits binds δ-serine, sharing some but not all features of δ-serine binding to GluN1 (Fig. 8F) (Naur et al., 2007). However, GluD2 receptor function remains poorly understood. Transgenic experiments show that insertion of a mutant GluD2 into GluD2(-/-) mice can rescue these mice from neurological deficits even when the inserted GluD2 has a mutation in the ion channel pore that either disrupts Ca2+ permeability (Kakegawa et al., 2007a) or abolishes current flow through the ion channel (Kakegawa et al., 2007b). In addition, GluD2 can induce presynaptic terminal differentiation even without its LBD, which contains the δ-serine binding site (Kuroyanagi et al., 2009; Torashima et al., 2009). These data suggest that GluD2 does not influence cerebellar function through actions as a ligand-gated ion channel. No data has yet shown functional ionic currents in wild-type GluD2 receptors. However, a mutation in M3, GluD2(A654T), within the highly conserved SYTANLAAF gating motif causes spontaneously active channels (Kakegawa et al., 2007b). In addition, GluD2 can induce presynaptic terminal differentiation even without its LBD, which contains the δ-serine binding site (Kuroyanagi et al., 2009; Torashima et al., 2009). These data suggest that GluD2 does not influence cerebellar function through actions as a ligand-gated ion channel.

B. N-Methyl-D-aspartate Receptor Agonists

NMDA receptors are unique among the glutamate receptor family in that the simultaneous binding of glycine to GluN1 and glutamate to GluN2 is required for activation (Kleckner and Dingledine, 1988). Crystal structures of the bilobed GluN1 LBD show that glycine and related agonists (Table 7) bind within the cleft between the D1 and D2 domains. The α-carboxyl group of glycine forms hydrogen bonds within the binding pocket with Arg522, Thr518, and Ser688, whereas the amino group of glycine interacts with the carbonyl oxygen of Pro516, the hydroxyl group of Thr518, and the carboxylate oxygen of Asp732 (Fig. 8D) (Furukawa and Gouaux,
Trp731 within the GluN1 binding pocket has been proposed to hinder glutamate binding because of steric clash between Trp731 and the glutamate ω-carboxyl group. In GluN2A, the smaller side chain of Tyr730 is in van der Waals contact with the ω-carboxylate of glutamate (Fig. 8C). GluN1 has Val689 corresponding to GluN2A Thr690, which leads to loss of a hydrogen bond donor that stabilizes the glutamate ω-carboxyl group in GluN2A (Fig. 8, C and D). Comparison between crystallographic structures of the GluN1 subunit bound to full and partial agonists indicates that the degree of closure of the LBDs’ D1 and D2 domains is not correlated with relative agonist efficacy, as has been demonstrated with the GluA2 LBD. Partial agonists 1-aminocyclobutane-1-carboxylic acid and 1-aminocyclopropane-1-carboxylic acid (Priestley et al., 1995) induce a similar degree of domain closure as glycine, differing by less than 0.5° (Inanobe et al., 2005).

In addition to glycine, the D- and L-isomers of serine and alanine are agonists at the GluN1 subunit (Pullan et al., 1987; McBain et al., 1989) (Table 7). D-Serine is more potent than L-serine and may be the primary ligand for GluN1 in regions such as the supraoptic nucleus (e.g., Panatier et al., 2006). D-Serine is synthesized from L-serine by serine racemase in both astrocytes and neurons (Mustafa et al., 2004; Miya et al., 2008; Wolosker et al., 2008). It is noteworthy that serine racemase is regulated by NMDA receptor activity, mGluR5 activation, nitrosylation, divalent cations, and nucleotides (Shoji et al., 2006; Baumgart and Rodriguez-Crespo, 2008; Balan et al., 2009; Mustafa et al., 2009), and deletion of serine racemase alters glutamatergic synaptic transmission and produces behavioral phenotypes (Basu et al., 2009).

Cyclic and halogenated analogs of glycine, including D-cycloserine, act as GluN1 partial agonists (Hood et al., 1989; Priestley and Kemp, 1994; Sheinin et al., 2001; Dravid et al., 2010) (Table 7). Although D-cycloserine is a partial agonist of GluN2A-, GluN2B-, and GluN2D-containing NMDA receptors, the responses of GluN2C-containing NMDA receptors are greater in D-cycloserine than those evoked by glycine (Sheinin et al., 2001; Dravid et al., 2010). This raises the possibility that potentiation of GluN2C-containing NMDA receptors could underlie the positive effects of D-cycloserine on cognition, fear extinction, and motor dysfunction (Kalia et al., 2008; Norberg et al., 2008) through action on GluN2C-expressing neurons (Monyer et al., 1994). It is noteworthy that the identity of the GluN2 subunit within the NMDA receptor determines the potencies of GluN1 agonists, which are least potent (highest EC50) for GluN1/GluN2A and most potent (lowest EC50) for GluN1/GluN2D (Kuryatov et al., 1994; Wafford et al., 1995; Furukawa and Gouaux, 2003; Chen et al., 2008) (Table 7).

Glutamate binding to GluN2A involves interactions of the agonist ω-carboxylate group with Arg518 and the agonist ω-carboxylate group with Tyr730 within the binding pocket, together with an interdomain hydrogen bond formed between Tyr730 and Glu413 (Fig. 8C; Furukawa et al., 2005). The crystal structure of the agonist-bound GluN1-GluN2A LBD heterodimer suggests a mechanism for selectivity for NMDA over AMPA receptors (Furukawa et al., 2005). The GluN2A subunit has Asp731 within the binding pocket, whereas the GluA2, GluK1, and GluK2 receptor subunits have a glutamate residue at the corresponding position that interacts with the agonist amino group (Fig. 8, A–C). Because the aspartate residue within the GluN2A subunit is a methylene group shorter than the glutamate residue found in GluA and GluK subunits, it cannot interact with the agonist ω-amino group of glutamate, which instead forms water-mediated hydrogen bonds to GluN2A Glu413 and Tyr761. Surprisingly, the charge-conserving substitution GluN2A(D731E) and GluN2B(D732E) renders the receptor nonfunctional (Williams et al., 1996; Laube et al., 2004; Chen et al., 2005), perhaps a result of interference with the water-mediated interactions at the ω-amino group of glutamate and/or a disruption of the binding pocket. The reduced side-chain length of Asp731 also

### TABLE 7

<table>
<thead>
<tr>
<th>Glycine-Site Agonist</th>
<th>GluN2A (%)</th>
<th>GluN2B (%)</th>
<th>GluN2C (%)</th>
<th>GluN2D (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycine</td>
<td>1.1 (100)</td>
<td>0.72 (100)</td>
<td>0.34 (100)</td>
<td>0.13 (100)</td>
</tr>
<tr>
<td>L-Serine</td>
<td>212 (85)</td>
<td>77 (88)</td>
<td>27 (110)</td>
<td>15 (98)</td>
</tr>
<tr>
<td>D-Serine</td>
<td>1.3 (98)</td>
<td>0.65 (96)</td>
<td>0.32 (110)</td>
<td>0.16 (93)</td>
</tr>
<tr>
<td>L-Alanine</td>
<td>96 (79)</td>
<td>36 (65)</td>
<td>28 (92)</td>
<td>13 (97)</td>
</tr>
<tr>
<td>D-Alanine</td>
<td>3.1 (96)</td>
<td>0.89 (84)</td>
<td>0.56 (96)</td>
<td>0.22 (99)</td>
</tr>
<tr>
<td>D-Cycloserine</td>
<td>19 (90)</td>
<td>8.2 (65)</td>
<td>3.3 (190)</td>
<td>2.9 (94)</td>
</tr>
<tr>
<td>HA 966</td>
<td>12 (12)</td>
<td>4.6 (14)</td>
<td>3.7 (79)</td>
<td>1.7 (81)</td>
</tr>
<tr>
<td>β-Cl-D-Alanine</td>
<td>21 (84)</td>
<td>9.9 (68)</td>
<td>1.0 (84)</td>
<td>0.40 (91)</td>
</tr>
<tr>
<td>β-F-D-Alanine</td>
<td>11 (92)</td>
<td>0.98 (88)</td>
<td>0.40 (84)</td>
<td>0.40 (91)</td>
</tr>
<tr>
<td>tri-F-Tr-Alanine</td>
<td>1.3 (130)</td>
<td>0.65 (64)</td>
<td>0.32 (110)</td>
<td>0.16 (93)</td>
</tr>
<tr>
<td>ACPC</td>
<td>1.3 (79)</td>
<td>0.65 (59)</td>
<td>0.35 (88)</td>
<td>0.083 (89)</td>
</tr>
<tr>
<td>ACBC</td>
<td>45 (13)</td>
<td>6.6 (33)</td>
<td>0.35 (88)</td>
<td>0.083 (89)</td>
</tr>
</tbody>
</table>

ACBC, 1-aminoacyclobutane-1-carboxylic acid; ACPC, 1-aminocyclopropane-1-carboxylic acid; HA 966, (−)/(1-hydroxy-3-aminopyrrolidine-2-one).
creates space for NMDA to fit within the GluN2A binding pocket. Modeling of NMDA into the GluN2A LBD suggests that the N-methyl group of NMDA is accommodated in the binding pocket by displacement of the water molecule that binds the α-amino group of glutamate (Furukawa et al., 2005). Other studies using mutagenesis and homology modeling of GluN2A and GluN2B LBDs have suggested that NMDA cannot bind to GluA subunits because of steric clashes of the N-methyl group of NMDA and Met708 in GluA2, which is conserved among all AMPA receptors (Laube et al., 2004; Chen et al., 2005).

GluN2 endogenous agonists include glutamate, d- and L-aspartate (Benveniste, 1989; Nicholls, 1989; Fleck et al., 1993; Schell et al., 1997; Wang and Nadler, 2007; Errico et al., 2008; Zhang and Nadler, 2009), homocysteate, and cysteinesulfinate (Do et al., 1986, 1988; Olney et al., 1987; Yuzaki and Connor, 1999) (Table 8). Cyclic analogs with conformationally constrained rings also act as potent GluN2 agonists, in some cases with EC_{50} values lower than glutamate (Shinozaki et al., 1989; Schoell et al., 1991; Erreger et al., 2007) (Table 8). The potencies and relative agonist efficacies of GluN2 ligands generally display a graded variation among GluN2A- through GluN2D-containing NMDA receptors, with the lowest potency at GluN2A-containing NMDA receptors and the highest potency at GluN2D-containing receptors (Kutsuwada et al., 1992; Monyer et al., 1992; Erreger et al., 2007) (Table 8). Selective agonists that distinguish between the GluN2 subunits have not been developed, although series such as the N-hydroxypyrazol-5-yl glycine derivatives show promising selectivity for some GluN2 subunits (Clausen et al., 2008) (Table 8). In addition, SYM2081 has a 46-fold lower EC_{50} value for GluN2D-containing receptors compared with GluN2A-containing NMDA receptors (Table 8). The modest subunit selectivity of SYM2081 may be due to steric clash of the 4-methyl substituent with the Tyr730, which in molecular dynamics simulations resides within the cleft of GluN2A but makes a hydrogen bond with the γ-carboxyl of glutamate in GluN2D (Erreger et al., 2007).

GluN3, like GluN1, binds glycine and can coassemble with other NMDA receptor subunits. Several differences exist between the manner by which GluN3 and GluN1 subunits bind glycine (Yao et al., 2008). Glycine and D-serine bind within the GluN3 cleft of the clamshell formed by domains D1 and D2, which causes a degree of closure similar to that caused by glycine when bound to GluN1. In GluN3A, the α-carboxyl group interacts with Arg638, Ser633, and Ser801, and the α-amino group interacts with Asp845, Ser631, and Ser633 (Fig. 8E) (Yao et al., 2008). Although both GluN1 and GluN3 subunits bind glycine, their LBDs are only ~30% homologous, and glycine affinity for the isolated GluN3 LBD is more than 600-fold higher than that for the isolated GluN1 LBD (Yao and Mayer, 2006). The ligand binding

### TABLE 8

**EC_{50} values in micromolar for agonists binding to the GluN2 subunit of the NMDA receptor**

<table>
<thead>
<tr>
<th>Glutamate-Site Agonist</th>
<th>GluN2A</th>
<th>GluN2B</th>
<th>GluN2C</th>
<th>GluN2D</th>
</tr>
</thead>
<tbody>
<tr>
<td>l-Glutamate</td>
<td>3.3 (100)</td>
<td>2.9 (100)</td>
<td>1.7 (100)</td>
<td>0.51 (100)</td>
</tr>
<tr>
<td>d-Glutamate</td>
<td>250 (99)</td>
<td>160 (120)</td>
<td>110 (100)</td>
<td>42 (110)</td>
</tr>
<tr>
<td>l-Aspartate</td>
<td>48 (99)</td>
<td>14 (78)</td>
<td>41 (78)</td>
<td>12 (91)</td>
</tr>
<tr>
<td>d-Aspartate</td>
<td>30 (103)</td>
<td>10 (91)</td>
<td>9.3 (91)</td>
<td>2.1 (90)</td>
</tr>
<tr>
<td>N-Methyl-l-aspartate</td>
<td>580 (99)</td>
<td>130 (69)</td>
<td>150 (66)</td>
<td>40 (75)</td>
</tr>
<tr>
<td>N-Methyl-d-aspartate</td>
<td>94 (93)</td>
<td>30 (78)</td>
<td>22 (86)</td>
<td>7.3 (92)</td>
</tr>
<tr>
<td>SYM2081</td>
<td>140 (72)</td>
<td>25 (89)</td>
<td>18 (71)</td>
<td>3.2 (75)</td>
</tr>
<tr>
<td>l-Homocysteinate</td>
<td>73 (91)</td>
<td>18 (94)</td>
<td>14 (70)</td>
<td>6.2 (84)</td>
</tr>
<tr>
<td>l-Homocysteinesulfinate</td>
<td>36 (89)</td>
<td>14 (99)</td>
<td>7.9 (92)</td>
<td>3.0 (100)</td>
</tr>
<tr>
<td>l-Homoquinolinate</td>
<td>34 (86)</td>
<td>8.1 (90)</td>
<td>12 (53)</td>
<td>3.4 (69)</td>
</tr>
<tr>
<td>d-Homoquinolinate</td>
<td>180 (92)</td>
<td>86 (94)</td>
<td>110 (74)</td>
<td>22 (87)</td>
</tr>
<tr>
<td>l-Cysteate</td>
<td>140 (110)</td>
<td>100 (81)</td>
<td>22 (100)</td>
<td>9.2 (95)</td>
</tr>
<tr>
<td>l-Cysteate</td>
<td>140 (95)</td>
<td>180 (77)</td>
<td>80 (82)</td>
<td>30 (83)</td>
</tr>
<tr>
<td>d-Cysteate</td>
<td>220 (21)</td>
<td>210 (67)</td>
<td>580 (110)</td>
<td>100 (97)</td>
</tr>
<tr>
<td>Homoquinolinate</td>
<td>22 (75)</td>
<td>16 (96)</td>
<td>81 (51)</td>
<td>32 (88)</td>
</tr>
<tr>
<td>Ibocaine</td>
<td>160 (99)</td>
<td>26 (89)</td>
<td>40 (72)</td>
<td>13 (78)</td>
</tr>
<tr>
<td>(R,S)-Tetrazol-5-ylglycine</td>
<td>1.7 (98)</td>
<td>0.52 (97)</td>
<td>0.49 (89)</td>
<td>0.99 (75)</td>
</tr>
<tr>
<td>L-CGC-IV</td>
<td>0.28 (99)</td>
<td>0.083 (120)</td>
<td>0.11 (90)</td>
<td>0.036 (110)</td>
</tr>
<tr>
<td>trans-ACBD</td>
<td>3.4 (91)</td>
<td>0.99 (81)</td>
<td>1.2 (67)</td>
<td>0.51 (81)</td>
</tr>
<tr>
<td>cis-ADA</td>
<td>890 (100)</td>
<td>220 (95)</td>
<td>80 (81)</td>
<td>32 (140)</td>
</tr>
<tr>
<td>trans-ACPD</td>
<td>470 (38)</td>
<td>170 (48)</td>
<td>95 (73)</td>
<td>50 (80)</td>
</tr>
<tr>
<td>cis-2,3-Piperidinedicarboxylic acid</td>
<td>61 (76)</td>
<td>21 (75)</td>
<td>22 (49)</td>
<td>11 (77)</td>
</tr>
<tr>
<td>(R)-NHP5G</td>
<td>21 (3)</td>
<td>38 (7)</td>
<td>120 (54)</td>
<td>40 (77)</td>
</tr>
<tr>
<td>(R,S)-Ethyl-NHP5G</td>
<td>47 (5)</td>
<td>88 (45)</td>
<td>91 (52)</td>
<td>43 (70)</td>
</tr>
<tr>
<td>(R)-Propyl-NHP5G</td>
<td>N.E.</td>
<td>105 (6)</td>
<td>449 (22)</td>
<td>153 (37)</td>
</tr>
</tbody>
</table>

trans-ACBD, trans-1-aminoacyclobutane-1,3-dicarboxylate; cis-ACPD, (1R,2R)-aminocyclopentane-2-carboxylate; ADC, azetidine-2,4-dicarboxylic acid; cis-ADA, cis-azetidine-2,4-dicarboxylic acid; L-CGG-IV, (2S,3R,4S)-2-(carboxyethylpropyl)glycine; N.E., no effect; NHP4G, 2-(N-hydroxy(pyrazol-4-yl)glycine; NHP5G, 2-(N-hydroxy(pyrazol-5-yl)glycine.
site of GluN3A is capped by Tyr605, which hydrogen bonds with the side chains of Ser631 and Glu522. These interactions are not present in GluN1 because all three amino acids differ. The differences in GluN1 and GluN3 residues within the binding pocket markedly alter the water molecule organization. Eight interdomain interactions between domains D1 and D2 of the GluN3 subunit are unique for the GluN3 subunit when glycine is bound and may contribute to the differences in ligand affinity (Yao and Mayer, 2006; Yao et al., 2008).

The GluN3 subunit forms functional dimer to membrane-attached GluN1/GluN3 receptors in X. laevis oocytes, and GluN3 may be incorporated into GluN1/GluN2/GluN3 receptors (Cavara and Hollmann, 2008; Schuler et al., 2008; Ulbrich and Isacoff, 2008). The exact nature and extent of GluN3 involvement in neuronal and glial receptors is an area of active study (Stys and Lipton, 2007). Within recombinant GluN1/GluN3 receptors expressed in heterologous systems, binding of glycine to GluN3 alone seems permissive for channel activation, in contrast to GluN1/GluN2 receptors, which require simultaneous binding of glycine to GluN1 and ligand to GluN2. Occupancy of the GluN1 subunit by ligand within GluN1/GluN3 receptors seems to facilitate desensitization. In GluN1/GluN3 receptors, GluN3 is activated fully by glycine and partially by D-serine and 1-aminocyclopropane-1-carboxylic acid (Chatterton et al., 2002; Smothers and Woodward, 2007), which may account for observations that D-serine antagonized GluN1/GluN3 receptors (Awobuluyi et al., 2007).

C. α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid and Kainate Receptor Competitive Antagonists

AMPA and kainate antagonists typically possess an α-amino group connected by a heterocyclic ring system to an acidic moiety (Szymańska et al., 2009). The first widely used competitive AMPA receptor antagonists were quinoxalinediones (CNQX, DNQX, NBQX), which were highly selective over NMDA receptors but antagonized kainate receptors. NBQX seems to be more selective for AMPA receptors (Wilding and Huettner, 1996) and is thus commonly used to block AMPA receptor-mediated currents (Table 9). Surprisingly, association of AMPA receptors with TARPs converts CNQX and DNQX, but not NBQX, from antagonists to weak partial agonists. CNQX and DNQX induce partial domain closure, consistent with the activity of a partial agonist (Armstrong and Gouaux, 2000). Although it is not known how interaction with TARPs results in the partial agonist activity of CNQX and DNQX, it is possible that the auxiliary subunits alter the extent of domain

![Table 9: Equilibrium dissociation constants in micromolar for AMPA receptor competitive antagonists](attachment://table_9.png)
propanoic acid (UBP282) stabilize the LBD in a hyperextended conformation compared with the apo state (Kasper et al., 2006; Ahmed et al., 2009), suggesting that the LBD has more flexibility than previously thought.

Several classes of GluK1-selective antagonists designed from different templates include the decahydroisoquinolines (3S,4aR,6S,8aR)-6-(4-carboxyphenyl)methyl)-1,2,3, 4,4a,5,6,7,8a-decahydroisoquinoline-3-carboxylic acid (LY382884) (Bortolotto et al., 1999) and 6-((2-carboxy-4, 4-difuoro-1-pyrrolidinyl)methyl)decahydro-3-isoquinolinecarboxylic acid (LY466195) (Weiss et al., 2006), and the 3-substituted phenylalanine analogs (Szymańska et al., 2009) (Table 10). LY382884 is a competitive antagonist of heteromeric kainate receptors, including GluK1/GluK2 and GluK1/GluK5, with similar potencies as at homomeric GluK1 (Bortolotto et al., 1999; Alt et al., 2004). The willardiine analogs UBP302 (More et al., 2004), (S)-1-(2-amino-2-carboxethyl)-3-(2-carboxythiophene-3-yl)-5-methylpyrimidine-2,4-dione (UBP310) (Mayer et al., 2006), and (S)-1-(2-amino-2-carboxethyl)-3-(2-carboxy-5-phenylthiophene-3-yl)-5-methylpyrimidine-2,4-dione (Dolman et al., 2007; Dargan et al., 2009) also are selective for heteromeric kainate receptors.

### Table 10

<table>
<thead>
<tr>
<th>Antagonist</th>
<th>GluK1</th>
<th>GluK2</th>
<th>GluK3</th>
<th>GluK1/GluK2</th>
<th>GluK1/GluK5</th>
<th>GluK2/GluK5</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNQX*</td>
<td>2.6</td>
<td>1.5</td>
<td></td>
<td>1.3</td>
<td>1.6</td>
<td>5.3</td>
</tr>
<tr>
<td>DNQX</td>
<td></td>
<td></td>
<td>0.35</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NBQX*</td>
<td>8.0</td>
<td></td>
<td>1.7</td>
<td>3'</td>
<td>6.2</td>
<td>4.2</td>
</tr>
<tr>
<td>ATPO</td>
<td>54'</td>
<td></td>
<td>&gt;540'</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NS102</td>
<td></td>
<td>1.4'</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NS1209</td>
<td>0.62'</td>
<td></td>
<td>13'</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LU97175*</td>
<td>0.088</td>
<td></td>
<td>0.31</td>
<td>0.022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LU115459*</td>
<td>1.3</td>
<td></td>
<td>0.37</td>
<td>0.21</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LU136541*</td>
<td>1.1</td>
<td></td>
<td>1.2</td>
<td>0.26</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kynurenic acid &amp;</td>
<td>130</td>
<td>1</td>
<td>33</td>
<td>160</td>
<td>99</td>
<td>N.E.</td>
</tr>
<tr>
<td>LY293558*</td>
<td>0.22</td>
<td></td>
<td>N.E.</td>
<td>0.65</td>
<td>0.80</td>
<td>N.E.</td>
</tr>
<tr>
<td>LY377770*</td>
<td>0.064</td>
<td></td>
<td>N.E.</td>
<td>0.13</td>
<td>0.16</td>
<td>N.E.</td>
</tr>
<tr>
<td>LY382884*</td>
<td>0.064</td>
<td></td>
<td>N.E.</td>
<td>1.3</td>
<td>0.64</td>
<td>N.E.</td>
</tr>
<tr>
<td>LY466195*</td>
<td>0.024</td>
<td></td>
<td>N.E.</td>
<td>0.024</td>
<td>0.064</td>
<td>N.E.</td>
</tr>
<tr>
<td>UBP296</td>
<td>0.6'</td>
<td></td>
<td>N.E.</td>
<td>374'</td>
<td>0.8'</td>
<td>1'</td>
</tr>
<tr>
<td>UBP304*</td>
<td>0.6'</td>
<td></td>
<td>N.E.</td>
<td>4.0'</td>
<td>0.8'</td>
<td>1'</td>
</tr>
<tr>
<td>UBP309*</td>
<td>0.12'</td>
<td></td>
<td>N.E.</td>
<td>111</td>
<td>0.12'</td>
<td>18'</td>
</tr>
<tr>
<td>UBP310*</td>
<td>0.010</td>
<td></td>
<td>N.E.</td>
<td>0.23'</td>
<td>0.008'</td>
<td>N.E.</td>
</tr>
<tr>
<td>ACET*</td>
<td>0.007</td>
<td></td>
<td>N.E.</td>
<td>0.092'</td>
<td>0.005'</td>
<td>N.E.</td>
</tr>
<tr>
<td>2,4-Epi-neoDH*</td>
<td>7.5</td>
<td>7.4</td>
<td>74</td>
<td>74 (7.7)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2-4-Epi-neoDH, 2,4-epi-neoerythrose; ACET, (S)-1-(2-amino-2-carboxyethyl)-3-(2-carboxy-5-phenylthiophene-3-yl)-methylpyrimidine-2,4-dione; CNQX, 6-cyano-7-mitroquinoline-2,3-dione; UBP115455, N-(4-(1-carboxyethyl)methyl-5,6,7,8-tetrahydrobenz[a]quinoline-2,3-(1H) dion-9-yl)pyrrol-3-yl)methyl-4-(4-carboxyphenyl)urea; UBP115451, N-(4-(1-carboxyethyl)methyl-5,6,7,8-tetrahydrobenz[a]quinoline-2,3-(1H) dion-9-yl)pyrrol-3-yl)methyl-3-(4-carboxyphenyl)urea; UBP115454, N-(4-(1-carboxyethyl)methyl-5,6,7,8-tetrahydrobenz[a]quinoline-2,3-(1H) dion-9-yl)pyrrol-3-yl)methylurea; ULP37775, 1-benzamido-7-pyrrol-1-yl-6-trifluoromethyl-8aR-(4-carboxyphenyl)methyl-3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid; N.E., no effect; NS102, 5-nitro-6,7,8,9-tetrahydrobenz[a]indole-2,3-dione-3-oxide; UBP206, (R,S)-1-(2-amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione; UBP302, 1-(2-amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione.

2-K values for NBQX, CNQX, kynurenic acid, LY293558, LY377770, and LY382884 are calculated using the Cheng-Prusoff correction with the IC50 values reported in Alt et al. (2004). *K values are for displacing [3H]AMPA binding to BKH cells stably transfected with GluK2 (Tygesen et al., 1985). †K values are calculated from the Cheng-Prusoff correction using IC50 values for displacement of [3H]kainate in GluK2 receptors expressed in HEK (Loscher et al., 1999). ‡K values are from the Cheng-Prusoff correction of IC50 values for inhibition of glutamate-activated Ca2+ influx in HERK23 cells stably transfected with rat recombinant receptors (Strange et al., 2006). ††K values are from inhibition of [3H]kainate binding to homomeric GluK2 expressed in HERK23 cells (Verdoorn et al., 1994). In functional studies, however, 10 μM NS102 caused only 50% inhibition of currents evoked from GluK2 by 300 μM glutamate and inhibited GluK2/GluA4 receptors 20%. In functional studies at rat cerebral cortical neurons or dorsal root ganglion neurons, taken to be AMPA receptors and kainate receptors, respectively, NS102 had a Kd of 114 μM and 6 μM, respectively (Wilding and Huettner, 1996). †‡K values are for inhibition of [3H]AMPA and [3H]kainate binding at recombinant human GluK1 and GluK2, respectively, expressed in HERK23 cells (Christensen et al., 2004b). ††K values for [3H]kainate to recombinant receptors expressed in HEK cells. LU7175 had a Kd of 1.3 μM and LU115455 had a Kd of 0.018 μM for displacement of [3H]AMPA at rat brain membranes (Loscher et al., 1999). †‡K values are for displacement of [3H]kainate at human receptors expressed in HERK23 cells (Weiss et al., 2006). ‡‡IC50 values are from the Cheng-Prusoff corrected IC50 values for inhibition of Ca2+ influx in HERK23 cells stably transfected with rat recombinant human receptors expressed in HERK23 cells (More et al., 2004). †*K values are for displacement of [3H]kainate from human GluK3 expressed in HERK23 cells (Dolman et al., 2006). ‡UBP206 is the active enantiomer of UBP296. ††K values are for inhibition of Ca2+ influx evoked by glutamate (100 μM) at human recombinant receptors expressed in HERK23 cells (Dolman et al., 2007). †‡IC50 values are for inhibition of currents activated by glutamate (30 μM) at HERK23 cells expressing recombinant receptors (Perrais et al., 2009). ††K values were calculated using the Cheng-Prusoff correction for inhibition of Ca2+ influx in HERK23 cells expressing human recombinant receptors (Dolman et al., 2006). †‡K values were calculated from displacement of [3H]kainate from human GluK3 expressed in HERK23 cells (Dolman et al., 2006). †‡Data for ACET at GluK1, GluK2, GluK1/GluK2, and GluK2/GluK5 are from Dolman et al. (2007). †‡IC50 values are for inhibition of currents activated by glutamate (100 μM) from HERK23/T17 cells expressing recombinant receptors (Lash et al., 2008). In the same assay, 300 μM 2,4-epi-neoDH failed to inhibit GluA4 receptors. †K values for displacement of [3H]kainate from HERK23/T17 cells expressing recombinant receptors are given in parentheses.
hydroquinoline-2-carboxylic acid; CGP-40116, D-((N-D).

GluK2 binding pockets. GluK1 selectivity is achieved as a result of steric clash between corresponding Glu705 in the carboxyl group of Glu723 in GluK5 (Glu705 in GluA2); in group of these ligands does not directly interact with the K

Data presented as

In contrast to other agonists and antagonists, the conformation that is more open than for quinoxalinediones. that the antagonists force the LBD of GluK1 to adopt a

data indicate GluK1- or GluK3-containing kainate receptors over GluK2 and GluK2 binding pockets.

D. N-Methyl-D-aspartate Receptor

Competitive Antagonists

Many competitive antagonists of the GluN1 subunits have been identified, including 7-chlorokynurenic acid and its analog 5,7-dichlorokynurenic acid (5,7-DCKA) (Birch et al., 1988; Kemp et al., 1988; Mayer et al., 1988; Kessler et al., 1989; Kleckner and Dingledine, 1989; McNamara et al., 1990) (Table 11). The GluN1 LBD shows 24° less domain closure when 5,7-DCKA is bound compared with when glycine is bound, suggesting that the antagonist stabilizes an open-cleft conformation (Furukawa and Gouaux, 2003). A majority of the contacts 5,7-DCKA forms with residues within the binding pocket are with domain D1 of the LBD. The carboxylate of 5,7-DCKA forms a hydrogen bond with Thr518 and interacts with Arg523, and the amino group forms a hydrogen bond with Pro516. Van der Waals interactions are formed between the aromatic rings of Phe408 and Trp731 and the chlorine atoms of 5,7-DCKA. Although GluN1 agonists have interdomain contacts formed between Glu405 and Trp731/Asp732, these interactions are disrupted by 5,7-DCKA (Furukawa and Gouaux, 2003). Like the GluN1 agonists, the GluN2 composition of the NMDA receptor influences the potencies of these antagonists by less than 10-fold (Ikeda et al., 1992; Kutsuwada et al., 1992; Buller et al., 1994; Priestley et al., 1995). The noble gas xenon exerts anesthetic actions independent of effects on GABAergic transmission and has been proposed to inhibit the NMDA receptor (Franks et al., 1998; de Sousa et al., 2000) through a

<table>
<thead>
<tr>
<th>Competitive Antagonist</th>
<th>Site</th>
<th>GluN2A</th>
<th>GluN2B</th>
<th>GluN2C</th>
<th>GluN2D</th>
</tr>
</thead>
<tbody>
<tr>
<td>7-CKA</td>
<td></td>
<td>0.6</td>
<td>0.2</td>
<td>0.17</td>
<td>0.09</td>
</tr>
<tr>
<td>5,7-DCKA</td>
<td></td>
<td>0.03</td>
<td>0.05</td>
<td>0.16</td>
<td>0.34</td>
</tr>
<tr>
<td>CGP-61594 (K&lt;sub&gt;i&lt;/sub&gt;)</td>
<td></td>
<td>0.43</td>
<td>0.045</td>
<td>0.16</td>
<td>0.34</td>
</tr>
<tr>
<td>CGP-58111 (K&lt;sub&gt;i&lt;/sub&gt;)</td>
<td></td>
<td>0.24</td>
<td>0.13</td>
<td>0.16</td>
<td>0.34</td>
</tr>
<tr>
<td>GV150,526A&lt;sup&gt;i&lt;/sup&gt;</td>
<td></td>
<td>0.08</td>
<td>0.08</td>
<td>0.11</td>
<td>0.05</td>
</tr>
<tr>
<td>GV196,711A&lt;sup&gt;i&lt;/sup&gt;</td>
<td></td>
<td>0.48</td>
<td>0.22</td>
<td>0.18</td>
<td>0.15</td>
</tr>
<tr>
<td>MDL105,519&lt;sup&gt;i&lt;/sup&gt;</td>
<td></td>
<td>0.012</td>
<td>0.015</td>
<td>0.012</td>
<td>0.018</td>
</tr>
<tr>
<td>ACEA-1011 (K&lt;sub&gt;i&lt;/sub&gt;)</td>
<td></td>
<td>0.33</td>
<td>0.46</td>
<td>0.21</td>
<td>0.74</td>
</tr>
<tr>
<td>ACEA-1021&lt;sup&gt;i&lt;/sup&gt;</td>
<td></td>
<td>0.004</td>
<td>0.004</td>
<td>0.003</td>
<td>0.11</td>
</tr>
<tr>
<td>L-689,560 (K&lt;sub&gt;i&lt;/sub&gt;)</td>
<td></td>
<td>0.004</td>
<td>0.02</td>
<td>0.05</td>
<td>0.05</td>
</tr>
<tr>
<td>L-701,324&lt;sup&gt;i&lt;/sup&gt;</td>
<td></td>
<td>0.005</td>
<td>0.005</td>
<td>0.005</td>
<td>0.005</td>
</tr>
<tr>
<td>(R)-AP5&lt;sup&gt;+&lt;/sup&gt;</td>
<td></td>
<td>0.28</td>
<td>0.46</td>
<td>1.6</td>
<td>3.7</td>
</tr>
<tr>
<td>(R)-AP5&lt;sup&gt;+&lt;/sup&gt;</td>
<td></td>
<td>0.49</td>
<td>4.1</td>
<td>6.4</td>
<td>17</td>
</tr>
<tr>
<td>PMPA&lt;sup&gt;+&lt;/sup&gt;</td>
<td></td>
<td>0.84</td>
<td>2.7</td>
<td>3.5</td>
<td>4.2</td>
</tr>
<tr>
<td>(R)-CPP&lt;sup&gt;+&lt;/sup&gt;</td>
<td></td>
<td>0.24</td>
<td>2.7</td>
<td>0.63</td>
<td>1.99</td>
</tr>
<tr>
<td>NVP-AAM077 (K&lt;sub&gt;i&lt;/sub&gt;)</td>
<td></td>
<td>0.015</td>
<td>0.078</td>
<td>0.096</td>
<td>0.13</td>
</tr>
<tr>
<td>PPDA</td>
<td></td>
<td>0.55</td>
<td>0.31</td>
<td>0.98</td>
<td>0.43</td>
</tr>
<tr>
<td>(R)-&lt;sup&gt;a&lt;/sup&gt;AA</td>
<td></td>
<td>0.65</td>
<td>26</td>
<td>44</td>
<td>110</td>
</tr>
<tr>
<td>PBPD</td>
<td></td>
<td>1.6</td>
<td>5.0</td>
<td>8.9</td>
<td>4.3</td>
</tr>
<tr>
<td>UBPI4&lt;sup&gt;i&lt;/sup&gt;</td>
<td></td>
<td>14</td>
<td>19</td>
<td>4.2</td>
<td>2.8</td>
</tr>
<tr>
<td>CGS-19755 (selfotel)&lt;sup&gt;i&lt;/sup&gt;</td>
<td></td>
<td>0.15</td>
<td>0.58</td>
<td>0.58</td>
<td>1.1</td>
</tr>
<tr>
<td>CGP-43487 (K&lt;sub&gt;i&lt;/sub&gt;)</td>
<td></td>
<td>0.28</td>
<td>1.6</td>
<td>0.89</td>
<td>0.31</td>
</tr>
<tr>
<td>CGP-40116 (K&lt;sub&gt;i&lt;/sub&gt;)</td>
<td></td>
<td>0.04</td>
<td>0.03</td>
<td>0.01</td>
<td>0.001</td>
</tr>
<tr>
<td>Con&lt;sup&gt;i&lt;/sup&gt;</td>
<td></td>
<td>0.68</td>
<td>0.14</td>
<td>0.14</td>
<td>0.14</td>
</tr>
<tr>
<td>Con&lt;sup&gt;G&lt;/sup&gt;</td>
<td></td>
<td>&gt;10</td>
<td>0.1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Con&lt;sup&gt;p&lt;/sup&gt;</td>
<td></td>
<td>&gt;10</td>
<td>0.2</td>
<td>&gt;10</td>
<td>1</td>
</tr>
<tr>
<td>Con&lt;sup&gt;p&lt;/sup&gt;</td>
<td></td>
<td>&gt;10</td>
<td>0.5</td>
<td>&gt;10</td>
<td>1</td>
</tr>
<tr>
<td>Con&lt;sup&gt;p&lt;/sup&gt;</td>
<td></td>
<td>&gt;10</td>
<td>&gt;10</td>
<td>&gt;10</td>
<td>&gt;10</td>
</tr>
<tr>
<td>Con&lt;sup&gt;H&lt;/sup&gt;</td>
<td></td>
<td>1</td>
<td>1</td>
<td>&gt;10</td>
<td></td>
</tr>
<tr>
<td>Con&lt;sup&gt;T&lt;/sup&gt;</td>
<td></td>
<td>3.2</td>
<td>2.9</td>
<td>3.2</td>
<td>2.9</td>
</tr>
</tbody>
</table>

α,AA, α-amino adipate; 7,5-DCKA, 5,7-dichlorokynurenic acid; 7-CKA, 7-chlorokynurenic acid; ACEA-1011, 5-chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinazoline; ACEA-1021, licostinel; AP5, 2-amino-5-phosphono pentanoic acid; AP7, 2-amino-7-phosphonopentanoic acid; CGP-61594, (+)-trans-4-{2-[4-azidophenyl]acetylaminol]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid; CGP-40116, (E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid; CGP-43487, (E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid methyl ester; CGF-58111, 7-chloro-4-hydroxy-3-phenyl-1H-quinolin-2-one. CGS-19755, (R)-4S-4-(phosphonomethyl)piperidine-2-carboxylic acid; CPP, 4-(3-phosphonopropyl)piperazine-2-carboxylic acid; GV150,526A, gavestinel; GV196,711A, (E)-4-(4-chloro-3-fluorophenyl)-3-(3-fluorophenyl)imidazolin-2-one; L-689,560, 4-(trans-2-carboxy-5,7-dichloro-4-phenylamino-carbonylamino)-1,2,3,4-tetrahydroquinoline; L-701,324, 7-chloro-4-hydroxy-3-(3-phenoxyphenyl)-2(1H)-quinolone; MDL105,519, (E)-3-(2-phenyl-2-carboxybenzylidene)-4,6-dichloro-1H-indole-2-carboxylic acid; PBPD, (2S,3R)-1-(biphenyl-4-carbonyl)piperazine-2,3-dicarboxylic acid; PMPA, (E)-5-(phosphonomethyl)piperazine-2-carboxylic acid; PPDA, (2S,3R)-1-(phenanthren-2-carbonyl)piperazine-2,3-dicarboxylic acid.

direct interaction within the glycine binding site (Dickinson et al., 2007). Thus, xenon, like ketamine, may target the glutamatergic system to provide anesthetic effects.

The GluN2 competitive antagonist (R)-2-amino-5-phosphonopentanoate and its analogs are used widely as pharmacological tools to distinguish NMDA receptor-mediated activity from AMPA and kainate receptor activity (Davies et al., 1981, 1986; Evans et al., 1981; Lester et al., 1990) (Table 11). Unfortunately, GluN2 subunit selectivity has been difficult to achieve for competitive antagonists. For example, the antagonist 3-(R)-2-carboxy-piperazin-4-yl-propyl-1-phosphonic acid shows ~50-fold preference for GluN2A over GluN2D but has intermediate affinities at GluN2B and GluN2C (Ikeda et al., 1992; Kutsuwada et al., 1992; Feng et al., 2005) (Table 11). The competitive antagonist (R)-(S)-1-(4-bromo-phenyl)-ethylaminolo-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl-phosphonic acid (NVP-AAM077), originally reported to have more than 100-fold selectivity for GluN2A-containing receptors over GluN2B-containing receptors, was used to evaluate physiological roles of GluN2A and GluN2B in rodent models of synaptic plasticity and neurotoxicity before a full pharmacological characterization was completed (Liu et al., 2004b; Massey et al., 2004; Zhou and Baudry, 2006). Subsequent determination of Kᵦ from Schild analysis suggested that the selectivity was only ~5-fold, precluding its use as a selective tool (Frizelle et al., 2006; Neyton and Paoletti, 2006). Antagonists with bulky, hydrophobic substituents, selective tool (Frizelle et al., 2006; Neyton and Paoletti, 2006), may be difficult to achieve because of high homology among GluN2 subunit LBDs. Of the 39 residues lining the binding pocket, only 8 are divergent in GluN2A to GluN2D. Of the 39 residues that come into direct contact with glutamate are conserved between GluN2 subunits (Furukawa et al., 2005; Kinarsky et al., 2005).

Conantokins, peptides of 17 to 27 amino acids that lack disulfide bonds and are rich in γ-carboxyglutamate residues, have both competitive and noncompetitive antagonist activity on NMDA receptors (Prorok and Castellino, 2007). Conantokin-G is 20-fold more potent on GluN2A and GluN2B-containing NMDA receptors than on GluN2C and GluN2D-containing receptors (Wittekindt et al., 2001; Sheng et al., 2007; Teichert et al., 2007), and conantokin-Br is more potent for the GluN2D-containing NMDA receptors than other conantokins (Table 11) (Twede et al., 2009). Although conantokin-G binds within the GluN2 ligand binding pocket, one molecular determinant of specificity of conantokin-G for GluN2B has been identified as a Met739 residue outside of the binding pocket within the D2 domain of the LBD. This residue is not conserved in GluN2A receptors but is present in GluN2C and GluN2D subunits (Teichert et al., 2007). Conantokin-R and conantokin-T are antagonists of NMDA receptors, but antagonism is not GluN2 subunit-specific (Klein et al., 2001; Sheng et al., 2007; Teichert et al., 2007). Conantokins R and G have been studied preclinically for their effectiveness in the treatment of chronic pain, stroke, and seizure (White et al., 2000; Layer et al., 2004; Hama and Sagen, 2009).

### E. Noncompetitive Antagonists

Several classes of noncompetitive antagonists at AMPA receptors have been used to selectively block AMPA but not kainate receptors, including 2,3-benzodiazepines and 1,2-dihydrophthalazines, as well as tetrahydroisoquinolines (Gitto et al., 2003). However, the most potent of the 2,3-benzodiazepines, 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine (GYKI-53655) (Table 12), blocks GluK2/GluK3 heteromeric and GluK3 homomeric receptors with an IC₅₀ that is approximately 10-fold higher than at AMPA receptors (Bleakman et al., 1996; Perrais et al., 2009). In contrast to the competitive antagonists CNQX and DNQX, GYKI-53655 remains an effective AMPA receptor antagonist in the presence of TARPs, with the potency of the antagonist

<table>
<thead>
<tr>
<th>Noncompetitive Antagonist</th>
<th>GluA1</th>
<th>GluA2</th>
<th>GluA3</th>
<th>GluA4</th>
<th>GluK1</th>
<th>GluK2</th>
<th>GluK3</th>
<th>GluK2/GluK5</th>
</tr>
</thead>
<tbody>
<tr>
<td>GYKI 52468</td>
<td>18–117</td>
<td>34</td>
<td>22–66</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GYKI 53405 (LY 293606)</td>
<td>24</td>
<td>28</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GYKI 53773 (LY 300164)</td>
<td>21</td>
<td>18</td>
<td>18</td>
<td>&gt;100</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GYKI 53655 (LY 300168)</td>
<td>6</td>
<td>5</td>
<td>&gt;100</td>
<td>198</td>
<td>63</td>
<td>&gt;100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GYKI 53784 (LY 303070)</td>
<td>3</td>
<td>3</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CP-465,022</td>
<td>0.5</td>
<td>0.5</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NS-3783</td>
<td>&gt;30</td>
<td>&gt;30</td>
<td>N.E.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*GYKI 52466, 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine; GYKI 53405, 1-(4-aminophenyl)-3-acetyl-4-methyl-3,4-dihydro-7,8-methylenedioxy-5H-2,3-benzodiazepine; GYKI 53655, 1-(4-aminophenyl)-3-methylcarbamoyl-4-methyl-3,4-dihydro-7,8-methylenedioxy-5H-2,3-benzodiazepine.*

*BLEAKMAN ET AL.* (1996): “Johansen et al. (1995): IC₅₀ value was determined from inhibition of Ca²⁺ influx activated by 30 μM glutamate at human GluA3 expressed in HEK69–8 cells (Varney et al., 1998). This compound is the active enantiomer of the compound directly above it. Cotton and Partin (2000). Perrais et al. (2009). Balannik et al. (2005). Lazzaro et al. (2002). Values are for inhibition of Ca²⁺ influx evoked by domoate (2 μM for GluK1 and 0.2 μM for GluK2) in HEK293 cells expressing recombinant human receptors (Christensen et al., 2004b). Values are for inhibition of glutamate-evoked currents at HEK293 cells expressing recombinant receptors (Christensen et al., 2004b).
increased (Menuz et al., 2007; Cokić and Stein, 2008). (S)-3-(2-Chlorophenyl)-2-[2-(6-diethylaminomethyl-pyridin-2-yl)-vinyl]-6-fluoro-3H-quinazolin-4-one (CP-465,022) (Menniti et al., 2000), an analog of quinazolinone, is approximately 100-fold more potent than GYKI-53655 at neuronal AMPA receptors (Bleakman et al., 1996; Menniti et al., 2000; Lazzaro et al., 2002) and seems 100-fold selective for AMPA over kainate receptors (Lazzaro et al., 2002). Mutagenesis studies suggest that GYKI-53655 and CP-465,022 share overlapping molecular determinants of action, requiring both S2–M4 and the S1–M1 linkers (Fig. 9; Balannik et al., 2005), the latter of which may be a critical element in gating (Sobolevsky et al., 2009) (see section VII.B and VII.D). The mechanism of block remains unclear but seems not to involve desensitization (Donevan and Rogawski, 1998).

A major advance in kainate receptor pharmacology was made with the identification of arylureidobenzoic acids as noncompetitive GluK1 receptor antagonists (Valgeirsson et al., 2003, 2004). The most potent of these 2-arylureidobenzoic acids is 4,6-bis(benzoylamino)-1,3-benzenedicarboxylic acid (NS-3763), a selective antagonist of homomeric GluK1 (Table 12) that has no activity at heteromeric GluK1/GluK2 or GluK1/GluK5, AMPA receptors, or NMDA receptors. NS-3763 exhibits 10-fold greater potency in inhibiting glutamate-evoked currents from GluK1–2b versus GluK1–1a, two splice variants differing in 15 extracellular amino acid residues in the ATD and a cytoplasmic domain (Christensen et al., 2004b). Because NS-3763 inhibits only homomeric GluK1 receptors, it has been useful in exploring native kainate receptor stoichiometry (Christensen et al., 2004a).

The first subunit-selective NMDA receptor antagonist was the phenylethanolamine ifenprodil, which defined a new class of noncompetitive, voltage-independent partial antagonists (maximal inhibition ~90%) of GluN2B-containing NMDA receptors (Table 13). Ifenprodil inhibits GluN2B-containing receptors with high affinity and is 200 to 400-fold more potent for GluN1/GluN2B receptors than for GluN1/GluN2A, GluN1/GluN2C, or GluN1/GluN2D receptors (Williams, 1993; Hess et al., 1998; IC_{50} ~150 nM). GluN1 splice variants do not influence the ability of ifenprodil to inhibit GluN2B-containing receptors (Gallagher et al., 1996), but triheteromeric receptors containing GluN1/GluN2A/GluN2B are proposed to be less sensitive to ifenprodil (Hatton and Paololetti, 2005), and insensitive to CP-101,606 (Brimecombe et al., 1997; Chazot et al., 2002). The kinetic properties of ifenprodil also are altered in triheteromeric receptors; the macroscopic association rate of ifenprodil in GluN1/GluN2A/GluN2B receptors was slower, whereas the dissociation rate was faster than in GluN1/GluN2B receptors.
prodil analogs such as Ro 25-6981 and CP-101,606 receptors, calcium channels, and hERG potassium channels. Ifenprodil inhibits NMDA receptor function as a noncompetitive antagonist. Similar to Zn²⁺, its actions might also be considered negative allosteric modulators upon the GluN2 subunit (Lovinger et al., 1989, 1993; Chenard et al., 1995; Fischer et al., 1997; Mott et al., 2006; Woods et al., 2006). Potency for Dynorphin A (1–13) is dependent upon GluN2 subunit, with the peptide being most potent for GluN2A-containing NMDA receptors (Loving, 2002; Maldve et al., 2002). However, recent studies suggest that recombinant NMDA receptor inhibition is modest at the U.S./U.K. drink-drive limit as well as at intoxicating levels (Otton et al., 2009). Dynorphin peptides have been reported to have a variety of actions on NMDA receptors, acting as noncompetitive antagonists (Chen and Huang, 1998; Kanemitsu et al., 2003; Oz et al., 2004) as well as potentiators under some circumstances (Zhang et al., 1997; Caudle and Dubner, 2003; Oz et al., 2004) as well as potentiators under some circumstances (Zhang et al., 1997; Caudle and Dubner, 2003). Dynorphin A (1–17) and (2–17) can displace glycine at GluN1 (Voorn et al., 2007) and can bind to an anionic intracellular epitope on GluN1 that may interact with dopamine receptors (Jackson et al., 2006; Woods et al., 2006). Potency for Dynorphin A (1–13) is dependent upon GluN2 subunit, with the peptide being most potent for GluN2A-containing NMDA receptors (Brauneis et al., 1996). Longer dynorphin peptides are more potent inhibitors [e.g., Dynorphin A (1–32); Chen and Huang, 1998]. Inhibition by dynorphin A.

### Table 13

<table>
<thead>
<tr>
<th>Antagonist</th>
<th>GluN2A</th>
<th>GluN2B</th>
<th>GluN2C</th>
<th>GluN2D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ifenprodil</td>
<td>39</td>
<td>0.15</td>
<td>29</td>
<td>76</td>
</tr>
<tr>
<td>Ro 25-6981</td>
<td>52</td>
<td>0.0090</td>
<td>N.E.</td>
<td>N.E.</td>
</tr>
<tr>
<td>CP-101,606</td>
<td>&gt;100</td>
<td>0.0339</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>Eliprodil</td>
<td>&gt;100</td>
<td>3.02</td>
<td>N.E.</td>
<td>N.E.</td>
</tr>
<tr>
<td>Felbamate</td>
<td>2600</td>
<td>520</td>
<td>2400</td>
<td>N.E.</td>
</tr>
<tr>
<td>Haloperidol</td>
<td>N.E.</td>
<td>3</td>
<td>N.E.</td>
<td>N.E.</td>
</tr>
</tbody>
</table>

IC₅₀ values in micromolar for noncompetitive GluN2B-selective NMDA receptor antagonists.

Data are for rat recombinant receptors, except for ifenprodil, which was characterized on human recombinant receptors. Data for ifenprodil are from Hess et al. (1998). Values for Ro 25-6981 are from Fischer et al. (1997) and values for CP 101,606 are from Mott et al. (1998). Values for eliprodil are from Avenet et al. (1997), and values for felbamate are from Harty and Rogawski (2000). Values for haloperidol are from Ilyin et al. (1996).

The GluN2B selective antagonist (3S,4R)-4-methylbenzyl 3-fluoro-4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate (MK-0657) unexpectedly increased both systolic and diastolic blood pressure. It is unclear whether these effects occur peripherally or centrally (Addy et al., 2009; Mony et al., 2009).

Certain quinazolin-4-one analogs of the noncompetitive AMPA receptor antagonist CP-465,022 can also inhibit recombinant NMDA receptors in a voltage-independent and noncompetitive fashion (Moslery et al., 2010). These data suggest that a new site for noncompetitive antagonism may exist on recombinant NMDA receptors. Some quinazolin-4-ones are greater than 50-fold more potent at recombinant NMDA receptors that contain GluN2C/GluN2D subunits over NMDA receptors that contain GluN2A/GluN2B subunits or AMPA/kainate receptors. These compounds could provide a starting point for the development of new classes of subunit-selective antagonists for NMDA receptors that contain GluN2C or GluN2D subunits.

Ethanol has been proposed to be a noncompetitive antagonist of NMDA receptors, with sensitivity dependent upon the GluN2 subunit (Loving, 1989, 1990; Kuner et al., 1993; Masood et al., 1994; Mirshahi and Woodward, 1995; Kash et al., 2008; Nagy, 2008) but independent of GluN1 splice variant, pH, Zn²⁺, or redox state (Kuner et al., 1993; Chu et al., 1995; Peoples and Weight, 1999). A wide range of studies has suggested that actions at native NMDA receptors contribute to the central effects of alcohol, which may involve perturbation of the interaction between glutamate and dopamine (Loving, 2002; Maldve et al., 2002). However, recent studies suggest that recombinant NMDA receptor inhibition is modest at the U.S./U.K. drive-drive limit as well as at intoxicating levels (Otton et al., 2009). Dynorphin peptides have been reported to have a variety of actions on NMDA receptors, acting as noncompetitive antagonists (Chen and Huang, 1998; Kanemitsu et al., 2003; Oz et al., 2004) as well as potentiators under some circumstances (Zhang et al., 1997; Caudle and Dubner, 1998; Lai et al., 1998). Dynorphin A (1–17) and (2–17) can displace glycine at GluN1 (Voorn et al., 2007) and can bind to an anionic intracellular epitope on GluN1 that may interact with dopamine receptors (Jackson et al., 2006; Woods et al., 2006). Potency for Dynorphin A (1–13) is dependent upon GluN2 subunit, with the peptide being most potent for GluN2A-containing NMDA receptors (Brauneis et al., 1996). Longer dynorphin peptides are more potent inhibitors [e.g., Dynorphin A (1–32); Chen and Huang, 1998]. Inhibition by dynorphin A.
is pH sensitive in that inhibition increases at lower pH (Kanemitsu et al., 2003; Oz et al., 2004).

F. Uncompetitive Antagonists

Open channel blockers require that the receptor pore be open to allow access to the blockers’ binding site to cause subsequent block of receptor activity (Neely and Lingle, 1986; Huettner and Bean, 1988; Kiskin et al., 1989) (Fig. 9). Because of this requirement, the onset of inhibition is use-dependent and increases with increasing channel open probability. After channel closure, some blockers can become trapped in the pore, and these antagonists are called trapping blockers [PCP, dizocilpine maleate (MK-801), ketamine at NMDA receptors, 1-trimethylammonio-5-(1-adamantane-methylammonio-pentane dibromide) (IEM-1460) at AMPA receptors] and partially trapping blockers (memantine at NMDA receptors). Channel block by trapping blockers is slow to reverse and requires channel reactivation by agonists before the blocker can dissociate (Brackley et al., 1993; Parsons et al., 1995; Blan pied et al., 1997; Magazanik et al., 1997).

A large number of naturally occurring AMPA and kainate receptor channel blockers, as well as a host of synthetic analogs, have been identified (Table 14), including argiotoxin-636 (Herlitze et al., 1993), Joro spider toxin (Blaschke et al., 1993), Ageltoxin-489 (Washburn and Dingledine, 1996), philantotoxin-433 (Jones et al., 1990), IEM-1460 (Magazanik et al., 1997), and N1-naphthylacetylserpine (Koike et al., 1997), which also blocks mutant Lurcher GluD2 channels. Some of these compounds have nonspecific actions at other ion channels (Welch et al., 2008). All of these uncompetitive antagonists have structural similarity (i.e., a polyamineamines in the polyamine moiety with either oxygen or nitrogen) and lead to potent and selective AMPA receptor blockers. Shortening the polyamine chain of PhTX-343 caused a marked decrease in potency at AMPA receptors (Mellor et al., 2003). Moreover, replacing the two secondary amines in the polyamine moiety with either oxygen or nitrogen (Kromann et al., 2005a) (see section II.F).

Structure-activity relationships of philantotoxins have highlighted the importance of the polyamine moiety and led to potent and selective AMPA receptor blockers. Shortening the polyamine chain of PhTX-343 produced a marked decrease in potency at AMPA receptors (Mellor et al., 2003). Moreover, replacing the two secondary amines in the polyamine moiety with either oxygen or nitrogen resulted in a complete loss of activity, whereas replacing only one with methylene improved potency 15-fold and increased selectivity for AMPA versus NMDA receptors to 100-fold (Mellor et al., 2003). Further modification of the polyamine tail of PhTX-343 resulted in PhTX-56 and PhTX-74, which differ in the

### Table 14

<table>
<thead>
<tr>
<th>Uncompetitive Antagonist</th>
<th>GluA1</th>
<th>GluA2</th>
<th>GluA3</th>
<th>GluA4</th>
<th>GluA1/GluA2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argiotoxin 636</td>
<td>0.35–3.4μM</td>
<td>N.E.</td>
<td>0.23μM</td>
<td>0.43μM</td>
<td>300μM</td>
</tr>
<tr>
<td>Joro spider toxin</td>
<td>0.04μM</td>
<td>N.E.</td>
<td>0.03μM</td>
<td>N.E.</td>
<td>N.E.</td>
</tr>
<tr>
<td>Philantotoxin 433</td>
<td>0.8</td>
<td>N.E.</td>
<td>N.E.</td>
<td>N.E.</td>
<td>270μM</td>
</tr>
<tr>
<td>Philantotoxin 343</td>
<td>2.8μM</td>
<td>N.E.</td>
<td>N.E.</td>
<td>N.E.</td>
<td>N.E.</td>
</tr>
<tr>
<td>Philantotoxin 56</td>
<td>33 pM</td>
<td>N.E.</td>
<td>1.6μM</td>
<td>N.E.</td>
<td>N.E.</td>
</tr>
<tr>
<td>Philantotoxin 74</td>
<td>1.7μM</td>
<td>N.E.</td>
<td>1.6μM</td>
<td>N.E.</td>
<td>N.E.</td>
</tr>
<tr>
<td>IEM-1460</td>
<td>0.08μM</td>
<td>N.E.</td>
<td>0.5</td>
<td>N.E.</td>
<td>N.E.</td>
</tr>
<tr>
<td>HPP-spermine⁴</td>
<td>0.5</td>
<td>N.E.</td>
<td>N.E.</td>
<td>N.E.</td>
<td>N.E.</td>
</tr>
</tbody>
</table>

HPP-spermine, N-[4-hydroxyphenylpropanoyl]serpine trihydrochloride; IEM-1754, 1-ammonio-5-(1-adamantane-methylammonio-pentane dibromide); N.E., no effect.

¹Herlitze et al. (1993); holding membrane potential was −70 mV. ²Brackley et al. (1993); holding membrane potential, −80 mV. ³Blaschke et al. (1993); holding membrane potential, −100 mV. ⁴Washburn and Dingledine (1996); holding membrane potential, −70 mV. Although IC₅₀ values were not calculated, initial experiments suggested that philantotoxin-433 had a lower affinity for GluA1 and GluA4 receptors compared with GluA3. ⁵Philantotoxin 56 has an IC₅₀ of 3.3 pM for recombinant GluA1 (Kromann et al., 2002); holding membrane potential, −80 mV. ⁶Magazanik et al. (1997); holding membrane potential, −80 mV. ⁷Schlesinger et al. (2005); holding membrane potential, −60 mV; recombinant human GluA2(R).
number of amines and intervening methylene (Kromann et al., 2007). PhTX-56 is highly selective for Ca\(^{2+}\)-permeable AMPA receptors, being 1000-fold more potent at GluA2-lacking receptors. PhTX-56 is 500-fold selective for AMPA over kainate receptors (Kromann et al., 2002). PhTX-74 inhibits GluA1/GluA2 but not GluA2/GluA3 receptors (Nilsen and England, 2007).

Uncompetitive NMDA receptor antagonists include Mg\(^{2+}\), polyanines (see section VIII.C), dissociative anesthetics phencyclidine and ketamine, MK-801, aminoadamantine derivatives memantine and amantadine, pentamidine, 9-tetrahydroaminoacridine, dextromethorphan, and its metabolite dextrorphan (Williams et al., 2003). The structure–activity relationship underlying the trapping nature of blockers is unrelated to lipophilicity, and thus blockers are not capable of escaping through the membrane (Mealing et al., 2001; Bolshakov et al., 2005). Partially trapping blockers, such as memantine and amantadine, bind after channel opening. However, these drugs also unbind rapidly (Blanpied et al., 1997, 2005; Chen and Lipton, 1999), which has been proposed to be therapeutically beneficial, because normal synaptic transmission may not be influenced by the drug, but overactivation of NMDA receptors should be decreased (Chen and Lipton, 2006) (see section X.G). Memantine may access multiple binding sites, one of which has been proposed to reside superficially near the extracellular end of the pore in GluN1/GluN2A. Occupancy of this superficial site may prevent full channel closure (Sobolevsky and Koshelev, 1998; Sobolevsky et al., 1998; Bolshakov et al., 2003); however, more work is needed to determine the exact location with respect to the gate of this superficial site. The presence of the superficial binding site also could be relevant for improved side effect profile for memantine (Kotermanski et al., 2009).

Most NMDA receptor channel blockers are either nonselective or at best weakly selective (<10-fold) for specific GluN2 subtypes (Yamakura et al., 1993). For example, MK-801 is ~10-fold more potent for GluN2A- and GluN2B-containing receptors than GluN2C- and GluN2D-containing receptors (Bresink et al., 1996; Dravid et al., 2007). However, aryl-polyamine derivatives show high potency as well as slightly better subunit selectivity, with \(N^1\)-dansyl-spermine and the tribenzyltriamine TB-3-4 showing approximately 40- to 50-fold lower IC\(_{50}\) values at GluN2A- than GluN2D-containing NMDA receptors (Chao et al., 1997; Igarashi et al., 1997; Jin et al., 2007). The molecular determinants of activity of channel blockers are not identical but overlap, with dependence on residues within the M2 reentrant pore region and residues in other pore-forming elements as well as the pre-M1 region (Yamakura et al., 1993; Yamakura and Shimoji, 1999; Kashiwagi et al., 2002; LePage et al., 2005; Jin et al., 2007). The sequence similarity within the pore-forming elements of NMDA receptors may constitute a challenge in the future development of subunit-selective compounds. It is noteworthy that the potencies of channel blocking compounds are sensitive to pH. Although acidic pH reduces NMDA receptor open probability (Traynelis and Cull-Candy, 1990), acidic pH paradoxically increases the association rate of the trapping blocker MK-801, which may reflect an interaction of MK-801 with the structural elements forming the gate of the receptor (Dravid et al., 2007). Several reports raise the possibility that trapping blockers do not passively reside in the pore when their

### TABLE 15

IC\(_{50}\) values in micromolar for uncompetitive NMDA receptor antagonists

<table>
<thead>
<tr>
<th>Uncompetitive Antagonist</th>
<th>GluN2A</th>
<th>GluN2B</th>
<th>GluN2C</th>
<th>GluN2D</th>
</tr>
</thead>
<tbody>
<tr>
<td>(++)-MK-801</td>
<td>0.015</td>
<td>0.009</td>
<td>0.024</td>
<td>0.038</td>
</tr>
<tr>
<td>(--) MK-801</td>
<td>0.35</td>
<td>0.32</td>
<td>0.038</td>
<td>0.17</td>
</tr>
<tr>
<td>(++)-Ketamine</td>
<td>1.6</td>
<td>1.1</td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>(++)-Norketamine</td>
<td>5.8</td>
<td>5.6</td>
<td>7.5</td>
<td>7.5</td>
</tr>
<tr>
<td>Dextromethorphan</td>
<td>1.1</td>
<td>1.1</td>
<td>5.4</td>
<td>5.4</td>
</tr>
<tr>
<td>Levomethorphan</td>
<td>1.1</td>
<td>1.1</td>
<td>2.6</td>
<td>2.6</td>
</tr>
<tr>
<td>Dextrophan</td>
<td>0.33</td>
<td>0.15</td>
<td>0.74</td>
<td>0.74</td>
</tr>
<tr>
<td>Levorphanol</td>
<td>1.2</td>
<td>0.58</td>
<td>2.1</td>
<td>2.1</td>
</tr>
<tr>
<td>Phencyclidine</td>
<td>0.16</td>
<td>0.16</td>
<td>0.22</td>
<td>0.22</td>
</tr>
<tr>
<td>PCA</td>
<td>1.6</td>
<td>1.6</td>
<td>1.7</td>
<td>1.7</td>
</tr>
<tr>
<td>CNS-1102</td>
<td>0.068</td>
<td>0.087</td>
<td>0.14</td>
<td>0.14</td>
</tr>
<tr>
<td>Amantadine</td>
<td>35</td>
<td>35</td>
<td>38</td>
<td>38</td>
</tr>
<tr>
<td>Remacemide</td>
<td>63</td>
<td>63</td>
<td>63</td>
<td>63</td>
</tr>
<tr>
<td>Pentamidine</td>
<td>9.1</td>
<td>9.1</td>
<td>9.1</td>
<td>9.1</td>
</tr>
<tr>
<td>9-aminoacridine</td>
<td>29</td>
<td>29</td>
<td>38</td>
<td>38</td>
</tr>
<tr>
<td>Memantine</td>
<td>0.52</td>
<td>0.52</td>
<td>0.54</td>
<td>0.54</td>
</tr>
<tr>
<td>Memantine–1 mM Mg(^{2+})</td>
<td>1.6</td>
<td>1.6</td>
<td>1.8</td>
<td>1.8</td>
</tr>
<tr>
<td>(++)-Ketamine</td>
<td>0.31</td>
<td>0.31</td>
<td>0.51</td>
<td>0.51</td>
</tr>
<tr>
<td>(++)-Ketamine–1 mM Mg(^{2+})</td>
<td>1.2</td>
<td>1.2</td>
<td>2.9</td>
<td>2.9</td>
</tr>
</tbody>
</table>

All values were measured in 0 Mg\(^{2+}\), unless otherwise indicated. Values for memantine and (++)-ketamine are from Kotermanski and Johnson (2009) with membrane potential held at ~66 mV. All remaining values are from Dravid et al. (2007) with membrane potential held at ~40 mV.

CNS-1102, aptiganel; PCA, 1-phenylethylhexamine.
exit path is removed as a result of channel closure, but rather stabilize the closed state, thereby promoting channel closure and their own subsequent trapping (Blanpied et al., 2005; Yuan et al., 2005). Recent work conducted on ketamine and memantine indicate that these antagonists may be more selective at physiological conditions than previously reported, because 1 mM Mg$^{2+}$ produced a 5- to 10-fold selectivity for GluN2C- and GluN2D-containing receptors over GluN2A and GluN2B (Table 15; Kotermanski and Johnson, 2009). These findings may be clinically and functionally significant, depending on concentrations of memantine reached in brain. These results also emphasize the need to study pharmacology under physiological conditions.

VI. Allosteric Regulation

Allosteric modulators for glutamate receptors have attracted attention because of their ability to fine-tune normal receptor function as well as for their potential utility as therapeutic agents. Drug-like positive or negative allosteric modulators have distinct therapeutic advantages over agonists and competitive antagonists, including higher potential for receptor subtype selectivity, because they often target less conserved regions than the agonist binding site (Figs. 2 and 9). Clinically, modulators are generally thought to be better tolerated because they modify existing levels and patterns of receptor activation, rather than constitutively blocking (as with antagonists) or overactivating (as with agonists) all receptors.

A. Positive and Negative Allosteric Modulators

A growing range of compounds potentiate AMPA receptor activity through modification of the deactivation and/or desensitization time course (Arai et al., 1994; Stäubli et al., 1994; Lauterborn et al., 2000). Binding of AMPA receptor agonists within the cleft of the LBD induces closure around the ligand, which has been proposed to create strain within the receptor complex that can be relieved by channel opening or relaxation of the LBD dimer interface to a desensitized state, in which agonist remains bound but the channel is closed (Sun et al., 2002; Sobolevsky et al., 2009) (Fig. 3). The receptor deactivates as the channel closes and the ligand fully unbinds, exiting the binding cleft. Positive AMPA receptor modulators bind at the LBD dimer interface, making a number of intraprotomer atomic contacts that stabilize the dimerized configuration and prevent transition to the relaxed state after agonist binding, thus preventing desensitization (Figs. 3 and 10B). Some of these compounds also can slow the rate of agonist exit, thus preventing deactivation.

At present, there are three structural classes of positive AMPA receptor modulators: 1) pyrrolidinone and related piperidine compounds [e.g., aniracetam, piracetam, oxiracetam, and the ampakines 2H,3H,6aH-pyrrolidino(2′,1′-3′, 2′)-1,3-oxazino(6′,5′-5,4′)benzo(e)1,4-dioxan-10-one (CX614), ampalex (CX156), and 1-(1,4-benzodioxan-6-ylcarbonyl)piperidine (CX546)], 2) benzothiazide compounds [e.g., cyclothiazide, diazoxide, (+)-3,3-dihydro-(3,4)cyclopentano-1,2,4-benzothiazine-1,1-dioxide (S18866), and 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiazidine- S,S-dioxide (IDRA-21)], and 3) biarylpropylsulfonamide compounds [e.g., PEPA, N-[2-(3-cyanobiphenyl-4-yl)propyl]pyrrole-2-sulfonamide (LY404187), N-(2-(4-thiophen-3-yl)phenyl)propylpyrrole-2-sulfonamide (LY392098), (R)-2-(4-(3,5-difluorobenzoyl)phenyl)-1-(2-propanesulfonamide)-propene (LY450108), LY451395, and LY503430] (Ito et al., 1990; Copani et al., 1992; Arai et al., 1996, 2000; Baumbarger et al., 2001a,b). Although positive AMPA receptor modulators fall into three structural classes, the most important difference between them is their mechanisms of action.

Aniracetam primarily slows the deactivation rate without changing agonist potency. In contrast, PEPA potentiates AMPA receptor function by attenuating the extent of receptor desensitization without any effect on deactivation (Sekiguchi et al., 2002). Cyclothiazide seems to slow the onset of desensitization and indirectly slow the channel closure rate by increasing agonist potency (Yamada and Tang, 1993; Partin et al., 1994, 1996; Sekiguchi et al., 2002; Arai and Kessler, 2007). LY404187 stabilizes the open state of AMPA receptors in the presence of agonist without altering the rate at which channels desensitize, thereby permitting desensitized AMPA receptors to make a transition to an open state either directly or through intermediate desensitized and/or closed states (Baumbarger et al., 2001b). Some compounds (e.g., CX614) inhibit both desensitization and deactivation; the mechanism underlying this is not well understood (Arai et al., 2000).

Further complexity arises from differences in the potencies of positive allosteric modulators for RNA splice variants of the AMPA receptors, particularly the flip/flop region within the LBD. Cyclothiazide almost completely eliminates desensitization of flip splice variants but only slows the entry into desensitized state for the flop splice variant (Johansen et al., 1995; Partin et al., 1996; Hennegriff et al., 1997; Sekiguchi et al., 2002). The specificity of cyclothiazide for flip splice variants arises from its interaction with Ser754, which is a larger Asn in flop variants and precludes tight cyclothiazide binding (Sun et al., 2002). Aniracetam has a similar potency at flip and flop splice forms, but the efficacy is greater for the flop form (Johansen et al., 1995). PEPA and CX614 are selective for the flop variants (Hennegriff et al., 1997; Sekiguchi et al., 1997, 1998). LY404187 and LY503430 suppress receptor desensitization with a distinct time-dependence in the presence of agonist; these compounds show the highest potency for flip variants of GluA2 and GluA4 (Miu et al., 2001; Murray et al., 2003).

The functional effects of the different positive allosteric modulators are complex because multiple partially
overlapping binding sites exist (Partin et al., 1996; Yamada and Turetsky, 1996; Lindén et al., 2001; Arai et al., 2002; Sun et al., 2002). The binding sites of compounds that affect desensitization reside within the dimer interface between the ligand binding domains, which supports the interpretation that desensitization involves rearrangement of the dimer interface. Crystallographic studies indicate that cyclothiazide, which mainly modulates desensitization, has two binding sites within the dimer interface, whereas CX614 and aniracetam, which control desensitization and deactivation time course, bind at a different site at the hinge of the dimer interface in two alternate orientations (Sun et al., 2002; Jin et al., 2005) (Fig. 10, A and B). Aniracetam and
CX614 bind to the center of the dimer interface and do not penetrate the ligand binding domain clamp. The binding sites for aniracetam/CX614 and cyclothiazide do overlap, with the endocyclic sulfonamide group from cyclothiazide overlapping with the site recognizing the five-member rings of CX614/aniracetam. Aniracetam and CX614 stabilize the closed-cleft conformation of the ligand binding domain, slowing the deactivation time course. Cyclothiazide, which does not significantly stabilize the closed-cleft conformation of the LBD, instead stabilizes the dimer assembly, leading to an attenuation of desensitization. These data indicate that the molecular and structural determinants of deactivation and desensitization are separable (Sun et al., 2002; Jin et al., 2005). The challenge is now to understand how these mechanistically distinct compounds differentially affect brain circuitry to produce effects on behavior that are therapeutically meaningful (Lynch, 2006).

Con A, a plant lectin from Canavalia ensiformis, irreversibly potentiates agonist-evoked currents from most kainate receptors by apparently reducing receptor deactivation and increasing agonist affinity (Huetttner, 1990; Partin et al., 1993; Wong et al., 1994; Bleakman et al., 2002). Lectins seem to bind to N-linked glycosylation within the ATD (Everts et al., 1997, 1999). The action of con A is state-dependent, because agonist-induced desensitization before application of con A eliminates potentiation (Fay and Bowie, 2006). Con A has been suggested to keep the activated channel in the open state and inhibit conformational changes leading to the desensitized state (Partin et al., 1993; Wong and Mayer 1993; Yue et al., 1995). Alternatively, con A may shift the contribution of different kainate receptor open states (Bowie et al., 2003). Although con A has proven experimentally useful for characterizing kainate receptor pharmacology, it does not alter synaptic kainate receptor currents and only weakly potentiates whole-cell currents from cultured hippocampal neurons (Wilding and Huetttner, 1997). Other lectins, however, including wheat germ agglutinin, soybean agglutinin, and saccinyl-concanavalin A, potentiate native kainate receptor function (Thio et al., 1993; Yue et al., 1995).

B. Divalent Ions

Multiple divalent cations influence glutamate receptor inactivation, voltage-dependent channel block, and agonist dissociation rates, in addition to potentiating and inhibiting receptor responses. Among divalent cations, extracellular Zn$^{2+}$ most potently inhibits native (Peters et al., 1987; Westbrook and Mayer, 1987) and recombinant NMDA receptors (Williams et al., 1996; Chen et al., 1997; Paololetti et al., 1997; Traynelis et al., 1998). The endogenous ion zinc is packaged into synaptic vesicles in axons terminating in the hippocampus, striatum, amygdala, neocortex, and cortex (Pérez-Clausell and Danscher, 1985; Frederickson, 1989; Valente et al., 2002; Danscher and Stoltenberg, 2005; Paololetti et al., 2009) and may be coreleased with glutamate from the vesicles into the synaptic cleft during neuronal activity. The expression of GluN2A- and GluN2B-containing NMDA receptors may allow zinc to act as an endogenous modulator of the NMDA receptor, depending on its synaptic concentration. Zn$^{2+}$ inhibition curves for GluN1/GluN2A receptors are biphasic, revealing high-affinity voltage-independent inhibition (IC$_{50}$ 10–30 nM) and low-affinity voltage-dependent channel block (IC$_{50}$ 20–100 μM). In the absence of voltage-dependent channel block, Zn$^{2+}$ inhibition is incomplete even at saturating concentrations. The high-affinity Zn$^{2+}$ binding site resides within the cleft of the GluN2A bilobed ATD and most likely involves Zn$^{2+}$ coordination by a series of histidine residues (Choi and Lipton, 1999; Fayyazuddin et al., 2000; Low et al., 2000). Removal of the GluN2A ATD by mutagenesis or alteration of this domain after cleavage by the endogenous serine protease plasmin at Lys317 eliminates or reduces voltage-independent high-affinity Zn$^{2+}$ inhibition, respectively (Gielen et al., 2009; Yuan et al., 2009a,b). Low-affinity voltage-dependent Zn$^{2+}$ inhibition involves residues inside the reentrant M2 pore loop similar to the Mg$^{2+}$ blocking site (Legendre and Westbrook, 1990; Paololetti et al., 2000).

Micromolar concentrations of Zn$^{2+}$ inhibit GluN2B-containing receptors in both a voltage-independent and voltage-dependent manner (Williams, 1996; Traynelis et al., 1998; Choi and Lipton, 1999; Rachline et al., 2005). Crystallographic coordinates of the GluN2B ATD show that a Zn$^{2+}$ binding site exists within the cleft of the clampshaped ATD (Everts et al., 1997) (Karakan et al., 2009), and mutagenesis suggests that this site can account for voltage-independent inhibition. As hypothesized for high-affinity binding of Zn$^{2+}$ to the GluN2A ATD (Paoletti et al., 2000), crystallographic studies of GluN2B show Zn$^{2+}$ binding stabilizes a closed-cleft conformation within the ATD through direct contact with residues His127 and Glu284. Mutation of these residues does not influence inhibition by the GluN2B-selective antagonist ifenprodil, suggesting that Zn$^{2+}$ and ifenprodil bind at unique sites within the GluN2B ATD. Residues Glu47 and Asp265, although not directly involved in Zn$^{2+}$ binding, influence Zn$^{2+}$ sensitivity, perhaps through coordination of water molecules that can interact with Zn$^{2+}$ (Karakan et al., 2009). It is noteworthy that mutations at GluN2B His127, one of the residues in contact with Zn$^{2+}$, also block potentiation of GluN2B receptors by Ni$^{2+}$ (Marchetti and Gavazzo, 2005; Gavazzo et al., 2009).

Studies with covalent modification of mutant GluN2A receptors that harbor a cysteine residue within the ATD cleft raise the idea that the extent of ATD closure around the Zn$^{2+}$ binding cleft negatively correlates with open probability, perhaps through actions at the LBD dimer interface (Gielen et al., 2009). Specifically, high-affinity Zn$^{2+}$ inhibition of NMDA receptors has been proposed to involve domain closure within the bilobed ATD around Zn$^{2+}$, and this has been suggested to destabilize the
dimer interface of the LBD (Mayer, 2006; Gielen et al., 2008) analogous to desensitization of AMPA and kainate receptors (Armstrong et al., 2006; Weston et al., 2006b; Plested and Mayer, 2007) (see sections II.D and V.I.E). In support of this idea, mutations that destabilize the LBD dimer interface enhance Zn$^{2+}$ sensitivity, whereas cysteine cross-linking of the dimer interface of mutant GluN1 and GluN2A receptors reduce Zn$^{2+}$ inhibition (Gielen et al., 2008). In addition to effects at the dimer interface, Zn$^{2+}$ shifts the proton inhibition curve leftward, suggesting that Zn$^{2+}$ binding to the ATD increases proton sensitivity (discussed below in section VI.D) and consequently increases the proportion of potentated, nonfunctional receptors at physiological pH (Choi and Lipton, 1999; Low et al., 2000). Fitting both macroscopic and single-channel data with kinetic models containing explicit Zn$^{2+}$ and proton binding steps suggests that association of Zn$^{2+}$ with its GluN2A binding site enhances proton binding (Erreger and Traynelis, 2005, 2008). Mutations at the same LBD dimer interface residues that alter Zn$^{2+}$ inhibition also strongly influence proton inhibition (Gielen et al., 2008), supporting a functional link between these two forms of modulation and confirming the hypothesis that Zn$^{2+}$ binding enhances proton inhibition. The potential link between proton inhibition and NMDA receptor LBD dimer interface stability fits well with previous observations that protons modify GluA receptor desensitization (Ihle and Patneau, 2000; Lei et al., 2001), a process unequivocally shown to involve rearrangement at the LBD dimer interface (see sections II.D and V.I.E). Chen et al. (1997) first described a rapid component of desensitization in the presence of extracellular Zn$^{2+}$ and postulated that Zn$^{2+}$ accelerated receptor desensitization. Subsequent studies, drawing from the mechanism of glycine-dependent desensitization (see section VII.E), showed that a positive intrasubunit interaction occurs between glutamate binding to the LBD and Zn$^{2+}$ binding to the ATD (Zheng et al., 2001). The working hypothesis, supported by multiple lines of evidence, suggests that binding of glutamate enhances Zn$^{2+}$ binding, which at subsaturating concentrations of Zn$^{2+}$ causes a relaxation to a new equilibrium as Zn$^{2+}$ binds to the receptor in a concentration-dependent fashion (Zheng et al., 2001; Erreger and Traynelis, 2005). Thus, the Zn$^{2+}$-dependent desensitization time course reflects the time course for Zn$^{2+}$ association with GluN2A receptors after a shift of the Zn$^{2+}$ binding site into a high-affinity state.

Calcium, barium, magnesium, and zinc ions can inhibit or potentiate current responses of recombinant and native AMPA receptors (Rassendren et al., 1990; Bresink et al., 1996; Dreixler and Leonard, 1997; Shen and Yang, 1999; Zhang et al., 2002; Blakemore and Trombley, 2004; Kreitzer et al., 2009) and kainate receptors (Hoo et al., 1994; Fukushima et al., 2003; Mott et al., 2008). Zn$^{2+}$ and Ca$^{2+}$ can permeate through AMPA/kainate receptors (Sensi et al., 1999; Weiss and Sensi, 2000) (see section VIII.B). Of these various actions, kainate receptors are most sensitive to inhibition by Zn$^{2+}$, which exerts voltage-independent inhibition, suggesting it acts as a noncompetitive antagonist (Fukushima et al., 2003). Zinc inhibition of kainate receptors is subunit-dependent, because GluK4- and GluK5-containing receptors have lower IC$_{50}$ values (1–2 μM) than GluK1–3 receptors (~70 μM). Inhibition by Zn$^{2+}$ is also dependent upon pH, because increasing the proton concentration decreases Zn$^{2+}$ potency by 2- to 9-fold for recombinant receptors and 15-fold for synaptic receptors (Mott et al., 2008). One possible mechanism for proton-dependent zinc inhibition of kainate receptors is that receptor protonation diminishes the ability of Zn$^{2+}$ to bind the receptor, but this has not been tested.

Although the GluD2 glutamate receptor has no known agonists or modulators, the spontaneously active *Lurcher* mutant GluD2 receptor is positively modulated by Ca$^{2+}$ (Wollmuth et al., 2000). The current amplitude of *Lurcher* GluD2 more than doubles in the presence of Ca$^{2+}$ in a voltage-independent manner unaffected by editing of the QRN site within the pore (Wollmuth et al., 2000). Potentiation by Ca$^{2+}$ reflects stabilization of the LBD dimer interface, which decreases desensitization of the active receptor (Hansen et al., 2009). Ca$^{2+}$ decreases the potency of D-serine, a ligand that inhibits *Lurcher* GluD2 currents, and crystallographic data of the GluD2 LBD show that Ca$^{2+}$ binds at the interface and is coordinated by residues Glu531, Asp535, and Asp782 (Naur et al., 2007; Hansen et al., 2009). Taken together, these results suggest that Ca$^{2+}$ binding stabilizes the LBD dimer interface, thereby reducing the ability of D-serine to cause dimer interface breakdown and desensitization (Hansen et al., 2009).

### C. Monovalent Ions

External monovalent ions, such as Na$^+$ and Cl$^-$, regulate the gating of kainate receptors, but not AMPA or NMDA receptors, through an allosteric mechanism involving both anions and cations (Bowie, 2002; Wong et al., 2007). Increased concentrations of external Na$^+$ and Cl$^-$ potentiate the amplitude and prolong deactivation of kainate receptor responses. Structural studies indicate that two Na$^+$ ions flank a single Cl$^-$ ion and bind in a charged pocket of the LBD dimer interface between two subunits, leading to a 50-fold increase in dimer affinity and a decrease in the rate of receptor desensitization (Plested and Mayer, 2007; Chaudhry et al., 2009). Other monovalent cations, including Li$^+$, K$^+$, Rb$^+$, and Cs$^+$, are capable of binding to kainate receptors, but these ions bind at lower affinity and are less efficacious than Na$^+$ (Plested et al., 2008). Mutation of a Met770 in the D1 domain of the GluK2 LBD dimer interface, although not directly involved in cation binding, can perturb the site (Paternain et al., 2003; Plested and Mayer, 2009).

Neuronal NMDA receptor function is potentiated up to 2-fold by increases in intracellular Na$^+$ to 40 mM,
with Na⁺ sensitivity set by the nonreceptor tyrosine kinase src (Yu and Salter, 1998, 1999). The enhancement of action by intracellular Na⁺ interacts with Ca²⁺-dependent inactivation (Xin et al., 2005). Increases in intracellular Na⁺ concentration peak during high frequency firing coincident with src activation (Yu and Salter, 1999), suggesting that this effect could be relevant to synaptic plasticity and cell death caused by overactivation of NMDA receptors (Yu, 2006).

**D. Protons**

Protons inhibit all glutamate receptors without changing ionization of the agonist (Christensen and Hida, 1990; Giffard et al., 1990; Tang et al., 1990; Traynelis and Cull-Candy, 1990; Vylický et al., 1990; Ihle and Patneau, 2000; Lei et al., 2001; Mott et al., 2003). Among NMDA receptors, proton IC₅₀ for inhibition varies with the GluN2 subunit, with IC₅₀ values near physiological pH for GluN2A, GluN2B, and GluN2D (7.0–7.4), leading to the idea that these receptors are under tonic inhibition (Traynelis et al., 1995; Gielen et al., 2009). Proton inhibition depends on alternative RNA splicing of the GluN1 subunit within the ATD (Traynelis et al., 1995), a region that controls proton sensitivity on its own (Gielen et al., 2009) and through association with Zn²⁺ (see section VI.B) or ifenprodil (Mott et al., 1998) (see section V.E). Proton inhibition is independent of voltage and ligand binding (Banke et al., 2005). At the single channel level, protons reduce open probability of GluN2B subunit-containing NMDA receptors, with modest effects on open duration and single channel conductance (Traynelis and Cull-Candy, 1991; Banke et al., 2005). Protons inhibit GluN1/GluN2A receptors somewhat differently than GluN1/GluN2B, reducing mean channel open time and open probability (Dravid et al., 2007; Erreger and Traynelis, 2008). Mutagenesis data show a cluster of residues that mediate pH sensitivity located near the gate and the LBD dimer interface (Low et al., 2003; Gielen et al., 2008; Sobolevsky et al., 2009), and it seems likely that the NMDA receptor gating elements are tightly coupled to the proton sensor. Evidence supporting tight coupling between protons and gating includes the ability of channel blockers to sense the protonation state of the receptor while entering the pore (see section V.F), and the observation that the proton sensor is a common downstream substrate for modulators binding to the ATD.

Extracellular protons inhibit AMPA receptors in a voltage-independent manner by enhancing receptor desensitization and lowering channel open probability (Christensen and Hida, 1990; Ihle and Patneau, 2000; Lei et al., 2001). Proton inhibition varies with receptor subunit and flip/flop isoform, because GluA4 flop receptors are most sensitive to proton inhibition (Ihle and Patneau, 2000). Extracellular protons also inhibit recombinant and native kainate receptors in a voltage-independent manner without altering the desensitization time course (Mott et al., 2003). The IC₅₀ values for GluK1 and GluK2 correspond to pH 6.9, indicating that receptors may be partially inhibited by protons at physiological pH. Like AMPA receptors, inhibition of kainate receptors by protons is subunit-dependent, because heteromeric receptors containing GluK5 are less sensitive to inhibition by protons, and GluK2/GluK4 heteromeric receptors are potentiated by protons (Mott et al., 2003). Mutant Lurcher GluD2 receptors are incompletely inhibited by protons in a voltage-independent manner but with an IC₅₀ corresponding to pH ~7.5 (Williams et al., 2003). Thus, pH sensitivity is a shared feature across the entire glutamate receptor family and could be important during processes that alter extracellular pH such as normal synaptic activity, glutamate release, kainate uptake (Siesjö, 1985; Chesler and Kaila, 1992), and neuropathological conditions including stroke and seizure (Balestrino and Somjen, 1988; Giffard et al., 1990; Nedergaard et al., 1991; Kaku et al., 1993; Hirano et al., 2003).

**E. Polyamines**

Voltage-dependent block of glutamate receptors by polyamines and their analogs is described in section VIII.C. In addition, extracellular polyamines such as spermine and spermidine enhance NMDA receptor responses in a voltage-independent manner by both glycine-dependent and -independent mechanisms. Glycine-dependent potentiation occurs in GluN2A- and GluN2B-containing NMDA receptors through enhancement of glycine binding (Ransom and Deschenes, 1990; Ransom, 1991; Williams et al., 1994; Zheng et al., 1994; Dingleidine et al., 1999) as a result of an allosteric interaction between polyamine binding to the ATD and glycine binding to the LBD (Masuko et al., 1999a; Han et al., 2008). Glycine-independent polyamine potentiation of NMDA receptor function occurs in saturating glycine concentrations only for GluN2B-containing NMDA receptors (for review, see Johnson 1996; Williams, 1997; Dingledine et al., 1999). Polyamine binding shifts the pKᵦ of the proton sensor to reduce tonic inhibition at physiological pH in NMDA receptors that lack the highly charged GluN1 exon5 (Durand et al., 1993; Traynelis et al., 1995; Williams et al., 1995; Kashikawa et al., 1996, 1997; Kumamoto, 1996; Masuko et al., 1999a).

Similar to its action on NMDA receptors, the endogenous polyamine spermine potentiates edited GluK2(R) receptor current response, apparently by relieving proton inhibition (Mott et al., 2003). Spermine potentiation is voltage-independent and affects neither the time course of desensitization nor agonist EC₅₀ (Mott et al., 2003). However, unedited GluK2(Q) is inhibited by spermine and spermidine in a manner similar to AMPA receptors (see section VIII.C). Polyamines accelerate the deactivation of GluK2(Q), possibly through increased closing rate and stabilization of closed states (Bowie and Mayer, 1995; Bowie et al., 1998). Studies on the effects of
polyamines on the Lurcher GluD2 receptors indicate that they undergo voltage-dependent channel block by endogenous and synthetic polyamines (Wollmuth et al., 2000; Williams et al., 2003).

F. Neurosteroids

NMDA receptors can be positively or negatively modulated by endogenous sulfated neurosteroids, the sulfate or negatively charged group at the C3 carbon being essential for activity (Wu et al., 1991; Park-Chung et al., 1997; Weaver et al., 2000). Unsaturated sulfated neurosteroids act as potentiators of NMDA receptors, whereas planar, saturated neurosteroids act as inhibitors (Weaver et al., 2000). Neurosteroid potentiation is subunit-dependent, because pregnenolone sulfate significantly potentiates GluN2A- and GluN2B-containing NMDA receptors but has much lower efficacy at GluN2C- and GluN2D-containing NMDA receptors (Malayev et al., 2002; Jang et al., 2004; Horak et al., 2005). This subunit-selectivity was used to identify the molecular determinants of potentiation for pregnenolone sulfate, which reside on the D2 domain of the GluN2 LBD (Jang et al., 2004; Horak et al., 2006; Stoll et al., 2007). Pregnenolone sulfate causes potentiation by increasing channel open probability, but no consensus has developed regarding the underlying mechanism (Bowly, 1993; Cecon et al., 2001; Malayev et al., 2002). Other saturated sulfated steroids, including pregnanolone sulfate, are use-dependent yet voltage-independent NMDA receptor inhibitors (Park-Chung et al., 1997; Petrovic et al., 2005). Pregnanolone sulfate reduces open probability, reduces channel open time, and increases receptor desensitization (Park-Chung et al., 1997; Petrovic et al., 2005; Kussius et al., 2009). Inhibition by pregnanolone sulfate is weakly subunit-dependent, being 2-fold more potent at GluN2C- and GluN2D-containing NMDA receptors than GluN2A- and GluN2B-containing receptors (Petrovic et al., 2005).

Although less work has been conducted on neurosteroid activity at AMPA and kainate receptors compared with NMDA receptors, studies have shown that sulfated steroids, such as pregnenolone sulfate, pregnanolone sulfate, and pregnenolone hemisuccinate inhibit GluA1 and GluA3 AMPA receptors and GluK2 kainate receptors (Yaghoubi et al., 1998; Shirakawa et al., 2005; Sedláček et al., 2008). Sulfated steroid inhibition is voltage-independent and non-competitive, reducing agonist efficacy but not potency. Steroids may bind AMPA receptors at the LBD (Spivak et al., 2004).

G. Fatty Acids

NMDA receptors are positively modulated through a direct interaction with polyunsaturated fatty acids, including arachidonic acid, oleic acid, and docosahexaenoic acid (Miller et al., 1992; Nishikawa et al., 1994). Potentiation by arachidonic acid occurs through an increase in open probability with no change in channel conductance (Nishikawa et al., 1994; Tabuchi et al., 1997; Casado and Ascher, 1998). The fatty acid binding site is not known. It is noteworthy that lysophospholipids reversibly inhibited the NMDA receptor in a voltage-independent manner (Casado and Ascher, 1998).

Although saturated fatty acids, such as myristic, palmitic, and stearic acids have no effect on kainate receptors, unsaturated fatty acids inhibit AMPA and kainate receptors in a voltage-independent and use-dependent manner (Kovalchuk et al., 1994; Wilding et al., 1998). Inhibition of kainate receptors by fatty acids depends on the residue at the QRN site within the re-entrant M2 loop (Wilding et al., 2005). GluK2(R) homomers and GluK1(R)/GluK2(R) heteromers are inhibited by docosahexaenoic acid, arachidonic acid, and linolenic acid (Wilding et al., 1998, 2005). However, GluK1(Q), GluK2(Q), and GluK1(Q)/GluK2(Q) heteromers containing at least one unedited subunit with Q at the QRN site are less sensitive to unsaturated fatty acids (Wilding et al., 2005).

H. Other Allosteric Modulators

In addition to the modulators discussed above, NMDA receptor function also is sensitive to osmotic pressure, with open probability reduced by compression and increased by stretch (Paoletti and Ascher, 1994; Casado and Ascher, 1998). Pb2+ is a voltage-independent antagonist of NMDA receptors that has been proposed to share a partially overlapping binding site with Zn2+ (Guilarte and Miceli, 1992; Büßelberg et al., 1994; Guilarte and McGlothan, 2003; Marchetti and Gavazzo, 2005; Gavazzo et al., 2008). The neuropeptide N-acetylaspartylglutamate is an inhibitor of NMDA receptor function, although some studies suggest that it may also act as a potentiator (Westbrook et al., 1986; Coyle, 1997; Greene, 2001; Bergeron et al., 2005, 2007; Fricker et al., 2009). Another peptide, the pituitary adenylate cyclase-activating polypeptide, increases NMDA receptor opening frequency (Wu and Dun, 1997; Liu and Madsen, 1998; Yaka et al., 2003; Yang et al., 2009). In addition, ATP may have actions on NMDA receptors (Kloda et al., 2004). It is noteworthy that aminoglycoside antibiotics (Masuko et al., 1999b) and histamine (Bekkers, 1993; Vorobjev et al., 1993; Williams, 1994; Burban et al., 2010) have been suggested to selectively potentiate the function of GluN2B-containing NMDA receptors. By contrast, some H3-histamine receptor competitive antagonists also bind to the GluN2B ATD to inhibit receptor function, perhaps at a site overlapping the histamine binding site (Hansen et al., 2010).

VII. Molecular Determinants of Gating

A. Time Course of Glutamate Receptor Activation and Deactivation

One of the most prominent features of glutamate receptors is their diversity in gating kinetics, which defines the time course of synaptic currents (Lester et al.,
1990) and their role in synaptic physiology and plasticity. The response time course varies among receptor subtypes, specific subunits within each subtype, alternative RNA splicing, posttranslational modifications, and accessory subunits. Recombinant AMPA receptor subtypes show fast activation and deactivation rates in addition to both rapid and strong desensitization (Table 16; Fig. 11), which restrict signaling to the millisecond time scale (Mosbacher et al., 1994; Edmonds et al., 1995; Erreger et al., 2004). In contrast, NMDA receptors show much slower gating kinetics, activating in milliseconds, deactivating between tens and thousands of milliseconds, with relatively weak or no desensitization (Monyer et al., 1992; Vicini et al., 1998; Wyllie et al., 1998) (Table 16; Fig. 11).

One idea advanced to explain the slow deactivation time course of the NMDA receptor was derived from structural data showing that GluN1 Tyr535 occupies a position in the GluN1/GluN2A LBD heterodimer analogous to that of the AMPA receptor potentiator aniracetam in GluA2 LBD homodimer (see section VI.A). Because Tyr535 is complexed at the protomer interface in a manner analogous to that of aniracetam, it may similarly modulate deactivation of NMDA receptors, assuming the two receptors share similar mechanisms underlying deactivation (Furukawa et al., 2005). The time course of deactivation of virtually all GluN1/GluN2 receptors can be described by multiple exponential components, which for GluN2A may reflect complex channel behavior (e.g., Erreger et al., 2005b; Zhang et al., 2008b). Heterologously expressed recombinant kainate receptors, like AMPA receptors, can show relatively fast gating kinetics and strong desensitization (Table 16). At synapses, the time course of a single evoked excitatory postsynaptic current mediated by AMPA receptors is faster than that mediated by NMDA receptors (Fig. 12). Native kainate receptors mediate a slower synaptic current than AMPA receptors (Castillo et al., 1997; Kidd and Isaac, 1999, 2001) (Fig. 12A).

### B. Mechanisms Linking Agonist Binding to Channel Gating

Many studies using varied approaches have addressed how ligand binding can lead to opening of the glutamate receptor pore. Glutamate receptors have, as core structural/functional elements, an LBD and an ion channel (see section II). Our current understanding of how agonist binding leads to channel opening has so far largely been driven by structural (e.g., crystallography or NMR) and functional (e.g., UV and IR spectrometric measurements) studies of the water-soluble LBD (S1S2 construct) combined with functional studies of the intact receptor. Structures of the LBD are available for representatives of all major GluR subtypes, including the unbound or apo state, the agonist-bound state, and with various competitive antagonists (Madden, 2002; Gouaux, 2004; Mayer, 2006; Oswald et al., 2007). The

---

**TABLE 16**

<p>| Kinetic parameters describing glutamate activation of AMPA, kainate and NMDA receptors |
|--------------------------------------|---------------------------------|
| <strong>EC50</strong>  | <strong>r-Deactivation</strong> | <strong>r-Desensitization</strong> | <strong>r-Recovery1,2</strong> | <strong>SS/Peak</strong> |</p>
<table>
<thead>
<tr>
<th>μM</th>
<th>ms</th>
<th>ms</th>
<th>ms</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>GluA1-flp</td>
<td>500–700</td>
<td>0.7–1.2</td>
<td>2.5–4.1</td>
<td>111–147</td>
</tr>
<tr>
<td>GluA1-dop</td>
<td>450</td>
<td>0.86–1.3</td>
<td>3.2–4.5</td>
<td>147–155</td>
</tr>
<tr>
<td>GluA2-flp</td>
<td>1390</td>
<td>0.62–1.1</td>
<td>5.9–9</td>
<td>11.7</td>
</tr>
<tr>
<td>GluA2-flpQ</td>
<td>1140–1380</td>
<td>0.54–0.9</td>
<td>1.2–1.9</td>
<td>31.3</td>
</tr>
<tr>
<td>GluA3-flp</td>
<td>1000–1970</td>
<td>0.56</td>
<td>3.0–4.1</td>
<td>15–70</td>
</tr>
<tr>
<td>GluA3-flpQ</td>
<td>1100–1870</td>
<td>0.63–1.05</td>
<td>1.1–2.8</td>
<td>55–142</td>
</tr>
<tr>
<td>GluA4-flp</td>
<td>44.3–35</td>
<td>0.8</td>
<td>3.6–5.1</td>
<td>6–21</td>
</tr>
<tr>
<td>GluA4-flpQ</td>
<td>4180</td>
<td>0.9</td>
<td>10</td>
<td>31–452</td>
</tr>
<tr>
<td>GluA1-flp/GluA2-flp</td>
<td>1180</td>
<td>2</td>
<td>10</td>
<td>31–452</td>
</tr>
<tr>
<td>GluA3-flpQ</td>
<td>1390</td>
<td>0.62–1.1</td>
<td>5.9–9</td>
<td>11.7</td>
</tr>
<tr>
<td>GluK1 Q</td>
<td>630</td>
<td>0.7</td>
<td>4.1–8.9</td>
<td>28–672</td>
</tr>
<tr>
<td>GluK2 Q</td>
<td>427–1040</td>
<td>1.6–2.5</td>
<td>3.4–5.3</td>
<td>1900–3020</td>
</tr>
<tr>
<td>GluK3,4</td>
<td>590–369</td>
<td>8.4–9.9</td>
<td>0.21–1.5</td>
<td>16</td>
</tr>
<tr>
<td>GluK1 Q/GluK5</td>
<td>191</td>
<td>2</td>
<td>0.5–4</td>
<td>47</td>
</tr>
<tr>
<td>GluK2 Q/GluK5</td>
<td>15–31</td>
<td>0.5–4</td>
<td>47</td>
<td>0.03</td>
</tr>
<tr>
<td>GluK4</td>
<td>647–334</td>
<td>2</td>
<td>3</td>
<td>2400–2700</td>
</tr>
<tr>
<td>GluK5</td>
<td>3.4</td>
<td>0.2</td>
<td>3.2</td>
<td>2.5–4</td>
</tr>
<tr>
<td>GluN1/GluN2A</td>
<td>1.8–7.7</td>
<td>22–2304</td>
<td>386–750</td>
<td>0.028–0.49</td>
</tr>
<tr>
<td>GluN1/GluN2B</td>
<td>0.9–4.1</td>
<td>71–583</td>
<td>100–495</td>
<td>0.027–0.038</td>
</tr>
<tr>
<td>GluN1/GluN2C</td>
<td>0.1–0.3</td>
<td>260–382</td>
<td>59–719</td>
<td>0.047</td>
</tr>
<tr>
<td>GluN1/GluN2D</td>
<td>0.25–8.5</td>
<td>1700–440</td>
<td>1014–2100</td>
<td>0.002–0.032</td>
</tr>
</tbody>
</table>

principles of agonist binding and channel gating seem to be common across all glutamate receptor subtypes and involve at least three sequential steps: 1) initial agonist association or binding, 2) a conformational change—so-called clam shell closure—that prevents agonist dissociation (Armstrong et al., 1998; Abele et al., 2000; Armstrong and Gouaux, 2000; Cheng et al., 2005), and 3) a conformational change in the ion channel that is tightly coupled to that in the LBD (Jin et al., 2003; Zhang et al., 2008a). The slower activation kinetics of NMDA receptors allows additional kinetically distinct conformational changes to be observed that have yet to be clearly linked to structural elements (see section VII.D).

Crystallographic studies unequivocally indicate that the agonist binding site is in the cleft of a clamshell-like structure (Armstrong et al., 1998; Abele et al., 2000; Armstrong and Gouaux, 2000; Cheng et al., 2005). These results show that the ligand initially makes contact with residues on D1, inducing a relatively slower second step during which D2 undergoes a transition to form further ligand-protein and D1-D2 interactions. This leads to closure of the clamshell and locking of the ligand into the agonist-bound conformation (Armstrong and Gouaux, 2000). Similar dock-and-lock mechanisms are well described for the LBD of the homologous G-protein coupled mGluRs (Lampinen et al., 1998; Salopek-Sondi et al., 2003).

Dimerization of the LBD of adjacent subunits is a key structural/functional feature that underlies coupling of cleft closure to conformational changes in the ion channel (Sun et al., 2002). Within the receptor, the four LBDs are arranged as 2-fold symmetric pairs, each pair composed of a back-to-back dimer interface that includes...
suggest that the distance between the linkers on the bottom of D2 in the LBD dimer is increased after agonist binding, consistent with a structural model for AMPA receptor activation in which cleft closure involves movement of D2, whereas D1 and the dimer interface remain relatively fixed. The D2 transition leads to displacement of the linker regions, which would reposition transmembrane segments (such as M3) in the intact subunit and drive channel opening (Erreger et al., 2004; Mayer, 2006; Hansen et al., 2007) (discussed further in section V.II.D).

Crystal structures, although valuable, are inherently static in nature and do not provide details of permitted motions that underlie the protein transitions under physiological conditions—a problem highlighted by findings that some functionally distinct partial agonists induce a similar degree of cleft closure in GluA2 (e.g., Holm et al., 2005) and by functional and crystallographic studies of GluN1 and GluN3 (Inanobe et al., 2005; Yao et al., 2008) (see section V.D). Computer-aided molecular dynamics (MD) simulations that are based on the growing number of LBD structures can be a useful tool to estimate protein fluctuations at physiological temperatures, provided the appropriate caveats are recognized (see section V.A). Such studies have provided hints about permissible intraprotein motions within the LBD during the cleft closure transition as well as interactions at the domain interface (Arinaminpathy et al., 2002; Kaye et al., 2006; Lau and Roux, 2007; Dravid et al., 2010). MD simulations can provide estimates of the stability of the ligand-protein interactions in the binding pocket, adding further detail to our understanding of ligand selectivity and efficacy (Mendieta et al., 2001, 2005; Erreger et al., 2005b; Kaye et al., 2006; Pentiäinen et al., 2006; Erreger et al., 2007). Additional experimental techniques that can test predictions obtained from MD simulations or crystal structures include NMR, ultraviolet or infrared spectroscopy, and fluorescence resonance energy transfer (McFeeters and Oswald, 2002, 2004; Cheng et al., 2005; Du et al., 2005; Madden et al., 2005; Valentine and Palmer, 2005).

C. Molecular Determinants and Mechanisms of Partial Agonism

Structural data have stimulated new work addressing the mechanism by which different ligands can occupy the same binding site yet have different relative efficacies. Partial agonists exist for all glutamate receptor subtypes (see sections V.A and V.B) and show different effects on the LBDs. A series of AMPA receptor partial agonists, the 5-substituted willardiines (Table 5), vary by a single atom and induce a differential degree of cleft closure that correlates with their relative efficacy (Partin et al., 1994; Jin et al., 2003). Single-channel studies show that willardiines with different relative efficacies activate different proportions of the same set of conduc-
Building on previous studies (Rosenmund et al., 1998; Smith and Howe, 2000), AMPA receptors have been proposed to ratchet open their channel as a function of the agonist-induced conformational changes within each subunit, with the probability that each subunit can partially open the gate increasing with the degree of agonist-induced cleft closure (Jin and Gouaux, 2003; Jin et al., 2003). This finding provides a structural mechanism underlying partial agonism at AMPA receptors in which the relative effectiveness or efficiency with which each agonist can activate a single subunit accounts for observed changes in single channel conductances (Jin et al., 2003). This mechanism has recently been extended to show that AMPA receptor subunit gating displays cooperativity, a property most notable at low agonist concentrations (Prieto and Wollmuth, 2010). Comparison of the structures of the GluK2 kainate receptor subunit in complex with full agonists (glutamate, SYM2081, quisqualate) and a partial agonist (kainate) reveals that the latter induces a lesser degree of cleft closure, consistent with the idea that the degree of cleft closure can influence agonist efficacy for GluK2 (Mayer, 2005).

The first structures available for the LBD of GluN1 complexed with ligands exhibited cleft closure that paralleled agonist- or antagonist-bound GluA2 structures (Furukawa and Gouaux, 2003; Furukawa et al., 2005; Inanobe et al., 2005). However, in contrast to GluA2, no substantial difference in the degree of cleft closure exists between the full agonist glycine, the partial agonist D-cycloserine, and a series of structurally related partial agonists. Thus, the isolated LBD of the GluN1 subunit shows no relationship between the degree of agonist-induced cleft closure and agonist efficacy. This finding suggests that important differences exist between AMPA and NMDA receptor subunits with respect to how intraprotein conformational changes are transmitted from the LBD to the channel gate.

![Image](https://example.com/image.png)
D. Molecular Determinants and Mechanisms of Gating

The three transmembrane helical segments (M1, M3, M4) are directly coupled to the LBD in all glutamate receptor subunits (Fig. 1). Not surprisingly, point mutations in all of these transmembrane helices, in the linkers that couple them to the LBD, and in the pore lining reentrant M2 loop can affect gating (Schneggenburger and Ascher, 1997; Zuo et al., 1997; Krupp et al., 1998; Villarroel et al., 1998; Ren et al., 2003). Hence, multiple structural determinants of closed and open conformations relate to atomic structure presents a daunting challenge.

The M3 segment is a key determinant of gating in glutamate receptors. The initial evidence for this came from the Lurcher M3 mutant GluD2(A654T), which produced constitutively active channels (Zuo et al., 1997). This led to a number of mutagenesis studies that described striking effects of M3 mutations on glutamate receptor function (Kohda et al., 2000; Jones et al., 2002; Yuan et al., 2005). This region in M3 contains the most highly conserved motif (SYTANLAAF) among the mammalian glutamate receptor subunits (Kuner et al., 2003). Several activity-dependent changes in the accessibility and reactivity of substituted cysteines have been identified in this region (Sobolevsky et al., 2002a; Chang and Kuo, 2008). The M3 segment in glutamate receptors is homologous to the major gating domain (the inner helix) in K⁺ channels (Doyle et al., 1998; Jiang et al., 2002; Yellen, 2002; Swartz, 2004).

An essential determinant of function in all channels is the activation gate—the structure that occludes the flux of ions in the closed state. Numerous mechanisms can be envisioned to account for an activation gate, including local potential changes, electrostatic repulsion, and steric hindrance (Hille, 2001). In certain K⁺ channel subtypes, the activation gate arises from tight steric closure (del Camino and Yellen, 2001) at the bundle helical crossing of the inner helix located at the end of the internal cavity (Swartz, 2004). In other K⁺ channels and the related cyclic nucleotide-gated channels, the activation gate is formed at the P-loop (Flynn and Zagotta, 2001; Bruening-Wright et al., 2002). The AMPA receptor structure, obtained in the antagonist-bound (closed) state, showed that positions (underlined residues) in the highly conserved gating motif as well as those located C-terminal to it in tetramer subunits A/C (SYTANLAAFLTVERM) and tetramer subunits B/D (SYTANLAAFLTVERM) are located near each other (Fig. 1). Given this finding, the high overall structural similarity to inverted K⁺ channels, and existing functional data, Sobolevsky et al., (2009) persuasively argue that this region represents the activation gate in the glutamate receptor family.

The idea that the activation gate was located at the external entrance to the pore was originally based on experiments, as in K⁺ channels, describing the state-dependent block by organic blockers and Mg²⁺ (Qian and Johnson, 2002). Most experiments have been carried out in NMDA receptors (but see Tikhonova et al., 2008) because of the diversity of channel blockers both in terms of size and kinetic properties. Uncompetitive NMDA receptor antagonists such as memantine and amantadine act as “trapping” blockers (see section V.F) (Blanpied et al., 1997). That is, the channel gate can close and agonist can unbind with the blocking molecule bound within the pore. The most likely explanation for this result is that the blocker is trapped in a cavity located internal to the activation gate but external to the apex of the reentrant M2 loop, an idea supported by the full-length GluA2 structure (Sobolevsky et al., 2009). Additional support for this model is provided by sequential blockers such as 9-aminoacridine (Benveniste and Mayer, 1995), larger amantadine derivatives (Antonov and Johnson, 1996; Antonov et al., 1998), and tetrapentylammonium (Sobolevsky et al., 1999). These molecules apparently bind in the same cavity as trapping blockers, but their large size interferes with the gating machinery located more externally, thus preventing channel closure.

Experiments evaluating accessibility of substituted cysteines to covalent modifying reagents found that the external entrance of the pore undergoes considerable rearrangements, becoming more restricted with channel closure (Beck et al., 1999; Sobolevsky et al., 2002a, 2003). Experiments by Chang and Kuo (2008) taking advantage of substituted cysteines, charge substitutions, and mutant cycle analysis with the GluN1 and GluN2B receptor subunits demonstrated that the activation gate was located within the SYTANLAAF motif, the underlined alanine representing the point of the bundle helical crossing.

At present, the mechanism by which the conformation change induced by ligand binding leads to opening of the activation gate is unknown, in part because of the absence of a structure of the intact receptor in the presence of glutamate. Nevertheless, given the structural similarity of GluA2 to known structures of open and closed K⁺-selective and nonselective cation channels (Doyle et al., 1998; Jiang et al., 2002; Alam and Jiang, 2009) and the available structures of the water-soluble LBDs in the antagonist- (closed) and agonist-bound states (see above), Sobolevsky et al. (2009) propose that the gate opens via a rotation of the M3 helices away from the central axis of the pore, comparable with that proposed for K⁺ channels (Doyle et al., 1998; Jiang et al., 2002). However, given that glutamate receptors lack a glycine hinge within their M3 transmembrane helix, a structural element proposed to be essential for K⁺ channel opening (Doyle et al., 1998; Jiang et al., 2002), there will be differences in detail of how the conformational changes in M3 occur.
The contribution of M1 and M4 transmembrane helices to channel function are unknown, other than data suggesting that mutations in M1 (Krupp et al., 1998; Villarroel et al., 1998) and M4 (Ren et al., 2003) can alter gating. M1 and M4 could act as anchors for the LBD, and the external location of M4 relative to the M3 gating element could serve to reduce M3 interactions with the bilayer (Fig. 13C). It is noteworthy that channels such as KcsA and inward rectifiers with only two transmembrane elements per subunit (eight per channel) can function independently of any structural elements with similarity to M4, as can the two transmembrane prokaryotic glutamate receptor subunit GluR0 (Chen et al., 1999a).

Yet the M4 segment appears to be required at least for NMDA receptor function, because truncated NMDA receptor subunits lacking M4 do not show detectable glutamate-activated currents (Schorge and Colquhoun, 2003). However, function can be restored if these truncated subunits were coexpressed with an independently encoded M4 segment. It is noteworthy that the M4 segment, which is found in all eukaryotic glutamate receptors subunits, is associated with the ion channel core (M1–M3) of an adjacent subunit (Fig. 13C).

Certain noncompetitive AMPA receptor antagonists (GYKI-53655, CP-465,022) interact with the external ends of the M1 and M4 transmembrane helices (Balannik et al., 2005). The linker region preceding the M1 transmembrane helix (the pre-M1 region; Fig. 13) makes a short helix that is oriented parallel to the plane of the membrane, making contacts with carboxyl and amino terminal ends of transmembrane helices M3 and M4, respectively. The M3 helices cross relative to each other.

![Diagram](image-url)
at this level along the permeation path for the agonist-bound closed GluA2 structure, raising the intriguing possibility that this pre-M1 helix may restrain M3 mobility in the closed state, yet with domain closure, promote channel opening in the ligand-bound state (Sobolevsky et al., 2009). If this structural feature were shared by NMDA receptors, and four pre-M1 helices were to move independently in the agonist-bound receptor, one might imagine these conformational changes could constitute rate limiting and kinetically distinct steps that precede concerted channel opening involving simultaneous rearrangement of all four M3 helices. Single channel studies of agonist-bound NMDA receptors have identified multiple kinetically distinguishable steps that precede channel opening via a concerted pore dilation involving all or no repositioning of M3 transmembrane helices (Banke and Traynelis, 2003; Popescu and Auerbach, 2003; Auerbach and Zhou, 2005; Erreger et al., 2005a; Schorge et al., 2005; Dravid et al., 2008). These rate-limiting and kinetically distinct steps must reflect rate limiting conformational changes that occur before rapid pore dilation (Schorge et al., 2005). It is noteworthy that the role for the pre-M1 linker proposed by Sobolevsky et al. (2009) provides an example of a potential structural rearrangement that could occur in a subunit-dependent fashion (Banke and Traynelis, 2003) and necessarily precede simultaneous rearrangement of all four M3 helices as the pore opens. Moreover, the mechanisms underlying multiple conductance levels for AMPA receptors and gating to the subconductance and main conductance states for NMDA receptors could lie in how this pre-M1 region interacts with the each M3 helix that contributes to the gate. Perhaps M3 rearrangement within individual subunits is permitted for AMPA receptors, giving rise to as many as four detectable conductance levels (Rosenmund et al., 1998; Banke et al., 2000; Smith and Howe, 2000; Jin et al., 2003; Prieto and Wollmuth, 2010), in contrast to GluN2A/B-containing NMDA receptors, for which all four M3 helices might move at once, giving rise primarily to a single conductance level (Table 17).

E. Molecular Determinants of Desensitization

All glutamate receptors undergo desensitization, which by definition is a reduction in response in the presence of a sustained stimulus. This process is fast in AMPA and kainate receptors, occurring within 20 ms and generating greater than 90% decrease in current amplitudes at steady state (Table 16). However, the onset of desensitization is slower and less extensive in NMDA receptors and is virtually absent for GluN2C- and GluN2D-containing NMDA receptors (Monyer et al., 1994; Krupp et al., 1996; Wyllie et al., 1998; Dravid et al., 2008). Our understanding of the structural mechanisms underlying rapid desensitization, particularly for AMPA and kainate receptors, has been dramatically accelerated through a broad range of structural studies on the isolated AMPA and kainate receptor LBDs in combination with extensive functional studies on the full-length receptor (Sun et al., 2002; Robert and Howe, 2003; Horning and Mayer, 2004; Klein and Howe, 2004; Robert et al., 2005; Armstrong et al., 2006; Weston et al., 2006a; Zhang et al., 2006a; Nayeem et al., 2009).

For GluA2, the initial step of desensitization is a rearrangement of the D1-D1 dimer interface between LBDs of adjacent subunits (Sun et al., 2002; Horning and Mayer, 2004). This idea was driven by LBD structures of wild type GluA2 and GluA2 containing a leucine-
to-tyrosine substitution GluA2(L483Y), a mutation that in
the intact receptor blocks desensitization (Stern-Bach et al.,
1998), and structures of GluA2 bound to cyclothiazide,
an inhibitor of AMPA receptor desensitization (Partin et al.,
1995; Sun et al., 2002). Ultracentrifugation studies,
which showed that both the mutation and cyclothiazide
increased dimer stability (Sun et al., 2002), suggested a
role for the dimer interface in desensitization (see section
VI.A). The mutation GluA2(L483Y) or cyclothiazide
stabilized the dimer formation, further suggesting that
stabilization of the LBD dimer interface in full-length
functional AMPA receptors can reduce desensitization
(Sun et al., 2002). On the atomic level, Leu483 is located
in the dimer interface, and mutation to tyrosine
promotes formation of additional interactions with residues
located on the opposite LBD (Fig. 10A).

The rate at which cysteine residues introduced at the
GluA2 dimer interface are modified by (2-sulfonatoethyl)me
thane thiosulfonate (MTSES) depends on whether
the receptor is resting, active or desensitized (Armstrong et al.,
2006). The mutation GluA2(4E486C) displays pro
nounced state-dependent modification by (2-sulfonato-
ethyl)methane thiosulfonate, being more accessible in
the desensitized state than in the resting or active
states. Crystallographic data show that GluA2 Glu486
participates in interactions at the dimer interface and is
largely inaccessible to solvent when the receptor is in
the active state. However, in the desensitized state,
Glu486 becomes solvent accessible, providing direct ev
eidence that desensitization in full-length AMPA recep
tors is accompanied by a rearrangement at the dimer
interface (Armstrong et al., 2006). The same study also
used variable length cross-linkers as molecular rulers to
restrict motion at the dimer interface and thus report on
the magnitude of the rearrangement. The structure of
an additional cross-linked mutant, GluA2(S729C), pos
sessed a conformation with the dimer interface separ
ated by distances that agreed well with those estimated
from cross-linking experiments at different residues. These
data suggest that the structure of cross-linked
GluA2(S729C) reveals a conformation similar to full
length desensitized AMPA receptors (Armstrong et al.,
2006). Furthermore, imaging studies suggest that the
separation of the dimer interface in the desensitized
state is not accompanied by significant changes in the
degree of domain closure in the isolated LBD (Du et al.,
2005). Thus, during receptor desensitization, the separa
tion of the dimer interface enables the linkers that
replace the transmembrane segments to move closer
together by 10 Å relative to the agonist-bound nonde
sensitized conformation, thereby preventing opening of
the ion channel (Fig. 3).

Mutations in the AMPA receptor binding pocket that
reduce steric collision between the agonist and the LBD
can increase agonist efficacy and desensitization (Mad
den et al., 2004; Holm et al., 2005). Furthermore, there
is a direct correlation between the degree of domain
closure with full and partial AMPA receptor agonists
and the degree of desensitization produced by those ago
nists (Jin and Gouaux, 2003; Jin et al., 2003; Frandsen
et al., 2005). Thus, the degree of agonist-induced LBD
closure seems to be the primary determinant of tension
at the LBD dimer interface and thus governs transition
into both the open and desensitized state.

Using the LBD crystal structure of the nonden
sensitizing GluA2(L483Y) as a guide, Weston et al. (2006b)
introduced cysteine residues in kainate receptor subunits at positions
where cross-linking should stabilize the dimer interface.
This yielded nondenensitizing GluK1, GluK2, and GluK3
responses. The AMPA receptor subunit GluA2 was ren
dered nondenensitizing when cross-linked at homologous
positions, thereby establishing that the dimer interface
rearrangement is necessary for kainate receptor desensi
tization (Weston et al., 2006b). However, not all interac
tions predicted on the basis of AMPA receptor studies are
necessary for kainate receptor desensitization (Fleck et al.,
2003; Nanao et al., 2005).

Desensitization of NMDA receptors has been studied
extensively (reviewed by Dingleine et al., 1999) and
involves a number of pathways, including glycine-de
pendent desensitization (Mayer et al., 1989; Benveniste
et al., 1990; Lester et al., 1993; Nahum-Levy et al., 2001;
Regalado et al., 2001). Ca2+-dependent inactivation
(Clark et al., 1990; Legendre et al., 1993, Vyklicky, 1993;
Rosenmund and Westbrook, 1993; Medina et al., 1995;
Vissel et al., 2002), Zn2+-dependent desensitization (see section VI),
and glycine/Ca2+-independent desensitization (Chen et al.,
2004; Hu and Zheng, 2005; Sessoms-Sikes et al., 2005). The molecular mechanisms for these
forms of desensitization are poorly understood.

VIII. Molecular Determinants of Ion Permeation
and Block

A. Nature of the Ion Permeation Pathway

The ion channel associated with all glutamate recep
tors consists of a water-filled pore divided into external
and internal cavities separated by a narrow constriction
at which the pore reaches its smallest dimension (see section II). The residues lining the pore, including those
positioned at the external and internal entrances, form
the permeation pathway and are the primary determi
nants of ion selectivity and unitary conductance. With
only rare exceptions, the conduction pathway is cation
selective. Glutamate receptors show a wide range of
single channel conductances that vary from <1 to ~30
pS for AMPA and kainate receptors and from 20 to 60 pS
for NMDA receptors (Table 17). AMPA receptors show
up to four different conductance levels, the presence of
which has been explained by their mechanism of activa
tion (see section VII). NMDA receptors show a pair of
conductance states, the amplitude and relative fre
quency of which depends on the GluN2 subunit present
and ionic conditions.
The pore of the glutamate receptor family is formed by three transmembrane helices and a reentrant loop, arranged with striking similarity to an inverted potassium channel (Doyle et al., 1998; Sobolevsky et al., 2009); this similarity had been predicted to exist on the basis of sequence similarity and from shared functional properties of a bacterial glutamate receptor and potassium channels (Wo and Oswald, 1995; Wood et al., 1995; Chen et al., 1999a; Panchenko et al., 2001; Kuner et al., 2003). Functional and biophysical experiments corroborate the available structure. For example, studies examining the channel block of NMDA receptors by organic cations and Mg\(^{2+}\) (Villarroel et al., 1995; Zarei and Dani, 1995; Antonov and Johnson, 1999), and the voltage-dependence of the reactivity rate for substituted cysteines (Sobolevsky et al., 2002a, 2003) suggested that the narrow constriction is located approximately halfway across the transmembrane electric field. Scanning mutagenesis studies correctly predicted that the re-entrant M2 pore loop lines the inner cavity with the QRN site located at the tip of this loop (Kuner et al., 1996, 2001; Wollmuth et al., 1996).

Immediately external to the tip of the reentrant pore loop lies a central cavity (Fig. 14A) (Sobolevsky et al., 2009), similar to that of potassium channels, lined primarily by M3 (Beck et al., 1999; Kashwagi et al., 2002; Sobolevsky et al., 2003). All glutamate receptor subtypes share a common transmembrane arrangement, but there are differences in permeation and block properties between subtypes. These differences imply some degree of molecular heterogeneity within the pore, most likely involving the narrowest constriction that sets the maximum rate of ion permeation either through steric or electrostatic effects.

A key determinant of the conductance and permeation properties of all glutamate receptors is the identity of the residue occupying a functionally critical position at the apex of the M2 loop, the QRN site. This site harbors either Gln (Q, unedited) or Arg (R, edited) in AMPA and kainate receptors (Hume et al., 1991; Verdoorn et al., 1991), Asn (N) in GluN1 and GluN2 receptors (Burnashev et al., 1992b; Mori et al., 1992), Gly (G) in GluN3 subunits, and Gln (Q) in GluD2 subunits. Not surprisingly, the key structural positioning of the QRN site allows this residue to influence single-channel conductance (Swanson et al., 1996, 1997b; Traynelis and Wahl, 1997), Ca\(^{2+}\) permeability (Burnashev et al., 1992a,b; Egebjerg and Heinemann, 1993), channel block by polyamines (Bowie and Mayer, 1995; Kamboj et al., 1995; Washburn et al., 1997), Mg\(^{2+}\) sensitivity (Burnashev et al., 1992b; Dingleidine et al., 1992; Mori et al., 1992), channel block by organic compounds (Kashiwagi et al., 2002; Chen and Lipton, 2005), and assembly into heteromeric complexes (Greger et al., 2003). In addition, homomerically edited R-forms of kainate receptor channels are no longer purely cation-selective, but are also permeable to Cl\(^{−}\) (Burnashev et al., 1996) (Table 18). Replacement of the QRN Asn with Gln in GluN1 or GluN2B yields channels with multiple conductance levels (Premkumar et al., 1997; Schneggenburger and Ascher, 1997). The functional effects of TARPs on AMPA receptors (Körber et al., 2007) and of membrane lipids on kainate receptors (Wilding et al., 2005) are influenced by editing at the QRN site. It is noteworthy that Sobolevsky et al. (2009) observed gaps between the transmembrane helices, which they predict may be filled by residues projecting from TARPs (see section II.H). This potential association with the pore could provide a means by

<table>
<thead>
<tr>
<th>Subunit Combination</th>
<th>Pore Diameter</th>
<th>(P_{\text{Ca}}/P_{\text{K}})</th>
<th>(P_{\text{Cl}}/P_{\text{K}}) (from (P_{\text{f}}))</th>
<th>(P_{\text{f}})</th>
<th>(P_{\text{Cl}}/P_{\text{K}})</th>
</tr>
</thead>
<tbody>
<tr>
<td>GluA1(^{a,b})</td>
<td>0.78(^{c})</td>
<td>1.6</td>
<td>(\approx 0.7)</td>
<td>3.2–3.6</td>
<td>0.14</td>
</tr>
<tr>
<td>GluA2 (Arg)(^{g})</td>
<td>0.7</td>
<td>0.03</td>
<td>0.11</td>
<td>0.54</td>
<td>(\approx 0)</td>
</tr>
<tr>
<td>GluA4</td>
<td>0.7</td>
<td>0.14–0.17</td>
<td>0.30–0.48</td>
<td>1.55–2.4</td>
<td>(\approx 0)</td>
</tr>
<tr>
<td>GluA2 (Arg)(^{e,f})</td>
<td>0.78</td>
<td>&lt;0.04</td>
<td>0.54</td>
<td>0.04</td>
<td>0.74</td>
</tr>
<tr>
<td>GluK2 (Gln)(^{b,d})</td>
<td>0.74</td>
<td>2.8–4.5</td>
<td>3.0–3.6</td>
<td>11.0–15.9</td>
<td>2.6–1.8</td>
</tr>
<tr>
<td>GluN1-GluN2A(^{b,c,f,g})</td>
<td>0.55(^{b,i})</td>
<td>3.6</td>
<td>3.6</td>
<td>15.9</td>
<td>8.2</td>
</tr>
<tr>
<td>GluN1-GluN2C</td>
<td>1.8</td>
<td>1.73</td>
<td>15.9</td>
<td>8.2</td>
<td>8.2</td>
</tr>
<tr>
<td>GluN1-GluN3A</td>
<td>0.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GluD2(^{e})</td>
<td>2.6–1.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^{a}\)Burnashev et al. (1995). \(^{b}\)Jatzke et al. (2002). \(^{c}\)Burnashev et al. (1996). \(^{d}\)The kainate receptor GluK2 is edited in three different locations: two in M1 (Ile, Tyr fully unedited and Val, Cys fully edited) and one in M2 (Gln in unedited, Arg in edited). All values shown are for receptors that are fully edited in M1. \(^{e}\)Sharma and Stevens (1996). \(^{f}\)Schneggenburger (1996). \(^{g}\)Schneggenburger (1998). \(^{h}\)Villarroel et al. (1995). \(^{i}\)Wollmuth et al. (1996). \(^{j}\)Perez-Otano et al. (2001). \(^{k}\)GluD2\(^{e}\) is a constitutively active form (Lurcher) of the GluD2 subunit. \(^{l}\)Wollmuth et al. (2000).
which TARPs influence ion permeation, conductance, and polyamine block.

NMDA receptors are obligatory heteromultimers likely composed of 2 GluN1 and 2 GluN2 subunits in a 1-2-1-2 arrangement (Sobolevsky et al., 2009). The narrow constriction in NMDA receptors is formed by, at minimum, the QRN site asparagine of GluN1 and an asparagine adjacent to the QRN site (i.e., QRN + 1 site) in GluN2 (Fig. 14A) (Wollmuth et al., 1996). It is noteworthy that there is also a functional asymmetry between QRN Asn residues in the various NMDA receptor subunits: substitutions at the GluN1 QRN site have strong effects on Ca\(^{2+}\) permeability but only weak effects on Mg\(^{2+}\) block, and equivalent substitutions of the QRN site in GluN2 produce opposite effects (Burnashev et al., 1992b). This functional and presumed structural asymmetry between subunits most likely reflects modest differences at the atomic scale. A highly conserved GluN2B tryptophan residue in the M2 loop also has been proposed to contribute to the narrow constriction (Williams et al., 1998), and the homologous tryptophan in GluN1 can influence channel block (e.g., Jin et al., 2007).

### B. Mechanisms of Ion Permeation

A major determinant of ion selectivity arises from the physical or electrical interactions of permeating ions with the pore wall within the narrow region of a channel in which ions and side chains or main-chain atoms of residues come close enough to create a permeation barrier. The dimensions of the smallest diameters of various glutamate receptor channels have been estimated from the permeability of differently sized organic cations (Table 18). The finding that channels containing one or more arginine residues at the QRN site have roughly the same dimension as channels containing the smaller glutamine residues suggests that the side chain of the QRN site does not define the dimensions of the narrow constriction and that its effect on permeation may be influenced by electrostatics (Kuner et al., 2001).

All mammalian glutamate receptor subunits are cation-selective and lack the highly conserved TVGYG sequence that defines selectivity in K\(^{+}\) channels. The prokaryotic GluR0 does have the TVGYG sequence and is K\(^{+}\)-selective (Chen et al., 1999a), but introduction of this sequence into mammalian glutamate receptor subunits does not confer K\(^{+}\) selectivity (Hoffmann et al., 2006a), probably because of different interactions of this region within the mammalian glutamate receptor compared with K\(^{+}\) channels. Indeed, in the membrane-spanning GluA2 structure, the extended region in the M2 loop is disordered, and this may reflect the absence of TVGYG and stabilizing interactions that underlie K\(^{+}\) selectivity in K\(^{+}\) channels. Moreover, under certain nonphysiological conditions, edited (R) forms of homomeric GluA2 and GluK2 subunits are permeable to Cl\(^{-}\) ions (Table 18). The central location of the QRN site and the fact that these homomeric receptor channels show mixed cation/anion permeability suggests other structural elements such as M2 loop dipole, carbonyl side chains in M2, and/or elements in the outer cavity may contribute to cation selectivity. Indeed, in K\(^{+}\) channels, the pore loop dipole alters the environment in the inner cavity (corresponding to the outer cavity in glutamate receptors) to allow a high flux while maintaining ion selectivity (Morais-Cabral et al., 2001). It is noteworthy that the GluA2 structure reveals various charged residues positioned near the apex of the M3 segment that could influence conductance. Consistent with this idea, mutations of homologous positions in GluN1 M3 reduce single channel conductance and Ca\(^{2+}\) permeability (Watanabe et al., 2002).

Selectivity, unitary conductance, and channel block can all be influenced by the number of ions that reside in the pore at any one time. Potassium channels can accommodate multiple permeating ions, and this is a key component of their high selectivity and transport rates (Doyle et al., 1998; Morais-Cabral et al., 2001; Zhou et al., 2001). Studies of NMDA receptors suggest that the pore contains only a single permeating ion (Zarei and Dani, 1994; Schneggenburger, 1996; Iino et al., 1997), which may reflect the nonselective nature of the pore. In K\(^{+}\) channels as well as in other highly selective channels, the interaction between the narrow constriction and permeating ions is tight and this reduces their free energy in this region. Allowing multiple permeating ions creates ion-ion interactions that are critical to facilitating high conductance rates (Morais-Cabral et al., 2001). In contrast, in the larger glutamate receptor channel, the interaction between the pore walls and permeating ions may be weaker (i.e., fewer waters of hydration are removed), which could prevent occupancy by multiple ions. The pore of NMDA receptors can energetically accommodate a blocking particle such as Mg\(^{2+}\) and additional permeant ions (Antonov et al., 1998; Antonov and Johnson, 1999), and these additional permeant ion-binding sites may make a significant contribution to ion selectivity and conductance in addition to effects on channel block.

Glutamate receptors show limited selectivity for alkali metal cations, which for GluN1/GluN2A is Cs\(^{+}\) > Rb\(^{+}\) > Na\(^{+}\) > Li\(^{+}\), for GluA1 is K\(^{+}\) > Rb\(^{+}\) > Cs\(^{+}\) > Na\(^{+}\) > Li\(^{+}\), and for GluK2(Q) is K\(^{+}\) > Cs\(^{+}\) > Rb\(^{+}\) > Na\(^{+}\) > Li\(^{+}\) (Tsuzuki et al., 1994; Jatzke et al., 2002). In terms of Eisenman sequences (Hille, 2001), NMDA receptors display type I weak-field-strength sites, whereas non-NMDA receptors display type IV sites. In terms of selectivity at a synapse (K\(^{+}\) versus Na\(^{+}\)), the differences are minimal (P\(K^{+}\)/P\(Na^{+}\) ≈ 1.14 for NMDA receptors and P\(K^{+}\)/P\(Na^{+}\) ≈ 1.25 for AMPA and kainate receptors). Thus, the current carried through most glutamate receptor channels is a mixture of monovalent cations (K\(^{+}\) and Na\(^{+}\)) plus Ca\(^{2+}\) (MacDermott et al., 1986; Mayer and Westbrook, 1987). Receptors containing the edited form of GluA2, GluK1, or GluK2 (Hume et al., 1991; Burnashev et al., 1992a), however, are impermeable to Ca\(^{2+}\)
The flux of Ca\(^{2+}\) through NMDA and Ca\(^{2+}\)-permeable AMPA receptor channels is a key factor contributing to various forms of synaptic plasticity (Gu et al., 1996; Bloodgood and Sabatini, 2007; Citri and Malenka, 2008) (sections IV and IX), gene regulation (section III), neuropathology (Choi, 1995; Kalia et al., 2008) (section X), and fast transmitter release (see section IX) (Chávez et al., 2006).

Three general approaches have been used to study the magnitude and mechanism of Ca\(^{2+}\) permeation in glutamate receptors, and include measurement of 1) relative Ca\(^{2+}\) permeability (\(P_{Ca}/P_{Monovalent}\)), 2) channel block by Ca\(^{2+}\), and 3) fractional Ca\(^{2+}\) currents (\(P_f\)), which are determined from whole-cell currents recorded in the presence of high concentrations of intracellular Fura-2 (Burnashev et al., 1995; Premkumar and Auerbach, 1996; Schneggenburger, 1996; Sharma and Stevens, 1996). The use of fractional Ca\(^{2+}\) currents is advantageous over the other methods for channels with a mixed Ca\(^{2+}\) and monovalent permeability because it has fewer assumptions about flux properties, directly quantifies the Ca\(^{2+}\) flux under physiological conditions, and allows the fraction of the total current carried by Ca\(^{2+}\) to be quantified over a wide voltage range (Neher, 1995).

NMDA receptors are approximately 3 to 4 times more permeable to Ca\(^{2+}\) than unedited Ca\(^{2+}\)-permeable AMPA or kainate receptors (Table 18). For NMDA receptors, there are subunit-specific differences, dictated by the GluN2 and GluN3 subunits, with receptors containing GluN2A/GluN2B showing the highest Ca\(^{2+}\) permeability, GluN2C showing a somewhat reduced Ca\(^{2+}\) permeability, and GluN3 showing the lowest permeability. Ca\(^{2+}\)-permeable AMPA receptors show a slightly greater Ca\(^{2+}\) permeability than kainate receptors. Mutant Lurcher GluD2 channels are Ca\(^{2+}\)-permeable (Table 18). The magnitude of Ca\(^{2+}\) influx through at least NMDA receptors can be regulated by phosphorylation (Skeberdis et al., 2006) and synaptic activity (Sobczyk and Svoboda, 2007).

It is noteworthy that NMDA receptors are highly permeable to Ca\(^{2+}\) yet show the peculiar property of being blocked by external Ca\(^{2+}\) in a largely voltage-independent manner (Ascher and Nowak, 1988; Premkumar and Auerbach, 1996; Sharma and Stevens, 1996), whichmanifests as areduction in single channel conductance (Gibb and Colquhoun, 1991; Stern et al., 1994; Premkumar and Auerbach, 1996). These results lead to the suggestion of multiple Ca\(^{2+}\) binding sites within the pore (Premkumar and Auerbach, 1996; Sharma and Stevens, 1996), including the QRN site as well as an external site for Ca\(^{2+}\). Moreover, NMDA receptors show an interaction between Ca\(^{2+}\) and monovalent ions in the pore, concentration-dependent \(P_{Ca}/P_{Monovalent}\) (Wollmuth and Sakmann, 1998), and block by Ca\(^{2+}\). However, the \(P_{Ca}/P_{Monovalent}\) value for NMDA receptors derived from the Goldman-Hodgkin-Katz equation, which assumes no ion-ion interactions in the pore (Hille, 2001), describes fractional Ca\(^{2+}\) currents over a wide voltage and concentration range (Burnashev et al., 1995; Schneggenburger, 1996, 1998; Jatzke et al., 2002). These differences could be reconciled if the pore, which is occupied by a single ion, largely existed in two states, both of which individually follow Goldman-Hodgkin-Katz, one with the pore occupied by Ca\(^{2+}\) and the other occupied by a monovalent ion. In this model, a competition for the pore occurs between Ca\(^{2+}\) and monovalent cations (Schneggenburger, 1998).

The process of Ca\(^{2+}\) influx in Ca\(^{2+}\)-permeable AMPA receptors might be less complex than that in NMDA receptors, because Ca\(^{2+}\)-permeable AMPA receptors do not select for or against divalent cations. \(P_{Ca}/P_{Monovalent}\) in Ca\(^{2+}\)-permeable AMPA receptors is approximately unity (not taking into account ion activities; Table 18). Ca\(^{2+}\)-permeable AMPA receptors are not blocked by Ca\(^{2+}\), and the predicted fractional Ca\(^{2+}\) current at \(-60\) mV in \(~150~\text{mM}~\text{monovalent ions and 1.8 mM Ca}^{2+}\) is \(-4\%\), in agreement with a channel that is nonselective for Ca\(^{2+}\) (\(P_{Ca}/P_{Monovalent} = 1\); Table 18; see Jatzke et al., 2002).

Ca\(^{2+}\) permeability is influenced by residues occupying the QRN site residing at the channel’s narrow constriction (see section VIII.A). NMDA receptors in which the QRN site asparagine is mutated to various other residues, including the glutamine found in AMPA receptors, show reduced Ca\(^{2+}\) permeability (Burnashev et al., 1992b) (Table 18). In addition to residues at or near the QRN sites within the narrow constriction, other elements in the inner cavity may also influence Ca\(^{2+}\) permeability, either directly or by altering the structure of the M2 loop (Ferrer-Montiel et al., 1996). One such residue is a negatively charged Glu in the M2 loop, located five positions C-terminal to the QRN site in GluN1. Mutation of this Glu to the positively charged Lys reduces Ca\(^{2+}\) permeability (Schneggenburger, 1998). In addition, in the GluN2A subunit, an adjacent position is occupied by the polar glutamine, and replacing it with a Glu (as in GluN2C subunits that have reduced Ca\(^{2+}\) permeability; Table 18) yields channels that show a reduced Ca\(^{2+}\) permeability (Vissel et al., 2002), suggesting that this position may underlie GluN2 subunit-specific differences in Ca\(^{2+}\) permeability. Nevertheless, it is unclear whether Ca\(^{2+}\) directly interacts with the side chain at this position or whether mutations at this position alter the structure of the QRN site, because this position is not water accessible (Kuner et al., 1996).

The high Ca\(^{2+}\) influx in NMDA receptors has been proposed to be due, at least in part, to an external Ca\(^{2+}\) binding site (Premkumar and Auerbach, 1996; Sharma and Stevens, 1996). The most likely determinant of this Ca\(^{2+}\) binding site is a cluster of charged residues, the DRPEER motif (Fig. 14), located C-terminal to the M3 segment in GluN1 but absent in all GluN2, GluA, GluD, and GluK subunits (Watanabe et al., 2002). This unique motif is positioned at the external entrance to the chan-
nel (Beck et al., 1999), and possesses a net negative charge, predicted from the three potentially (depending on local pKₐ values) negative and one positive water-accessible residues. In mutant channels with the negative charges in DRPEER neutralized (ARPAAR), Pᵣ values are reduced by approximately half at ~60 mV (Watanabe et al., 2002), suggesting that the negatively charged side chains represent an important determinant of high fractional Ca²⁺ currents in NMDA receptors. It is noteworthy that the GluN2A subunit has a net negative charge at positions homologous to the DRPEER motif, but mutation of these residues has no effect on Ca²⁺ permeability (Watanabe et al., 2002). One potential explanation that is consistent with structural data placing elements of the GluN1 M3-S2 linker (tetramer A/C subunits) in the vicinity of each other (Sobolevsky et al., 2009) is that the DRPEER motif lies closer to the permeation pathway than homologous positions in GluN2 (tetramer B/D subunits). It is noteworthy that substituting an Asn at the QRN site of AMPA receptors, which should make the narrow constriction more NMDA receptor-like, results in only a modest increase in fractional Ca²⁺ current from 4% to 5% (Wollmuth and Sakmann, 1998). Part of the difference in Ca²⁺ permeability between AMPA and NMDA receptors may reflect the absence of the DRPEER motif in non-NMDA receptors (Fig. 14; Jatzke et al., 2003).

For NMDA receptors, coexpression of GluN3 subunits (which contain a Gly at the QRN site) with GluN1 or GluN1/GluN2 results in channels with reduced single channel conductance, decreased Ca²⁺ permeability, and reduced Mg²⁺ block (Perez-Otano et al., 2001; Matsuda et al., 2003) (Table 18), suggesting that GluN3 directly influences the structure of the permeation path. Additional evidence for this idea was provided by Wada et al. (2006), who showed that cysteine-substitutions in the M3 segment of GluN3A were modified by extracellular cysteine-reactive reagents and suggested that some residues lining the pore may differ from GluN1 and GluN2 subunits. Nevertheless, molecular mechanisms regulating conductance and permeability in GluN3-containing receptors are poorly understood.

C. Voltage-Dependent Channel Block by Endogenous Ions

A number of endogenous ions can regulate glutamatergic receptor function, including protons, Zn²⁺, Mg²⁺, and polyamines (see section VI). Of these, the multivalent ions Zn²⁺, Mg²⁺, and polyamines have voltage-dependent block mechanisms that have important implications for neuronal function independent of the dynamic regulation of their concentrations. We will consider the mechanism and implications of block of the pore by Mg²⁺ and polyamines, both of which endow receptors with the ability to detect previous neuronal activity, and thus have roles in short- and long-term plasticity. Although channel block by Zn²⁺ may be important in some situations (Vogt et al., 2000), Zn²⁺ channel block is relatively low affinity, rapidly reversing, and will not be considered further.

Mg²⁺ block represents perhaps the most distinctive feature of the NMDA receptor and was first described in a now-classic series of studies from multiple laboratories (Mayer et al., 1984; Nowak et al., 1984; Ascher et al., 1988; Dingledeine et al., 1999). Because of the strong voltage-dependence of block, NMDA receptors act as coincident detectors, sensing postsynaptic depolarization at the same time as or shortly after release of glutamate or other excitatory amino acids. This block allows NMDA receptors to mediate cellular mechanisms of learning and memory (see section IX). The most prominent biophysical feature of extracellular Mg²⁺ block is its strong voltage-dependence. Indeed, the major blocking site for Mg²⁺ is at or near the narrow constriction (for review, see Dingledeine et al., 1999), located approximately 50% across the channel. Part of the additional voltage-dependence is due to the presence of permeant ion-binding sites in the external and internal cavities (Antonov and Johnson, 1999; Zhu and Auerbach, 2001a,b; Qian et al., 2002). Occupancy of these ion-binding sites by Na⁺ or K⁺ alters the association and dissociation rates of Mg²⁺ from its blocking site. The nature of these permeant ion-binding sites differs between GluN2 subunits (Qian and Johnson, 2006) and hence may underlie some GluN2-specific effects on Mg²⁺ block (Monyer et al., 1994; Kuner and Schoepfer, 1996).

An advance in our mechanistic understanding of extracellular Mg²⁺ block has come from studies of the rate of Mg²⁺ block and unblock, which provides a physiological view of the actions of Mg²⁺. As a first approximation, the block and unblock by extracellular Mg²⁺ was considered instantaneous; however, this simplifying assumption would limit the role of NMDA receptors in dendritic integration. A variety of studies show that the rate of unblock and reblock of the channel is not instantaneous, showing both fast and slow components (Nowak et al., 1984; Vargas-Caballero and Robinson, 2003, 2004; Kampa et al., 2004; Clarke and Johnson, 2006) with rates depending on the GluN2 subunit (Clarke and Johnson, 2006). For GluN2B, the slow component of Mg²⁺ unblock arises from inherent voltage dependence of NMDA receptor gating (Clarke and Johnson, 2008).

These rates for Mg²⁺ unblock and reblock at the synapse will alter the response time and can lengthen the window of opportunity for back-propagating action potentials and local synaptic activity to modulate current flux (including Ca²⁺) through NMDA receptors. It is noteworthy that receptors containing GluN2C or GluN2D unblock more rapidly—almost instantaneously—than those containing GluN2A or GluN2B, the latter of which shows the slowest unblock (Clarke and Johnson, 2006). Given the possible regulation of Mg²⁺ block by membrane lipids (Parnas et al., 2009), perturbations in ion concentrations during activity, and GluN2
subunit-specific differences in rates of unblock and re-block, mechanisms regulating NMDA receptor block by $\text{Mg}^{2+}$ at a synapse are likely to be diverse.

Regulation of NMDA receptor activity by extracellular $\text{Mg}^{2+}$ is well known for its contribution to synaptic plasticity and associative learning. Less well known is the potential role in short-term synaptic plasticity played by the block of $\text{Ca}^{2+}$-permeable non-NMDA receptors by internal polyamines such as spermine, spermidine, and putrescine. Polyamine block of AMPA and kainate receptors is dependent on membrane potential, which may reflect interaction in the pore between monovalent ions and polyamines, rather than membrane voltage itself (Bowie et al., 1998). Polyamines interact with the pore at various sites in the M2 loop including the QRN site and a negatively charged residue (Asp in AMPA receptors and Glu in kainate receptors) located C-terminal to the QRN site (for review, see Dingledine et al., 1999; Patchenkov et al., 1999). Polyamines can dissociate from open channels to either the internal or external solution and thus permeate the channel (Bähring et al., 1997). Under physiological conditions, unedited AMPA and kainate receptors have doubly rectifying current-voltage relations reflecting block by internal polyamines at depolarized membrane potentials and permeation of internal polyamines at even more positive membrane potentials. Surprisingly, polyamine block is also state-dependent. The affinity for polyamines is higher in closed than in open channels, but the kinetics of polyamine block are slower in closed channels (Bowie et al., 1998; Rozov et al., 1998). As a result, synaptic $\text{Ca}^{2+}$-permeable AMPA receptors can be blocked by polyamines in resting synapses. Synaptic activity partially relieves this polyamine block, and block recovers slowly, so that the response to subsequent synaptic events can be potentiated (Rozov and Burnashev, 1999; Shin et al., 2005). The degree of potentiation depends on the frequency of synaptic events. If the frequency is too low, block of closed channels returns to its equilibrium level between the first and second synaptic events, and no potentiation occurs. Alternatively, if the frequency is sufficiently high, block does not re-equilibrate during the brief interval between synaptic events, and the response to the second synaptic event is potentiated. Thus, state-dependent polyamine block of postsynaptic AMPA receptors could act as a high-pass filter for synaptic activity and may be an important component of circuit function in which information is encoded by synaptic timing (Abbott and Regehr, 2004).

IX. Role in Synaptic Function and Plasticity

A. Synaptic $\alpha$-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors

Within the mammalian CNS, the vast majority of fast excitatory synaptic transmission is mediated by heteromeric AMPA receptors assembled from differing combinations of the four subunits, GluA1 to GluA4. Expression of all subunits is developmentally regulated, region and cell-type specific, and activity-dependent (Ashby et al., 2008). Within adult forebrain principal neurons, including hippocampus and cortex, the predominant GluA subtype comprises GluA1 and GluA2 with a secondary minor role played by GluA2/3 receptors (Lu et al., 2009). By virtue of its edited QRN site, the presence or absence of GluA2 is a critical determinant of GluA function and dictates the single channel conductance and $\text{Ca}^{2+}$-permeability of the native AMPA receptor (see section VIII.B). An absence of GluA2 also renders the channel pore sensitive to extra- and intracellular polyamine block, endowing GluA receptors with an inwardly rectifying current-voltage relationship and a novel postsynaptic mechanism of short-term plasticity involving the use-dependent unblock of polyamines (Isaac et al., 2007) (see section VIII.C). In many neurons, GluA2 expression is developmentally regulated, with low early postnatal expression levels, which, coupled with the transient high expression of GluA4, renders many neonatal forebrain receptors $\text{Ca}^{2+}$-permeable (Pickard et al., 2000; Zhu et al., 2000). This $\text{Ca}^{2+}$-permeability may play a role in synapse maturation and circuit development (Aizenman et al., 2002; Kumar et al., 2002; Eybalin et al., 2004; Ho et al., 2007; Migues et al., 2007). In the forebrain, as GluA2 expression increases throughout the early postnatal period, GluA4 is down-regulated. In adult, GluA4 expression remains highly enriched primarily in cerebellar tissue, where it exists as heteromeric GluA2/GluA4 in granule cells and in non-neuronal Bergmann glia as homomeric GluA4 (Petralian and Wenthold, 1992; Martin et al., 1993).

At a prototypical synapse, binding of glutamate to synaptic AMPA receptors triggers a brief, rapidly rising conductance that decays rapidly (1–2 ms; Fig. 12) as a result of the deactivation of the agonist-receptor complex. The kinetics and amplitude of the excitatory synaptic response are determined by the biophysical properties of the receptor subunit combination (Table 17; Fig. 12; see section VII.A) and the density of receptor expression, convolved with the time course of glutamate release and uptake. Receptor subunit composition and the kinetics of the synaptic response are tailored to the role played by the synapse and cell type in the circuit in which they are embedded. For example, many cortical local circuit inhibitory interneurons express AMPA receptors that comprise homomeric GluA1 (Isaac et al., 2007). These receptors have rapid kinetics such that the overall synaptic conductance time course is complete in less than a millisecond. The subsequent excitatory postsynaptic potential (EPSP) is large, rises and decays rapidly, and is capable of triggering action potentials within a narrow temporal window (Geiger et al., 1997). Such receptor assemblies are typical in cells involved in the timing of oscillatory activity (Lawrence and McBain, 2003; Jonas et al., 2004; Isaac et al., 2007).
Although the subunit composition is a major determinant of synaptic conductance kinetics, synapses typically are distributed across often elaborate dendritic trees. The resulting EPSP can be subject to extensive cable attenuation as it travels from its source (e.g., spines or smooth portions of narrow dendrites) to the site of action potential initiation. Consequently, in many neurons, synaptic potentials are often capable of triggering appreciable intrinsic voltage-dependent sodium, calcium, and/or potassium conductances that can normalize the impact of dendritic location or alter the temporal voltage window initiated by the synaptic conductance (Bloodgood and Sabatini, 2008).

Systematic mRNA and immunohistochemical profiling of GluA subunit expression in individual neurons has provided a detailed picture showing how receptor types are linked to the functional properties of the cell. However, such profiling is complicated by the observation that single neurons often manufacture AMPA receptors of different subunit compositions and target them to different synaptic inputs across the somatodendritic axis (Tóth and McBain, 2000). How individual neurons differentially target such receptor assemblies to often overlapping afferent inputs remains to be determined. However, in neurons of the lateral geniculate nucleus, Ras and Rap2 drive bidirectional trafficking of GluA1 between the deliverable and synaptic pools at retinogeniculate synapses (GluA1 dominant) but not at corticogeniculate synapses (GluA4 dominant), despite the existence of intracellular pools of GluA1 at both synapses (Kielland et al., 2009). This suggests that intrinsic activity within the vision-dependent pathway preferentially drives GluA1 between deliverable and synaptic pools at retinogeniculate synapses. Furthermore, in cortical principal cells, where the dominant AMPA receptor configuration is composed of GluA1 and GluA2, significant intracellular pools of GluA2-lacking Ca$^{2+}$-permeable receptors exist that can reach the surface under certain conditions (Ju et al., 2004; Clem and Barth, 2006; Plant et al., 2006; Sutton et al., 2006), suggesting that AMPA receptor expression is a dynamic and highly regulated process.

B. Synaptic Kainate Receptors

Since the binding studies of Monaghan and Cotman (1982), it has been clear that high-affinity kainate receptor binding sites are prevalent throughout the CNS. Translating early binding studies into a function for all kainate receptor subunits in synaptic transmission has proved harder than would have been expected. In recombinant systems, GluK1 to GluK3 form functional homomeric receptors, whereas GluK4 and GluK5 do not. These latter two subunits are believed to play a supporting role by modifying both the pharmacological and biophysical receptor properties (Contractor and Swanson, 2008). Unlike AMPA and NMDA receptors (although exceptions exist), kainate receptors can play prominent roles at both pre- and postsynaptic sites. The rules of subunit assembly and combination remain unclear, and kainate receptors show strong developmental and regional regulation (Contractor and Swanson, 2008). During development, synaptic transmission at thalamocortical synapses is initially mediated by slow kainate receptors but switches during the first postnatal week to AMPA-receptor-mediated transmission, representing a novel developmental form of LTP (Kidd and Isaac, 1999). This switch from kainate receptor to AMPA receptor subunits as the primary mediators of synaptic transmission shortens the window for coincidence detection and output timing in this circuit (Bannister et al., 2005; Daw et al., 2006). A similar activity-dependent switch from kainate to AMPA receptor-mediated transmission also has been observed at synapses onto perirhinal cortex Layer I/II neurons (Park et al., 2006).

Unlike currents through recombinant kainate receptors (see section VII.A), synaptic kainate receptors often possess a slower time course (decay time constants often >100 ms) and typically are activated only after short bursts of presynaptic activity (Contractor and Swanson, 2008). The best studied site of kainate receptor-mediated synaptic transmission is at the mossy fiber-CA3 pyramidal cell synapse. There, heterotetramers formed by GluK2 and GluK5 are found postsynaptically, whereas receptors formed from combinations of GluK1 to GluK3 are located presynaptically. At mossy fiber synapses, kainate receptors act in a concerted manner to amplify synaptic integration and frequency-dependent spike transmission (but see Kwon and Castillo, 2008; Sachidhanandam et al., 2009). Long-term depression of the kainate receptor component of the mossy fiber EPSC was traced to internalization of kainate receptors, mediated by a protein interacting with C kinase/synapto-some-associated protein 25/PKC complex (Selak et al., 2009). In contrast, kainate receptors are absent at association/commissural synapses and also made onto CA3 pyramidal cells, indicating another example of target-specific localization of glutamate receptors (Tóth and McBain, 2000). Elsewhere in cortical circuits, GluK2 is widely expressed at synapses on local circuit inhibitory interneurons (Cossart et al., 1998, 2002; Frerking et al., 1998; Mulle et al., 2000), where they have been implicated in the generation of $\theta$ and $\gamma$ oscillatory activity (Fisahn et al., 2004; Goldin et al., 2007). GluK1-containing receptors have been described on inhibitory axons presynaptic to principal cells and inhibitory interneurons, where they function to set the inhibitory tone of the hippocampal network (Cossart et al., 1998; Semyanov and Kullmann, 2001; Fisahn et al., 2004).

In addition to their role as ionotropic receptors, kainate receptors also signal via G-protein-coupled second-messenger cascades to downstream effectors (Rodríguez-Moreno and Lerma, 1998). By triggering a PKC-signaling cascade, GluK2-containing receptors modulate the slow-
medium-duration afterhyperpolarization conductance in CA1 and CA3 pyramidal cells (Melyn et al., 2002; Fisahn et al., 2005). Moreover, different subunits within the receptor complex have been proposed to independently control the ionotropic (GluK2) and metabotropic (GluK5) actions of kainate (Ruiz et al., 2005). However, knockout of GluK4 and GluK5 eliminated kainate-mediated EPSCs at mossy fiber-CA3 synapses but failed to eliminate the kainate-mediated modulation of the slow afterhyperpolarization, demonstrating that GluK4 and GluK5 are essential for normal ionotropic function but are not linked to the proposed metabotropic function of native kainate receptors (Fernandes et al., 2009).

C. Synaptic and Extrasynaptic N-Methyl-d-aspartate Receptors

At virtually all central synapses, NMDA receptors colocalize with AMPA receptors to form the functional synaptic unit, such that presynaptically released glutamate typically coactivates both NMDA and AMPA receptors (Petralia and Wenthold, 2008). The ratio of AMPA receptor- to NMDA receptor-mediated synaptic current varies across a wide range. Synaptic NMDA receptors are thought to be heterotetramers comprising two GluN1 subunits and two GluN2 or GluN3 subunits (Wenthold et al., 2003); evidence also exists for native triheteromeric receptors composed of GluN1/GluN2A/GluN2B, GluN1/GluN2A/GluN2C, and GluN1/GluN2B/GluN2D (see section II.B). Like AMPA receptor subunits, GluN subunit expression is under developmental and regional control during the early postnatal life. Because GluN1 is an obligate receptor subunit for channel function, development is targeted primarily toward GluN2 and GluN3 expression. The best example of this developmental expression is the switch from GluN1/GluN2B receptors in cortex, hippocampus, and cerebellum, which predominate in the first weeks of postnatal life, to GluN1/GluN2A-containing receptors (van Zundert et al., 2004). GluN1/GluN2B receptors are important for circuit formation and development, and this switch to GluN1/GluN2A results in NMDA receptor-mediated EPSCs with a more rapid decay. In hippocampal principal cells, this subunit switch is triggered by agonist binding (Barria and Malinow, 2002) and can be driven by stimulus protocols that produce long-lasting potentiation (Bellone and Nicoll, 2007). Likewise, sensory experience drives this subunit switch at thalamocortical synapses in primary sensory neocortex (Quinlan et al., 1999; Barth and Malenka, 2001; Lu et al., 2001). In mossy fiber-cerebellar granule cell synapses, a further subunit switch to GluN1/GluN2C is observed around P40 and is accompanied by a slowing of current kinetics and a reduction in Mg^{2+} sensitivity (Cathala et al., 2000). NMDA receptors containing GluN2D are most common in early postnatal life in neurons of the diencephalon, brainstem, and cerebellum; mRNA expression levels persist in subpopulations of interneurons in, for example, the hippocampus (Monyer et al., 1994). The signaling mechanism(s) underlying these regulatory steps are unknown. GluN3A is expressed primarily in early postnatal life, whereas GluN3B is found in adult brainstem and spinal cord (Petralia and Wenthold, 2008). GluN3A expression seems to be a critical step in synaptogenesis and spine formation, and it maintains receptors in an immature state (Pérez-Otano et al., 2006), perhaps with enhanced neuroprotection (Nakanishi et al., 2009). Subsequent down-regulation of GluN3A expression is important for synapse maturation and the emergence of a competent state for synaptic plasticity (Roberts et al., 2009). The potential roles for the myriad of glutamate receptor compositions have been discussed elsewhere (Petralia and Wenthold, 2008). Although exceptions exist, GluN2B-, GluN2D-, and GluN3A-containing receptors generally predominate early in postnatal life, whereas GluN2A- and GluN2C-containing receptors become more abundant in adult brain (Watanabe et al., 1992, 1993, 1994a,b,c).

At some synapses, there may be a correlation between the types of AMPA- and NMDA-receptors expressed. Synapses between mossy fiber axons of the dentate gyrus granule cells and stratum lucidum interneurons are composed of two AMPA receptor types. At GluA2-lacking AMPA receptor synapses, the NMDA to AMPA receptor ratio is low compared with that observed at GluA2-containing AMPA receptor synapses (Lei and McBain, 2002). At GluA2-lacking AMPA receptor synapses, NMDA receptors comprise GluN2B subunits that have a low open probability and contribute currents of small amplitude and long duration. By contrast, synapses with GluA2-containing AMPA receptors typically use GluN2A-containing NMDA receptors (Bischofberger and Jonas, 2002; Lei and McBain, 2002). This coregulation may reflect gene expression, receptor assembly, or trafficking (Barria and Malinow, 2002). Like AMPA receptor subunits, examples exist of cells targeting NMDA receptors of distinct subunit composition to different locations across their somatodendritic axis (Köhrl, 2006). Thus, NMDA receptor subunit composition and location are major determinants of glutamatergic postsynaptic properties. Moreover, NMDA receptors spatially interact with voltage-dependent conductances in spines or dendrites to shape the synaptic signal (Bloodgood and Sabatini, 2008) (see section VIII.C).

Although the synaptic composition of NMDA receptors varies throughout the brain, most mature cortical synapses contain GluN2A, whereas GluN2B-containing receptors are often extrasynaptic. Although there is pharmacological evidence that extrasynaptic receptors composed of GluN2B can participate in the induction of long-term depression, data suggesting synaptically located receptors comprising GluN2A can induce long-lasting potentiation (Liu et al., 2004b; Massey et al., 2004) have been compromised by poor selectivity of the competitive antagonist NVP-AAM077 (see section V.D). Moreover,
D. Synaptic Plasticity

1. N-Methyl-D-aspartate Receptors. The enormous volume of work exploring mechanisms for postsynaptic expression of NMDA-dependent LTP and LTD brought an unexpected bonus. The combination of electrophysiological, biochemical, and cell biological approaches used to dissect potential presynaptic and postsynaptic mechanisms involved in LTP and LTD also advanced our understanding of receptor assembly and trafficking, providing the basis for a careful dissection of the myriad proteins that interact with AMPA and NMDA receptors (see section II.G). Several excellent reviews on these protein-protein interactions exist (Collingridge et al., 2004; Malenka and Bear, 2004; Shepherd and Huganir, 2007; Ashby et al., 2008; Pelkey and McBain, 2008).

Within the hippocampus, a brief high-frequency train of stimuli delivered to the Schaffer collateral input to CA1 pyramidal cells initiates a long-lasting strengthening of synaptic transmission. Induction of this form of LTP is unambiguously NMDA receptor-dependent at most synapses onto principal neurons. When NMDA receptors embedded in the postsynaptic grid are activated, the subsequent increase in intracellular Ca\(^{2+}\) (see section VIII.B) triggers a long-lasting change in AMPA receptor-mediated synaptic transmission. This plasticity has been the most widely studied form of LTP and has been posited as a cellular correlate underlying learning and memory (Kessels and Malinow, 2009). NMDA receptors, by virtue of their voltage-dependent Mg\(^{2+}\) block, function as coincidence detectors whose participation satisfies the requirement for synapse specificity, associativity, and cooperativity. Within hippocampal CA1 pyramidal cells, NMDA receptors are assemblies of GluN1 in combination with GluN2A or GluN2B, with GluN2A-containing receptors being predominant in the adult. Overexpression of GluN2B enhances LTP and shifts the frequency-dependence of induction to lower frequencies, consistent with the longer synaptic conductance time course mediated by GluN2B (Tang et al., 1999; Erreger et al., 2005a).

Downstream of the NMDA receptor-associated increase in intracellular Ca\(^{2+}\), a number of effector mechanisms, such as CaMKII, PKC, and PKA are thought to be involved in LTP induction. CaMKII is the principal resident of the postsynaptic density, optimally positioned to sense the transient \(Ca^{2+}\) elevation. PKA seems to be a key mediator of LTP induction in young animals, whereas CaMKII is necessary and sufficient for early-phase NMDA receptor-dependent LTP in older animals. Roles for the atypical PKC isofrom PKM\(_{\tau}\), the nonreceptor tyrosine kinase src, and nitric-oxide synthase have been described previously (Pelkey and McBain, 2008).

The original observation of “silent” synapses (i.e., synapses that contain functional NMDA receptors but lack functional AMPA receptors) paved the way for the subsequent deluge of studies that demonstrated AMPA receptor delivery and retrieval as a mechanism underlying long-lasting plasticity (Kerchner and Nicoll, 2008). In the original studies (Isaac et al., 1995; Liao et al., 1995), silent synapses were subjected to an LTP-induction protocol, which then triggered the appearance of AMPA receptor-mediated currents with no change in NMDA receptor-mediated events. This emergence of AMPA receptor-mediated currents suggested that the Ca\(^{2+}\) entry after NMDA receptor activation triggered an insertion of nascent AMPA receptors into the postsynaptic density, a hypothesis that has received strong experimental support (Collingridge et al., 2004; Ashby et al., 2008; Pelkey and McBain, 2008). To summarize, this model suggests that LTP arises from the interplay between the trafficking of two distinct AMPA receptor species in hippocampal principal neurons. GluA1/GluA2 heteromers are typically excluded from synaptic sites in the absence of appropriate LTP conditioning stimuli. After LTP induction, GluA1/GluA2 receptors are rapidly incorporated into either silent or active synapses. In the original model, GluA2/GluA3 receptors, which were active in constitutive cycling, then replaced GluA1/GluA2 receptors at recently potentiated or unsilenced synapses. However, emerging evidence suggests only a minor role for GluA2/GluA3 receptors at these synapses (Lu et al., 2009). The original evidence that GluA1/GluA2 were inserted was based on the observation that the vast majority of AMPA receptors in pyramidal cells contain GluA2. However, homomeric GluA1 receptors are preferentially incorporated into synapses after LTP induction protocols or by active CaMKII (Shi et al., 2001). In addition, principal neurons contain substantial reserve pools of GluA2-lacking AMPA receptors, and evidence suggests that GluA2-lacking Ca\(^{2+}\)-permeable AMPA receptors, presumably GluA1 homomers, are inserted immediately after LTP induction, only to be replaced by GluA2-containing receptors 20 min after induction (Plant et al., 2006; but see Adesnik and Nicoll, 2007). The role for GluA1 in LTP is strengthened by the observed defects of conventional high frequency-induced NMDA receptor-dependent LTP in adult mice lacking the GluA1 subunit; however, a slowly developing form of \(\theta\) burst-induced LTP remains (Zamanillo et al., 1999; Mack et al., 2001). In contrast, LTP is enhanced in GluA2 and GluA2/GluA3 knockout mice, which may reflect the increased Ca\(^{2+}\) influx through the remaining Ca\(^{2+}\)-permeable AMPA receptors (Jia et al., 1996; Meng et al., 2003).
2. \(\alpha\)-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors. Native GluA1 subunits undergo regulated phosphorylation at two sites (Ser831 and Ser845) in their C-terminal tails (see section IV.A). Ser831 is a substrate for both CaMKII- and PKC-dependent phosphorylation, whereas Ser845 is a substrate for PKA phosphorylation (Roche et al., 1996; Mammen et al., 1997). LTP is markedly diminished in adult mice bearing a GluA1 knock-in phosphomutant that lacks both serine residues (Lee et al., 2003). However, the incomplete block of LTP, especially at the earliest time points after induction, argues against a role for either of these sites in high-frequency stimulation-induced NMDA receptor-dependent LTP. Moreover, recombinant mutant GluA1(S831A) receptors are still driven into synapses after an LTP induction protocol or active CaMKII treatment (Esteban et al., 2003). In contrast, the mutant GluA1(S845A) cannot be driven into synapses by constitutively active CaMKII. In addition, PKA phosphorylation of Ser845 is insufficient to drive GluA1 homomers into synapses, suggesting that the Ser845 site may be important for anchoring newly inserted receptors before their turnover to the stable population (Lee et al., 2003). Given that neither of these sites is a substrate for CaMKII-mediated receptor insertion suggests that other signaling cascades are also subject to CaMKII phosphorylation, such as the Ras family of GTPases and mitogen-activated protein kinases (Pelkey and McBain, 2008).

CaMKII- and PKA-dependent phosphorylation of recombinant GluA1 Ser831 and Ser845 also increases channel open probability and single-channel conductance (see section IV.A). Although evidence for a change in open probability after LTP is lacking, evidence supports an increase in AMPA receptor conductance as a mechanism for LTP expression (Benke et al., 1998; Lüthi et al., 2004; Palmer et al., 2004). CaMKII can still phosphorylate GluA1 Ser831 in recombinant GluA1/GluA2, but this does not increase the single-channel conductance, as observed in homomeric GluA1, unless a TARP such as stargazin is coexpressed (Oh and Lüthi et al., 2004; Palmer et al., 2004). CaMKII-mediated receptor insertion suggests that other signaling cascades are also subject to CaMKII phosphorylation, such as the Ras family of GTPases and mitogen-activated protein kinases (Pelkey and McBain, 2008).

CaMKII- and PKA-dependent phosphorylation of recombinant GluA1 Ser831 and Ser845 also increases channel open probability and single-channel conductance (see section IV.A). Although evidence for a change in open probability after LTP is lacking, evidence supports an increase in AMPA receptor conductance as a mechanism for LTP expression (Benke et al., 1998; Lüthi et al., 2004; Palmer et al., 2004). CaMKII can still phosphorylate GluA1 Ser831 in recombinant GluA1/GluA2, but this does not increase the single-channel conductance, as observed in homomeric GluA1, unless a TARP such as stargazin is coexpressed (Oh and Derkach, 2005; Jenkins et al., 2010). Moreover, the potential insertion of GluA2-lacking receptors (which possess a higher conductance than GluA2-containing receptors) into the synapse after LTP could account in part for the conductance change (Plant et al., 2006). It is clear that more work is needed to untangle the overlapping roles of CaMKII and PKA phosphorylation.

A second mechanism of plasticity comes from the emerging role of TARPs in AMPA receptor trafficking (Tomita et al., 2005a,b). The original observation that overexpression of \(\gamma-2\) could rescue AMPA receptor-mediated transmission in the \textit{stargazer} mutant mouse suggested a role for TARPs in the biosynthetic and trafficking pathway of the AMPA receptors (Chen et al., 2000, 2003). Indeed, TARP association in the endoplasmic reticulum is essential for export to the Golgi apparatus and ultimate surface expression. An absence of TARP association renders receptors unstable and ultimately targets them for degradation (Tomita et al., 2003). TARP-associated AMPA receptors are inserted into the plasma membrane at extrasynaptic sites and subsequently incorporated at synapses via an interaction of the TARP C-terminal tail and PSD-95. This synaptic incorporation requires CaMKII/PKC-dependent serine phosphorylation of the TARP C-terminal tail, and this active incorporation differs from the constitutive insertion of AMPA receptors at extrasynaptic sites (Milstein and Nicoll, 2009). A critical role for TARP C-terminal phosphorylation in synaptic incorporation, but not delivery to the plasma membrane, was demonstrated using a truncated form of \(\gamma-2\) in which substantial extrasynaptic receptors accumulated in the absence of significant synaptic incorporation. In this model, AMPA receptors ready for delivery to the plasma membrane are held in an extrasynaptic pool before being incorporated into synapses in an activity-dependent manner (Chetkovich et al., 2002; Bats et al., 2007). The relative simplicity of the TARP two-step model of AMPA receptor incorporation into synapses is an attractive hypothesis to explain many features of synaptic plasticity.

X. Therapeutic Potential

A. Glutamate Receptor Antagonists and the Prevention of Acute Neuronal Death

Cerebrovascular accident is projected to become the fourth most prevalent cause of disability by 2020 (Michaud et al., 2001) and remains a leading cause of death, which continues to fuel investigation of glutamate receptor ligands for therapeutic use in preventing acute neuronal death caused by cerebral ischemia and traumatic brain injury (TBI) (Kalia et al., 2008). The NMDA receptor is strongly implicated in this acute neurotoxicity, and NMDA receptor antagonists targeted at the glutamate binding site, the glycine binding site, the channel pore, and an allosteric site on the GluN2B subunit are all neuroprotective in multiple preclinical models (Green, 2002; Parsons et al., 2002; Lo et al., 2003; Hoyte et al., 2004; Small and Tauskela, 2005; Wang and Shuaib, 2005; Muir, 2006). These data supported the clinical investigation for utility in preventing death and long-term disability after stroke and TBI in man. Several large clinical trials have been undertaken (Dyker et al., 1999; Lees et al., 2000; Albers et al., 2001; Sacco et al., 2001; Yurkewicz et al., 2005). Unfortunately, all clinical tests of glutamate antagonists for neuroprotection have failed.

The reasons for the failure of the NMDA antagonists in stroke and TBI trials have been extensively discussed (Dawson et al., 2001; Danyasz and Parsons, 2002; Gladstone et al., 2002; Muir and Lees, 2003; Doppenberg et al., 2004; Hoyte et al., 2004; Small and Tauskela, 2005; Muir, 2006). In some cases, failure is attributable to class-specific factors. For the channel blockers and the
glutamate site antagonists, the levels of occupancy needed for neuroprotection can also alter cardiovascular function and disrupt cognition, leading to psychotomimetic effects (Small and Tauskela, 2005; Muir, 2006). For the channel blocker aptiganel (Cerestat; CNS 1102), these side effects limited plasma concentrations tested in phase III trials to the minimum predicted for neuroprotection, thereby limiting chances for efficacy (Dyker et al., 1999; Albers et al., 2001). In contrast, the glycine site antagonist gavestinel (GV150526) was well tolerated and administered to plasma concentration and duration significantly above those predicted to be neuroprotective, yet gavestinel also failed to improve outcome in stroke (Lees et al., 2000; Sacco et al., 2001). In this case, the relative lack of CNS side effects raised the question of whether adequate brain exposure was achieved. The uniform clinical failures of the NMDA antagonists must also call into question the hypothesis that blockade of NMDA receptors alone is sufficient to yield improved clinical outcome. Stroke and TBI trigger a number of potentially neurotoxic cascades in addition to NMDA receptor-mediated toxicity (Lo et al., 2003, 2005; Rogawski et al., 2006; Doyle et al., 2008; Green, 2008). In addition to neuron loss, white matter damage may be particularly significant to outcome in humans (Dewar et al., 1999). Unique NMDA receptors have been identified on oligodendrocytes (Karádóttir et al., 2005; Salter and Fern, 2005; Micu et al., 2006; Stys and Lipton, 2007), and it is unclear whether inhibition of these receptors is sufficient to prevent ischemia-induced white matter loss (Baltan et al., 2008; Baltan, 2009). There is also strong evidence indicating that NMDA receptor inhibition can impede recovery of function of neurons damaged but not killed during ischemia (Yu et al., 2001; Ikonomidou and Turski, 2002). Thus, the duration of NMDA receptor inhibition in relation to the phase of injury may be a critical variable (Ikonomidou and Turski, 2002). Another aspect of this dual role is that NMDA receptors in different subcellular compartments may mediate beneficial or deleterious effects (Hardingham, 2006; Papadia and Hardingham, 2007; Léveillé et al., 2008). In particular, deleterious effects can be mediated by extrasynaptic receptors containing GluN2B subunits (Tu et al., 2010). However, the GluN2B-selective antagonist CP-101,606 was apparently insufficient to achieve efficacy in severe TBI (Yurkewicz et al., 2005).

Many of the issues raised above are perhaps surmountable with different pharmacologies, pharmacodynamics, and durations of treatment. However, a factor not easily addressed is the time between onset of brain injury and initiation of drug treatment. The preclinical literature indicates that efficacy with NMDA receptor antagonists can be realized with treatment initiated up to ~2 h after injury (Dirnagl et al., 1999), although the optimal timing may be shorter (Hoyte et al., 2004). However, a 2-h time window is challenging in typical critical care units. Thus, out of necessity, treatment windows in previous clinical trials were extended to hours after the onset of injury, reducing potential neuroprotective effects of NMDA receptor antagonists. Despite the extended window, patients still were enrolled before the extent of injury was characterized, exacerbating heterogeneity in sampled populations. In sum, the narrow treatment window meant that trials had to capture small effects from a highly variable patient sample. This was probably a significant, if not principal, factor in the across-the-board failure of the NMDA antagonists as neuroprotectants. Nevertheless, NMDA receptor antagonists remain an attractive target for treatment of acute brain injury, and clinical trials such as the FAST-MAG trial have demonstrated the feasibility of initiating treatment within 2 h of the onset of injury (Saver et al., 2004), which should allow a more rigorous evaluation of the neuroprotective potential of NMDA receptor antagonists.

An alternative to preventing glutamate-induced neurotoxicity is to target overactivation of AMPA and kainate receptors. Interest in this mechanism arose from the neuroprotective efficacy of NBQX and analogs (Sheardown et al., 1990; Catarzi et al., 2007), as well as protective effects of AMPA receptor antagonists on white matter injury (McDonald et al., 1998; Follett et al., 2000, 2004). These compounds are competitive AMPA receptor antagonists that also inhibit NMDA and kainate receptors to varying degrees (Bleakman and Lodge, 1998). The efficacy of these compounds in a variety of preclinical models of neuronal injury is more robust than that of the NMDA receptor antagonists (Gill, 1994), perhaps with a longer therapeutic window (Xue et al., 1994; Hoyte et al., 2004). These compounds also protect against ischemia-induced white matter damage (Follett et al., 2000). However, the poor solubility of NBQX and another early clinical candidate [6-(1H-imidazol-1-yl)-7-nitro-2,3-(1H,4H)-quinoxalinedione] prevented successful development (Akins and Atkinson, 2002). A second generation compound, (1,2,3,4-tetrahydro-7-morpholinyl-2,3-dioxo-6-(trifluoromethyl)quinoxalin-1-yl)methylphosphonate (ZK200775) (Turski et al., 1998), had improved pharmaceutical properties, but development was halted in phase II trials because of CNS depression and a resultant transient worsening in National Institutes of Health stroke scale score during treatment (Walters et al., 2005). Results of phase II trials with another second generation compound, [2,3-dioxo-7-(1H-imidazol-1-yl)-6-nitro-1,2,3,4-tetrahydroquinoxalin-1-yl]-acetic acid monohydrate (YM872) (Takahashi et al., 2002), in ischemic stroke are not yet available.

The CNS-depressant effects of AMPA receptor antagonists that led to the halting of the ZK20075 trial are not unexpected, given that AMPA receptors mediate fast excitatory synaptic transmission. However, it is unclear whether the remarkable neuroprotective efficacy of the quinoxalinediones in preclinical models actually requires AMPA receptor inhibition. Two findings prompt this question. First, a series of decahydroisoquinoline
competitive antagonists that varied in specificity for AMPA and kainate receptors were evaluated in a global ischemia model and found to differ in neuroprotective efficacy (O’Neill et al., 1998). Significantly, efficacy was not correlated with either AMPA or kainate receptor inhibition. Second, the quinazolineone CP-465,022, a noncompetitive antagonist highly specific for AMPA receptors (Lazzaro et al., 2002; Balannik et al., 2005), failed to demonstrate efficacy in ischemia models under conditions identical to those in which NBQX was highly efficacious (Menniti et al., 2003). These findings challenge whether AMPA receptor inhibition per se can account for the efficacy of NBQX and related molecules. This line of inquiry may help identify new glutamate receptor targets to prevent neuronal death, perhaps while circumventing the CNS-depressant liability of AMPA receptor inhibition. There are a wealth of structurally diverse non-NMDA receptor antagonists that could be explored (Gill, 1994; Bleakman and Lodge, 1998; O’Neill et al., 1998; Elger et al., 2006; Catarzi et al., 2007).

Clinical study over the last decade has brought the future of glutamate receptor antagonists as neuroprotectants to an impasse. The Stroke Therapy Academic Industry Roundtable (STAIR) initiative continues to lead an effort to integrate preclinical and clinical research in stroke to guide development of new neuroprotective stroke therapies. Particularly relevant is the idea of a multimodal neuroprotective approach (Rogalewski et al., 2006; Fisher et al., 2007), which may include glutamate receptor antagonists. Extension of the treatment initiation time window also is a relevant concept (Saver et al., 2009). Success in these efforts, together with clinical strategies to administer treatment within two hours (Saver et al., 2004), may reinvigorate the study of glutamate receptor antagonists for acute brain injury.

B. The Next Generation α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid and Kainate Receptor Antagonists

There are two AMPA receptor antagonists in late stage clinical development (Swanson, 2009). Talampanel (GYKI 53773, LY300164; Howes and Bell, 2007) and perampanel (E2007) are noncompetitive antagonists that are highly selective for AMPA over other glutamate receptors. Talampanel demonstrated efficacy in phase II trials in patients with refractory partial seizures (Chappell et al., 2002), and perampanel is under study. There remains an interest in AMPA receptor inhibition as a neuroprotective strategy, and talampanel is currently in a phase II clinical trial for amyotrophic lateral sclerosis (Duncan, 2009). It has also been reported that perampanel had efficacy against neuropathic pain (Swanson, 2009).

Although kainate receptors are widely expressed in the brain, much less is known about their physiological function compared with AMPA and NMDA receptors. This is due in large part to the slow development of specific pharmacological tools (reviewed by Jane et al., 2009). To date, the most advanced of these are a series of decahydroisoquinolines that are competitive inhibitors of GluK1, with varying degrees of selectivity for competitive inhibition of AMPA receptors (Bortolotto et al., 1999; Bleakman et al., 2002). Localization of GluK1 to dorsal root ganglion neurons and the results of studies in preclinical models of neuropathic pain suggested that inhibitors of GluK1 may have therapeutic analgesic activity. This hypothesis received preliminary support in humans with the activity of LY293558 (tezampanel, prodrug NGX424) in a clinical model of dental pain (Gilron et al., 2000). The results of preclinical studies also suggest a utility in migraine, and again this hypothesis received preliminary support in a small study with this same compound in patients suffering acute migraine (Sang et al., 2004). Preclinical data suggest additional indications for GluK1 inhibitors, including in epilepsy and neuropsychiatric conditions (Jane et al., 2009).

C. The Next Generation N-methyl-D-aspartate Receptor Antagonists

The side effect liabilities of NMDA antagonists, although potentially manageable in life-threatening situations, pose significant problems in less acute neuropsychiatric conditions. However, the complex nature of NMDA receptor modulation and block offers the opportunity for pharmacological manipulations that may nonetheless provide an advantageous therapeutic benefit-to-side effect ratio. For example, the NMDA receptor antagonist memantine has achieved approval for treatment of moderate to severe Alzheimer’s disease (Reisberg et al., 2003; Tariot, 2006; Winblad et al., 2007). Memantine also benefits patients with moderate to severe vascular dementia (Möbius and Stöfller, 2003) and the dementia of Parkinson’s disease (Aarsland et al., 2009), although it is not yet approved for such use. Memantine primarily improves activities of daily living and reduces caregiver burden in these severely impaired patients (Doody et al., 2004). Significantly, memantine is well tolerated at clinically used doses in healthy persons and in patients with dementia.

The tolerability profile of memantine seems paradoxical, given the cognitive disruption and poor tolerability of other NMDA receptor channel blockers such as ketamine, phencyclidine, and MK-801 (Schmitt, 2005; Muir, 2006; Wolff and Winstock, 2006). However, memantine differs mechanistically from potent first generation channel blockers in its lower affinity, faster dissociation kinetics, the distinct mechanism by which it becomes trapped in the channel (Parsons et al., 1999; Danyasz et al., 2000; Chen and Lipton, 2006; Kotermanski et al., 2009; Kotermanski and Johnson, 2009) (see section V.F), and its potent blocking action of α7-nicotinic receptors (Aracava et al., 2005). These properties
may allow memantine to effectively re-establish activity-dependent NMDA receptor channel block disrupted by the pathological conditions of the Alzheimer brain (Danysz et al., 2000). It has been suggested that the affinity, kinetics, and mechanism of memantine block at the NMDA channel are such that the compound preferentially blocks aberrantly activated NMDA receptors that contribute to pathology but spares physiological levels of activity essential for tolerability (Chen and Lipton, 2006). Memantine may preferentially inhibit extrasynaptic NMDA receptors involved in triggering toxic signaling cascades (Léveillé et al., 2008). Emerging literature suggests NMDA receptor inhibition paradoxically augments the activity of glutamatergic pyramidal neurons through inhibition of GABAergic interneurons (Krystal et al., 2002). Whereas this “hyperglutamatergic” state results in cognitive and behavioral disruption in healthy persons who are administered high-affinity channel blockers, it possible that such an effect is beneficial in boosting the activity of underactive circuitry in the mid- to late-stage Alzheimer’s disease. It remains to be established whether memantine has longer-term effects on the neurodegenerative process (Chen and Lipton, 2006).

Memantine demonstrates that clinical success can be achieved with NMDA antagonists of unique pharmacological characteristics. Another class of compounds that has gained attention as having such potential is the GluN2B subunit-selective NMDA receptor antagonists (Chazot, 2004; Gogas, 2006; Mony et al., 2009), for which a rich pharmacology exists (Chenard and Menniti, 1999; Nikam and Meltzer, 2002; McCauley, 2005; Layton et al., 2006). By blocking only one NMDA receptor subtype, these compounds could have therapeutic benefits but minimize off-target side effects. GluN2B-selective antagonists act as negative modulators, and a small degree (~10%) of receptor function remains even at saturating concentrations, which may also limit undesirable effects. GluN2B-selective antagonists have efficacy in a wide variety of preclinical models (Chizh et al., 2001; Chazot, 2004; Gogas, 2006; Mony et al., 2009; Wu and Zhuo, 2009). It is noteworthy that GluN2B antagonists do not cause behavioral disruption in preclinical species, suggesting that specifically targeting the GluN2B subunit may capture the efficacy afforded by pan-NMDA receptor inhibition and retain good tolerability. Clinical data in support of this hypothesis has emerged from recent studies with CP-101,606 (see section X.D). Although the clinical study of CP-101,606 has ended, several new GluN2B antagonists, including MK-0657 and radiprodil, are under consideration for clinical development.

D. N-Methyl-D-aspartate Antagonists

1. Neuropathic Pain

Extensive preclinical literature indicates that NMDA receptor inhibition reduces or prevents the development of neuropathic pain (Petrenko et al., 2003). These data suggest that hyperalgesic states arise from NMDA receptors-dependent maladaptive plasticity in neuronal pain pathways (Woolf and Thompson, 1991; Woolf and Salter, 2000). Clinical support for this hypothesis is most clearly demonstrated for the channel blocker ketamine in short-term treatment of pain resulting from surgery, cancer, peripheral nerve disease, and spinal cord injury (Hocking and Cousins, 2003; Visser and Schug, 2006; Bell, 2009). However, psychotomimetic effects and a relatively short half-life relegate ketamine to second- or third-tier treatment (Hocking and Cousins, 2003). Cardiovascular side effects also have impeded the development of a newer high-affinity channel blocker, N-(2-chloro-5-(methylmercapto)phenyl)-N'-methylguanidine monohydrochloride (CNS 5161) (Forst et al., 2007). In search of better tolerability, lower affinity channel blockers have been investigated but with mixed results. Clinical studies of dextromethorphan, which is metabolized to the more potent antagonist dextromethorphan (Wong et al., 1988), suggest efficacy for short-term treatment of postoperative pain, phantom limb pain, and diabetic neuropathy but not postherpetic neuralgia (Ben-Abraham and Weinbroum, 2000; Weinbroum et al., 2000, 2001, 2002, 2003, 2004; Sang et al., 2002; Ben Abraham et al., 2003; Siu and Drachtman, 2007). Memantine has modest or no efficacy for diabetic neuropathy and postherpetic neuralgia (Sang et al., 2002), pain after surgery (Nikolajsen et al., 2000), and phantom limb pain (Maier et al., 2003). Although positive results have been reported for complex regional pain syndrome (Sinis et al., 2007), more studies are needed (Rogers et al., 2009). Taken together, these clinical data suggest that NMDA receptor channel block may provide efficacy for the short-term treatment of neuropathic pain and reduce the development of hyperalgesic states, although higher affinity channel block seems to correlate with clinical efficacy, and treatments with channel blockers may be limited by side effects.

Preclinical pharmacological (Taniguchi et al., 1997; Boyce et al., 1999; Suetake-Koga et al., 2006) and genetic (Wei et al., 2001; Tan et al., 2005) studies indicate that GluN2B subunit-containing NMDA receptors may be specifically targeted to treat neuropathic pain (Chizh et al., 2001; Wu and Zhuo, 2009). Prompted by these data, the analgesic efficacy of a single dose of CP-101,606 was tested in a small number of patients suffering from pain due to spinal cord injury and monoradiculopathy, and a clinically meaningful reduction in reported pain was observed (Sang et al., 2003). CP-101,606 infusion was associated with cognitive adverse events, although these were insufficiently severe to halt infusions. Further study of dose response relationships for GluN2B antagonists in a variety of neuropathic pain conditions is needed to determine whether an acceptable therapeutic index can be achieved.

There also has been long-standing interest in the use of NMDA antagonists to modify the analgesic response
to opiates and to block tolerance (Wiesenfeld-Hallin, 1998; Mao, 1999; Ko et al., 2008). Clinical support for such effects was evident in a meta-analysis of 40 small clinical trials (McCartney et al., 2004). Large scale clinical study of this concept has been conducted around Morphine, a combination of morphine and dextromethorphan (Caruso and Goldblum, 2000). However, this combination did not prove to be advantageous over morphine in a series of late-stage clinical trials (Galer et al., 2005). Further work is needed to realize the benefit in this concept.

2. Major Depression. Major depression is the most prevalent neuropsychiatric disorder and a major cause of disability (Kessler et al., 2003). Multiple classes of compounds are used to treat this disorder (Hansen et al., 2005b; Gartlehner et al., 2008; Cipriani et al., 2009). However, all treatments show poor efficacy in as many as half of the patients (Insel, 2006; Trivedi et al., 2006), and require multiple weeks of treatment before a substantial benefit is realized (Anderson et al., 2000; Mitchell, 2006). Recent clinical data suggest that short-term NMDA receptor inhibition may address these shortcomings.

Skolnick and coworkers (Paul and Skolnick, 2003; Skolnick et al., 2009) first suggested that NMDA antagonists may have antidepressant effects. Clinical proof-of-concept was established by Berman et al. (2000) in a small study using ketamine. Forty-minute infusion of ketamine produced clear antidepressant efficacy within 2 h, and this effect was maintained for 3 days. A similar effect was reported in treatment-resistant patients (Zarate et al., 2006a; Mathew et al., 2009). Furthermore, the prolonged antidepressant effect of brief ketamine infusion was sustained with repeated dosing when the drug was administered every 2 days over a 12-day period (aan het Rot et al., 2010). In these studies, ketamine infusion was accompanied by psychotomimetic effects. However, these were confined to the infusion period, in contrast to the antidepressant effects, which endured for days. By contrast, memantine failed to demonstrate antidepressant activity when administered at the well tolerated doses used to treat Alzheimer’s disease (Zarate et al., 2006b).

More recently, the antidepressant effects of CP-101,606 were investigated in treatment-resistant patients (Preskorn et al., 2008). In that trial, a small number of patients received a high dose of drug, and several suffered dissociative effects. When the dose was reduced, so were the incidence and severity of dissociative effects. Analysis of the combined dose groups indicated an antidepressant effect that was maintained in some patients for as long as 30 days. It is noteworthy that approximately half of the patients that responded to treatment experienced no dissociative episodes during drug infusion.

These clinical studies suggest that NMDA antagonists may provide antidepressant efficacy that is robust and of rapid onset in treatment-resistant patients. On the basis of the Preskorn et al. (2008) study with CP-101,606, it seems that antidepressant effects can be realized in the absence of significant psychotomimetic effects, at least with GluN2B antagonists. These results also indicate that episodic dosing is sufficient to provide long-lasting efficacy, which in some ways mirrors effects of electroconvulsive shock therapy (Fink and Taylor, 2007) and sleep deprivation (Giedke and Schwäzler, 2002). This raises the interesting possibility that the antidepressant effects observed with these latter treatments may stem from brief inhibition of NMDA receptors. Clinical trials in depression with the glycine-site partial agonists and the mixed GluN2A and GluN2B antagonists are ongoing.

3. Parkinson’s Disease. The glutamatergic system has long been considered a target for the treatment of Parkinson’s disease (Greenamyre and O’Brien, 1991). NMDA receptor antagonists have multiple advantageous effects in animal models of Parkinson’s disease, including on primary parkinsonian symptoms and on dopamine agonist-induced side effects (Hallett and Standaert, 2004). However, the clinical translation of these findings has been mixed. The low-affinity NMDA antagonist amantadine (Table 15) has been used as an adjunct to L-DOPA therapy, producing a modest potentiation of the antiparkinsonian effects and reducing dyskinesias (Crosby et al., 2003a,b). Memantine seems to have similar effects against primary symptoms but not for dyskinesias (Rabey et al., 1992). However, a meta-analysis found insufficient clinical data to definitively establish the therapeutic value of either compound (Lang and Lees, 2002). Remacemide, another low-affinity channel blocker (Table 15), demonstrated a trend toward improvement in primary motor symptoms in patients treated with L-DOPA in a 279 patient phase II trial (Shoulson et al., 2001). However, the results were insufficiently robust to underwrite further development. Recent phase II studies of GluN2B antagonists also provide mixed results. MK-0657, administered as a single dose in the absence of a dopamine agonist, failed to improve primary motor symptoms in Parkinson’s patients (Addy et al., 2009). Infusion of CP-101,606 alone at two different rates (before initiating a coinfusion with L-DOPA) provided no effect on primary motor symptoms (Nutt et al., 2008), but was associated with a decrease in L-DOPA-induced dyskinesias. It is noteworthy that although both infusion rates had equivalent efficacy against dyskinesias, there was a clear dose response with regard to dissociative effects, suggesting that it may be possible to separate efficacy from side effects.

E. α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid and Kainate Receptor Potentiation

Considerable therapeutic potential is associated with augmentation of synaptic AMPA receptor activity (Lynch and Gall, 2006; Lynch, 2006), and a diverse class of compounds that modulate AMPA receptor deactivation and desensitization have been discovered (see section VI.A). Extensive preclinical work with these com-
pounds suggests that therapeutic benefit may be derived from effects on synaptic network dysfunction, synaptic plasticity, and activity-dependent production of the neurotrophin BDNF (Lynch and Gall, 2006). All of these functional effects may influence learning and memory (Lynch, 2002; O’Neill and Dix, 2007). In addition, the potential up-regulation of BDNF suggests utility in the treatment of depression, Parkinson’s disease, Huntington’s disease (O’Neill and Witkin, 2007; Simmons et al., 2009), and possibly neurodegenerative conditions (Destot-Wong et al., 2009).

The compound for which there is the most clinical data is CX516 (Danysz, 2002; Lynch, 2006), a low-affinity AMPA receptor modulator that primarily slows receptor deactivation (see section VI). Initial clinical studies in aged healthy volunteers found CX516 facilitates recognition memory performance (Ingvar et al., 1997; Lynch et al., 1997). This compound also facilitated attention and reduced memory deficits in schizophrenic patients taking clozapine (Goff et al., 2001), although it was without dramatic effect when used as sole treatment (Marenco et al., 2002). Unfortunately, the results of larger studies of patients with schizophrenia showed no effect of CX516 on cognitive dysfunction (Goff et al., 2008b). CX516 was without effect on cognitive dysfunction in patients with Fragile X syndrome (Berry-Kravis et al., 2006). CX717 is a second generation AMPA receptor potentiator with improved potency and pharmaceutical properties. Nonhuman primate and human studies suggest a beneficial effect on decreased vigilance and cognitive function caused by sleep deprivation. The compound failed to have an effect in a phase II study simulating shift work (Wesensten et al., 2007). Another AMPA potentiator of the same class, farampator, showed acute effects on short term memory in a preliminary study in aged healthy human volunteers (Weizenberg et al., 2007).

Another class of AMPA receptor modulators is represented by LY451395 (Chappell et al., 2007), which slows both desensitization and deactivation and has the potential to more robustly potentiate AMPA receptor responses. To date, LY451395 has been tested in a phase II trial for efficacy in patients with mild to moderate Alzheimer’s disease but failed to improve cognitive function assessed by ADAS-Cog (Chappell et al., 2007). S18986 (Desos et al., 1996) represents a class of compounds with impact on AMPA receptor function intermediate between that of CX516 and LY451395. S18986, and N-((3R,4S)-3-(4-(5-cyano-thiophen-2-yl)phenyl)-tetrahydro-2H-pyran-4-yl)propane-2-sulfonamide (PF-4778574) are all under consideration for clinical development.

F. N-Methyl-d-aspartate Receptor Potentiation

The majority of pharmaceutical development related to NMDA receptors has focused on antagonists. However, there is substantial therapeutic potential in augmentation of NMDA receptor activity (Lisman et al., 2008). Indeed, overexpression of some NMDA receptor subunits (GluN2B) can enhance learning and memory in model systems (Tang et al., 1999, 2001; Cao et al., 2007). As with antagonists, the complexity of these receptors offers opportunities for pharmacological manipulation in ways that may provide a therapeutic benefit-to-side effect ratio. The recognition that NMDA inhibitor-induced behavioral effects closely mimic the symptoms of schizophrenia (Luby et al., 1959; Javitt and Zukin, 1991) engendered the hypothesis that NMDA receptor dysfunction may be a causative factor in the disease (Olney et al., 1999; Krystal et al., 2002; Tsai and Coyle, 2002; Yamada et al., 2005; Javitt, 2007; Morita et al., 2007). This hypothesis directly led to the idea that NMDA receptor potentiation may have therapeutic benefit (Heresco-Levy, 2000), a strategy explored in clinical trials of agonists at the glycine site on the NMDA receptor (Coyle and Tsai, 2004; Shim et al., 2008; Labrie and Roder, 2010). A meta-analysis of seven small studies of glycine and D-serine as adjuncts to first-line therapy antipsychotics found evidence for a moderate reduction of negative symptoms and a trend toward a decrease in cognitive symptoms but no evidence for a beneficial effect on positive symptoms (Tuominen et al., 2005). A recent clinical trial indicated a beneficial effect of the glycine site agonist D-alanine on positive and negative symptoms (Tsai et al., 2006). The effect of glycine was examined in a larger patient population in the CONSIST trial (Buchanan et al., 2007). Surprisingly, there was no efficacy against any symptom domain. The majority of patients enrolled in CONSIST were taking second-generation antipsychotic medications, and this may account for the failure to replicate the earlier positive findings.

D-Cycloserine, an antibiotic and glycine site ligand, was the first synthetic compound examined for augmentation of primary antipsychotic therapy. This compound is a partial agonist at the glycine site and may preferentially activate NMDA receptors containing the GluN2C subunit (Sheinin et al., 2001; Dravid et al., 2010) expressed on interneurons and cerebellar granule cells (Monyer et al., 1994). Initial clinical studies of D-cycloserine indicated a beneficial effect on negative symptoms over a narrow dose range (Goff et al., 1999). However, in meta-analysis of five trials, evidence of benefit was not supported (Tuominen et al., 2005). D-Cycloserine was also examined in the CONSIST trial, and no evidence of efficacy was found (Buchanan et al., 2007). However, the preclinical data suggest the possibility of tachyphylaxis to glycine site ligands, leading to examination of the effects of D-cycloserine intermittently dosed, which improved negative symptoms compared with placebo in patients suffering schizophrenia (Goff et al., 2008a).

D-Cycloserine has been studied as an adjunct to behavioral therapy to promote the extinction of maladaptive associations. This therapy is based on the hypothe-
sis that D-cycloserine will augment therapy-directed learning through potentiation of NMDA receptor-dependent learning. In clinical trials, D-cycloserine increased the efficacy of behavioral therapy in patients suffering acrophobia (Ressler et al., 2004), social anxiety disorder (Hofmann et al., 2006b), and obsessive compulsive disorder (Kushner et al., 2007; Wilhelm et al., 2008). In a meta-analysis of the preclinical and clinical data, Norberg et al. (2008) stress that the timing of D-cycloserine treatment relative to the period of learning consolidation is a key factor in attaining efficacy, in terms of both promoting learning consolidation and avoiding tachyphylaxis.

The work summarized above evidences both considerable progress and remaining hurdles in developing the therapeutic potential of NMDA receptor augmentation. The first and most obvious hurdle is the need for improved pharmaceutical agents. Problems inherent in the use of glycine, including the very high dose (60 g/day), poor brain penetration, and poor tolerability, make it difficult to use for detailed hypothesis testing. D-Serine and D-alanine suffer the same issues, albeit to a lesser degree. Fortunately, there are two new molecular targets being pursued that offer unique pharmacology and the promise of more attractive small molecules. The more advanced target is the inhibition of glycine re-uptake by GlyT1 in the perisynaptic region (Javitt, 2008, 2009). Preclinical studies indicate GlyT1 inhibitors augment NMDA receptor-dependent processes in vitro and in vivo (Sur and Kinney, 2007; Bridges et al., 2008; Yang and Svensson, 2008). Clinical proof of concept has been obtained with sarcosine, a naturally occurring intermediate in glycine metabolism that is a low-affinity GlyT1 inhibitor (Zhang et al., 2009a,b). Sarcosine improves positive and negative symptoms in schizophrenic patients stabilized on antipsychotic medication (Tsai et al., 2004, see also Lane et al., 2006) or those suffering an acute exacerbation of symptoms (Lane et al., 2005), although it is only weakly efficacious in the absence of antipsychotic medication (Lane et al., 2008). There are now several synthetic GlyT1 inhibitors in early clinical development, including N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydro-2-ylmethyl)aminomethylcarboxylic acid (SCH 900435 or Org 25935), and 1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-4-fluoro-benzyl)-(3-methyl-3-aza-bicyclo[3.1.0]hex-6-yl methyl)-amide (PF-03463275). A second new approach to augmenting NMDA receptor activity targets D-serine metabolism. In the last decade, D-serine has been recognized as a principal physiological coagonist at the glycine binding site of the NMDA receptor (Mothe et al., 2000; Wolosker, 2007). In brain, D-serine is degraded by D-amino acid oxidase (DAAO) (Mothe et al., 2000; Wang and Zhu, 2003), and there is genetic evidence for an involvement of DAAO in schizophrenia (Chumakov et al., 2002, but see Williams, 2009). DAAO inhibitors may increase levels of endogenous D-amino acids or block the metabolism of exogenously administered compounds (Horio et al., 2009; Smith et al., 2009).

Despite the positive findings noted above, the fact remains that efficacy with glycine and related analogs in schizophrenia has been modest and primarily confined to negative symptoms. This is in contrast to the dramatic efficacy by which NMDA antagonists recapitulate positive, negative, and cognitive symptom domains. Improved efficacy may come with better pharmaceutical tools and better understanding of optimal dosing intervals. Nonetheless, the clinical data may also be read to suggest limited efficacy through targeting the glycine site. The physiological underpinnings of this limit may stem from the relative affinities of different GluN2-containing receptors for glycine. Specifically, the potency for glycine is higher for GluN2B-, GluN2C-, and GluN2D-compared with the GluN2A-containing receptors (see section V). Thus, if GluN2A were a key target, glycine therapy might be expected to yield only modest results. It is noteworthy that the clinical finding that the GluN2B selective antagonist CP-101,606 produces dissociative effects, at least at high doses, suggests that GluN2B subunit-containing receptors could be an important target. Several preclinical studies of mice over-expressing the GluN2B subunit suggest that GluN2B-selective potentiators may indeed have procognitive efficacy (Tang et al., 2001; Cao et al., 2007). More data on GluN2-selective potentiation could provide needed clarity on the therapeutic potential for NMDA receptor augmentation in schizophrenia.

XI. Conclusions

Without question, the field of glutamate receptors has entered a new, structural era. Crystallographic data sets have created new opportunities to design functional studies from a perspective that previously was largely conjecture. Such studies promise to achieve a new level of understanding on how glutamate receptors link agonist binding to channel gating and will aide in defining how channel activation is controlled by receptor subtypes, stoichiometry, post-translational modifications, and protein-protein/protein-lipid interactions. These studies are essential because the gating machinery at all glutamate receptors represents a promising target for modulating neuronal and glial function for therapeutic gain in an unusually wide range of neurological diseases. Emerging clarity in how cells regulate synaptic glutamate receptor function and control localization provide further understanding that aids in elucidating the role of glutamate receptors in normal functions such as learning and memory as well as in disease. Progress toward the initial promise of new glutamate receptor-based clinical agents is being made despite early setbacks. This progress is accompanied by the very real prospect of breakthrough medicines that expand treatment options for many patients. Indeed, rather than
winding down as newer topics compete for investigator interest, glutamate receptor biology is instead poised for an increase in interest and activity in the coming decade, driven by emerging structural concepts.

Acknowledgments. This work was supported by the National Institutes of Health National Institute of Neurological Disorders and Stroke [Grants NS065371, NS036654, NS068464 (all to S.F.T.)], the National Institutes of Health National Institute of Mental Health [Grant MH066892 (to L.P.W.); the National Institute of General Medical Sciences [Grant T32-GM008602 (to K.K.O.)]; the National Institutes of Health National Institute on Drug Abuse [Grant T32-DA01504006 (to K.M.V.)]; the National Institutes of Health National Institute of Mental Health [Grant MH066892 (to L.P.W.); the National Institutes of Health National Institute of Stroke [Grants NS065371, NS036654, NS068464 (all to R.D.)]; the National Institutes of Health National Institute of General Medical Sciences [Grant T32-GM008602 (to K.K.O.)]; the National Institutes of Health National Institute on Drug Abuse [Grant T32-DA01504006 (to K.M.V.)]; the National Institutes of Health National Institute of Environmental Health Sciences [Grant T32-ES012870 (to K.M.V.)]; the National Institutes of Health National Institute of Environmental Health Sciences [Grant T32-ES012870 (to K.M.V.)]; the Michael J. Fox Foundation (to S.F.T.); the Lundbeck Foundation (to K.B.H.); and the Villum Kann Rasmussen Foundation (to K.B.H.). We are grateful to Stefan Ayenina, Ruth Rank Hall, Richard Huganir, Meag Jenkins, Jon Johnson, John Isaac, Mark Mayer, and Ken Velkey for providing critical comments on portions of the manuscript, as well as the reviewers for their painstaking and careful reading of the manuscript. We also thank Drs. Howe, Furukawa, Mott, Rosconi, Sobolevsky, Gouaux, and others for uploading unpublished data and Polina Lyuboslavsky and Kimberly Vellan for excellent technical assistance.

REFERENCES


GLUTAMATE RECEPTOR ION CHANNELS


forebrain NMDA receptors containing the NR1 C2 exon: direct demonstration of NMDA receptor regulation by microtubule-associated protein 1A/1B-light chain 3. J Neurosci 28:6139–6147.


Chen HS and Lipton SA (2005) The Glutamate Receptors 477


Quantal release of glutamate generates pure kainate and mixed AMPA/kainate receptors. Neuron 16:59–68.
GLUTAMATE RECEPTOR ION CHANNELS

Dunah AW and Standaert DG (2003) Subcellular segregation of distinct heteromeric NMDA receptors in the striatum is not metal-dependent. 
*Neuroreport* 14:1329–1332.

Dunah AW, Yasuda RP, and Wolfe BB (1998b) Developmental regulation of tyrosine phosphorylation of the NR2D NMDA glutamate receptor subunit in rat central nervous system. 

Dunah AW (2009) The role of AMPA receptor-mediated excitotoxicity in ALS: is it necessary for survival? 


*JAMA* 298:530–532.


Fisahn A, Heinemann SF, and McIlain CJ (2005) The kainate receptor subunit GluR6 mediates metabolic regulation of the slow and medium AHP currents in mouse hippocampal neurons. 

*J Pharmacol Exp Ther* 283: 1256–1262.


Flynne GE and Zagotta WN (2001) Conformational changes in S2 coupled to the opening of cyclic nucleotide-gated channels. 

Follett PL, Miceli MA, and Dui WP (2005) Competitive inhibition of AMPA receptors by direct interaction of calmodulin with the NR1 subunit. 
*J Neurosci* 25:14124–1420.


Frophies H, Steinberg PA, and Rosenfeld GB (2006) NMDA receptor subtype expression in the myocardium: implications for cardiac disease. 
*Cardiol Rev* 14: 1–11.


*Br J Clin Pharmacol* 64:75–82.


*J Neurochem* 75: 745–748.

*J Neurochem* 75: 745–748.

*Br J Clin Pharmacol* 64:75–82.

*J Neurochem* 75: 745–748.


GLUTAMATE RECEPTOR ION CHANNELS


Hosey JR (1996) Homomeric and heteromeric ion channels formed from the kainate-type subunits GluR6 and KA2 have very small, but different, unitary conductances. *J Neurophysiol* 76:510–519.


Husl H, Ward MA, Choudary JS, Blackstock WP, and Grant SG (2000) Proteomic...


Jin R and Gouaux E (2003) Probing the function, conformational plasticity, and synaptic dimer contacts of the GluR2 ligand-binding core: studies of S-substituted willardines and GluR2 S112 in the crystal.


Kash TL, Matthews RT, and Winder DG (2008) Alcohol inhibits NR2B-containing NMDA receptors in the ventral bed nucleus of the stria terminalis.


Purkinje cell synapse formation, and cerebellar long-term depression in GluR6 


Lin DT and Huganir RL (2007) PICK1 and phosphorylation of the glutamate receptor 2 (Glur2) AMPA receptor subunit regulates GluR2 recycling after NMDA receptor-induced internalization. J Biol Chem 282:19530–19536.


Pelkey KA and McBain CJ (2008) Ionotropic glutamate receptors in synaptic plas-

Papadia S and Hardingham GE (2007) The dichotomy of NMDA receptor signaling.

Pentikainen OT, Settimo L, Keinanen K, and Johnson MS (2003) Selective agonist

Peoples RW and Weight FF (1999) Differential alcohol modulation of GABA(A) and

Parsons CG, Danysz W, and Lodge D (2002) Introduction to glutamate receptors,

Parsons CG, Danysz W and Lodge D (2002) Glutamate receptors: structure and func-

Park Y, Jo J, Isaac JT, and Cho K (2006) Long-term depression of kainate receptor-


Perris D, Pinheiro PS, Jane DR, and Mulle C (2009) Antagonism of recombinant


Pietra RG, Wang YX and Wenthold RJ (1994) The NMDA receptor subunits NR2A


Pietra RG, Wang YX and Wenthold RJ (1994) The NMDA receptor subunits NR2A


Pietra RG, Wang YX and Wenthold RJ (1994) The NMDA receptor subunits NR2A


Pietra RG, Wang YX and Wenthold RJ (1994) The NMDA receptor subunits NR2A


Pietra RG, Wang YX and Wenthold RJ (1994) The NMDA receptor subunits NR2A


Pietra RG, Wang YX and Wenthold RJ (1994) The NMDA receptor subunits NR2A


Pietra RG, Wang YX and Wenthold RJ (1994) The NMDA receptor subunits NR2A


Pietra RG, Wang YX and Wenthold RJ (1994) The NMDA receptor subunits NR2A


Shihomi K, Ishida M, Shimamoto K, and Ohfune Y (1989) A conformationally restricted analogue of L-glutamate, the (2S,5R,4s)-isomer of L-alpha-carboxy-2,4-azepinopropylglutamate, activates the NMDA-type receptor more markedly than NMDA in the isolated rat spinal cord. Brain Res 488:355–359.


Shinozaki H, Ishida M, Shimamoto K, and Ohfune Y (1989) A conformationally restricted analogue of L-glutamate, the (2S,5R,4s)-isomer of L-alpha-carboxy-2,4-azepinopropylglutamate, activates the NMDA-type receptor more markedly than NMDA in the isolated rat spinal cord. Brain Res 488:355–359.


Shinozaki H, Ishida M, Shimamoto K, and Ohfune Y (1989) A conformationally restricted analogue of L-glutamate, the (2S,5R,4s)-isomer of L-alpha-carboxy-2,4-azepinopropylglutamate, activates the NMDA-type receptor more markedly than NMDA in the isolated rat spinal cord. Brain Res 488:355–359.

GluTAMATE RECEPTOR ION CHANNELS

Staudley and Bandy D (2000) Role of glycosylation in ionotropic glutamate


Stein E, Cox JA, Seedorf PH, and Verdoorn TA (1992) Complex pharmacological profiles of recombinant alpha3-9-methylisoxazole-5-propionate


thio-ATPA, a new potent and selective GluR5 agonist. Eur J Pharmacol 64:214–
253.


90.


90.


neurotransmission stabilizes synaptic function via tonic suppression of local dendritic protein synthesis in rat hippocampus [129,375–709].


GLUTAMATE RECEPTOR ION CHANNELS 493


five NMDA receptor channel subunit mRNAs in the cerebellum. J Comp Neurol 353:518–539.


nes with high affinity and selectivity for N-methyl-D-aspartate receptor glycine site.


Zhu Y and Auerbach A (2001b) Na\(^{+}\) occupancy and Mg\(^{2+}\) block of the N-methyl-D-aspartate receptor channel. *J Gen Physiol* **117**:275–286.


Correction to “Glutamate Receptor Ion Channels: Structure, Regulation, and Function”

In the above article [Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, and Dingledine R (2010) Pharmacol Rev 62:405–496], the enantiomer (-)-ketamine is mislabeled in Table 15 in the first column of the third row. The correct entry should be (+)-ketamine. Please see below for the corrected table.

### TABLE 15
IC50 values in micromolar for uncompetitive NMDA receptor antagonists
All values were measured in 0 Mg2+, unless otherwise indicated. Values for memantine and (-)-ketamine are from Kotermanski and Johnson (2009) with membrane potential held at -66 mV. All remaining values are from Dravid et al. (2007) with membrane potential held at -40 mV.

<table>
<thead>
<tr>
<th>Uncompetitive Antagonist</th>
<th>GluN2A</th>
<th>GluN2B</th>
<th>GluN2C</th>
<th>GluN2D</th>
</tr>
</thead>
<tbody>
<tr>
<td>(+)-MK-801</td>
<td>0.015</td>
<td>0.009</td>
<td>0.024</td>
<td>0.038</td>
</tr>
<tr>
<td>(-)-MK-801</td>
<td>0.35</td>
<td>0.32</td>
<td>0.038</td>
<td>0.17</td>
</tr>
<tr>
<td>(+)-Ketamine</td>
<td>16</td>
<td>1.6</td>
<td>1.1</td>
<td>1.5</td>
</tr>
<tr>
<td>(±)-Norketamine</td>
<td>51</td>
<td>8.7</td>
<td>5.6</td>
<td>7.5</td>
</tr>
<tr>
<td>Dextromethorphan</td>
<td>11</td>
<td>3.7</td>
<td>1.1</td>
<td>5.4</td>
</tr>
<tr>
<td>Levomethorphan</td>
<td>13</td>
<td>2.2</td>
<td>1.1</td>
<td>2.6</td>
</tr>
<tr>
<td>Dextrophan</td>
<td>1.3</td>
<td>0.33</td>
<td>0.15</td>
<td>0.74</td>
</tr>
<tr>
<td>Lovoranphol</td>
<td>1.8</td>
<td>1.2</td>
<td>0.58</td>
<td>2.1</td>
</tr>
<tr>
<td>Phencyclidine</td>
<td>0.82</td>
<td>0.16</td>
<td>0.16</td>
<td>0.22</td>
</tr>
<tr>
<td>PCA</td>
<td>19</td>
<td>3.9</td>
<td>1.6</td>
<td>1.7</td>
</tr>
<tr>
<td>CNS-1102</td>
<td>0.13</td>
<td>0.068</td>
<td>0.087</td>
<td>0.14</td>
</tr>
<tr>
<td>Amantadine</td>
<td>130</td>
<td>70</td>
<td>35</td>
<td>38</td>
</tr>
<tr>
<td>Remacimide</td>
<td>81</td>
<td>35</td>
<td>92</td>
<td>63</td>
</tr>
<tr>
<td>Pentamidine</td>
<td>0.72</td>
<td>1.5</td>
<td>10</td>
<td>9.1</td>
</tr>
<tr>
<td>9-Aminopyriphene</td>
<td>7.8</td>
<td>7.5</td>
<td>29</td>
<td>38</td>
</tr>
<tr>
<td>Memantine</td>
<td>0.80</td>
<td>0.57</td>
<td>0.52</td>
<td>0.54</td>
</tr>
<tr>
<td>Memantine–1 mM Mg2+</td>
<td>13</td>
<td>10</td>
<td>1.6</td>
<td>1.8</td>
</tr>
<tr>
<td>(+)-Ketamine</td>
<td>0.33</td>
<td>0.31</td>
<td>0.51</td>
<td>0.83</td>
</tr>
<tr>
<td>(+)-Ketamine–1 mM Mg2+</td>
<td>5.4</td>
<td>5.08</td>
<td>1.2</td>
<td>2.9</td>
</tr>
</tbody>
</table>

CNS-1102, aptiganel; PCA, 1-phenylcyclohexylamine.